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ABSTRACT 
BONNIE RACHEL JOUBERT: Human Genetic Susceptibility to Mother-To-Child-
Transmission of HIV: A Study of Mother-Infant Pairs in Malawi 
(Under the direction of Steven Meshnick, M.D., Ph.D.) 
 
 Mother-To-Child Transmission of HIV (HIV MTCT) is a worldwide public health 
problem and particularly burdens mothers and children in Sub-Saharan Africa, where in 
2006, over 500,000 infants were newly infected with HIV 1.  To more clearly understand 
the mechanisms of transmission, we studied genetic exposures and HIV MTCT in 
consenting mother-infant pairs receiving antenatal care in Blantyre, Malawi. 
 We first examined infant genetic susceptibility to maternal infection through a 
genome wide association (GWA) scan of 655,000 SNPs.  Top associations with HIV 
MTCT were found for 20 SNPs within 7 genes (p<5 x 10-5, Bonferroni p=1), including 
rs8069770, located within the gene, HS3ST3A1, which facilitates the biosynthesis of a 
subtype of Heparan Sulfate that plays a role in viral infection.   
 We then applied our GWA data to determine how genetic variation in our Malawi 
population compares to that of African ancestry (AFA) populations from the International 
HapMap Project.  Allele frequency in the Malawian population was highly correlated to 
that of AFA populations (r2>0.90) but not with other ancestry populations (r2<0.51).  
Similar findings were observed for adjacent linkage disequilibrium (AFA r2>0.80, other 
ancestry r2<0.54).  Frequencies of 4 SNPs in the lactase gene (LCT) varied greatly 
between the Malawi population and Maasai in Kenyawa, Kenya (Bonferroni p<1x10-33).  
The Malawi population was genetically homogenous but distinct from other populations.   
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 Finally, we examined the regulation of chemokine co-receptor 5 (CCR5) 
expression in human placenta by infant polymorphisms and maternal infection.  The 
CCR5 promoter polymorphisms CCR5-2554T (rs2734648, β= -0.67, 95% CI= -1.23, -
0.11) and -2132T (β=-0.75, 95% CI=-0.131, -0.18) were significantly associated with 
reduced placental expression of CCR5.  An incremental increase in CCR5 expression by 
expression of HS3ST3A1 (β=0.27, 95% CI=0.18, 0.35) and HS3ST3B1 (β=0.11, 95% 
CI=0.06, 0.18) was observed.  CCR5 expression was up-regulated for higher maternal 
HIV viral load (β=0.76, 95% CI=0.12, 1.39; p=0.020) and malaria infection (β=0.37, 
95% CI=-0.43, 1.18, p=0.362), with variable statistical significance. This cumulative 
body of work provides a fresh look at genetic factors involved in the risk of HIV MTCT 
as well as how such findings can be generalized to other populations in Africa. 
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CHAPTER 1 REVIEW OF THE LITERATURE 
1.1 Summary 
 This dissertation examines genetic risk factors for mother-to-child transmission of 
HIV (HIV MTCT) in a population of mother-infant pairs from Blantyre, Malawi.  The 
first goal of this project was to describe infant genomic susceptibility to HIV 
transmission from infected mothers.  In order to assess the generalizability of this work to 
other populations of different ancestries, allele frequency and other measures of genetic 
diversity in the Malawi study population was compared to International HapMap 
populations within and outside of Africa.   The second goal of this work was to describe 
the association between placental expression of known immunologically relevant genes 
and the risk of HIV MTCT.  The overall objective of thesis is to provide new insights into 
our understanding of the genetic etiology of HIV MTCT and to quantify genetic diversity 
across African populations. 
 This chapter briefly reviews what we currently know about HIV MTCT, including 
the definition of HIV MTCT, the methods of transmission, the epidemiology of HIV 
MTCT, environmental and behavioral risk factors, and the known genetic risk factors 
described to date.  It will also discuss in detail the functional relevance for genes of 
interest, and finally, genetic epidemiology methodological issues relevant to this project. 
1.2 Types of Mother-to-Child Transmission of HIV 
 Mother-to-child transmission of HIV occurs when a woman infected with HIV 
passes the infection to her fetus or infant. This type of HIV transmission can occur during 
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pregnancy, (intrauterine transmission, IU), during labor and delivery (intrapartum 
transmission, IP), or through breast feeding (postpartum transmission, PP).   
1.2.1 Intrauterine Transmission 
 IU transmission occurs during pregnancy, before the onset of labor.  It may be 
associated with accelerated HIV-1 maternal disease progression and increased risk of first 
trimester abortions 2.  However, early in utero infection is believed to be relatively rare, 
and most likely vertical transmission occurs later in pregnancy 3.  Polymerase Chain 
Reaction (PCR) testing is used as a sensitive way to test infants at birth.  However, if 
viral sequestration occurs, i.e. in the lymph nodes or central nervous system, newly born 
infants with IU can have a negative HIV test and will test positive a few days after the 
labor. Therefore, IU can be misclassified as IP transmission.  IU transmission is also 
likely to be underestimated due to unreported HIV results for miscarriage events. 
1.2.2 Intrapartum Transmission 
 IP transmission occurs during labor and delivery.  In IP, the fetus can become 
infected prior to birth, possibly through an infection from the vagina or cervix that 
ascends to the amniotic fluid and fetal membranes.  In addition, the fetus can become 
infected during the birth process, i.e. by having contact with maternal blood and genital 
secretions in the birth canal 4.   
 Disruption of the placental barrier that separates the infant from the mother may 
increase the risk of transmission.  There is evidence of maternal-fetal microtransfusions 
increasing the risk of IP HIV MTCT, as reported in Kwiek et al. in 2006 5.  This study 
measured placental alkaline phosphatase (PLAP), an enzyme unable to cross an intact 
placental barrier, in umbilical vein serum as an indicator of maternal-fetal 
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microtransfusion.  Cord PLAP activity was associated with an increased risk of HIV 
MTCT in vaginal deliveries, demonstrating the evidence of microtransfusions as a risk 
factor for vertical transmission of HIV5. 
 Birth order has been noted as a risk factor for HIV MTCT, but likely serves as a 
proxy for contact with viral-rich maternal blood and fluid, facilitating IP transmission.  
Studies of birth order among twins demonstrated an increased risk of HIV MTCT for the 
first born vaginally delivered twin 6; 7.  One explanation for this observation is that the 
first born infant has greater exposure to the virus through contact with HIV-infected 
maternal blood and fluids in the birth canal compared to the second born infant.  The 
rates of transmission in one study were 35% for the first born infant compared to 8% for 
the second 6.  These findings suggest that intrapartum exposures experienced by the 
infant during birth and delivery contribute a substantial portion of the risk of HIV MTCT 
for singleton and for multiple birth infants. 
1.2.3 Postpartum Transmission 
 Another means of transmission of HIV to the infant from an infected mother 
occurs during breastfeeding.  Transmission through breastfeeding likely occurs through 
repetitive and prolonged exposure to infectious milk in the infants’ oral and 
gastrointestinal tracts 2.  However, refraining from breastfeeding to avoid HIV MTCT 
may not be appropriate, as breast milk contains IgA and other nutrients that boost the 
infant immune system allowing the infant to more adequately combat infection, a major 
cause of infant death in African countries 8.   Furthermore, premature cessation of 
breastfeeding followed by replacement with food may increase the risk of HIV MTCT, 
possibly because the food can cause damage to the immature gastrointestinal tract of the 
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infant, increasing permeability in the tract, and thereby facilitating HIV transmission 8.  
The recommendation from the World Health Organization as of October 2006 is for 
women to exclusively breastfeed infants the first six months of life unless replacement 
feeding is acceptable, feasible, affordable, sustainable and safe 9.  Because the alternative 
is atypical in many African settings, the most common recommendation in Africa is 
exclusive breastfeeding. 
1.3 Epidemiology of HIV MTCT and High Risk Populations 
An estimated 33 million people worldwide were living with HIV/AIDS in 2008, 
two-thirds of which reside in sub-Saharan Africa and over 2 million of which were 
children 10.  Approximately 30% of women attending antenatal clinics in sub-Saharan 
Africa in 2005 were HIV positive 1 and over 330,000 new infections in children were 
reported in 200710.  In the absence of anti-retroviral treatment, vertical transmission rates 
range from 16 -20% in Europe and North America 11; 12 compared with 25-42% in 
African countries 1; 13.  In Malawi alone, there were 91,000 children aged 0 to 14 years 
living with HIV in 2006 1.  The discrepant rates by region may reflect breastfeeding 
practices, elective Caesarians, prematurity 3 or other unrecognized causes.  Children born 
with HIV or that seroconvert within 1 year of birth experience twice the mortality rate of 
uninfected children under age 5 13. 
A common HIV MTCT prevention method is administration of single-dose 
nevirapine to  both mother and infant , which can reduce transmission by up to 50% 14, 
However, only a subset of women eligible for treatment may actually be reached in the 
developing world and treatment has been associated with resistance and treatment failure 
in subsequent pregnancies 15-17.   
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1.4 Environmental  and Behavioral Risk Factors for HIV MTCT 
 There are multiple non-genetic risk factors for HIV MTCT that can occur 
simultaneously or sequentially.  Obstetrical factors can occur during labor and delivery 
that may expose the infant to the infectious blood of the mother.  Some of the known 
obstetrical risk factors include placental tears, premature rupture of the membranes 
(PROM), or prolonged labor and ruptured membranes for greater than 4 hours 18.  Infant 
exposure to HIV-1 in the birth canal 19, hemorrhage during labor, the presence of blood in 
the amniotic fluid 20, neonatal gastric aspirate of blood 4, prepartum and intrapartum 
bleeding 3, and invasive procedures such as amniocentesis 21 have all been associated 
with an increased risk of HIV transmission to the infant.  Nosocomial infections 
(infections resulting from treatment in a hospital or healthcare unit) and/or iatrogenesis 
(adverse effects or complications resulting from medical treatment) may also contribute 
to the risk of HIV MTCT in resource-poor hospitals in the developing world.  
The cellular composition of the placenta, which changes through gestation, can also 
play a role in the risk of infection.  For example, CD4 and CCR5 receptors are variably 
expressed on Hofbauer and trophoblast cells, and facilitate the cell entry of HIV 3; 22.  
Chorioamnionitis, an infection of the chorion and amnion (membranes that surround the 
fetus) and of the amniotic sac, is also associated with HIV MTCT of HIV.  Previously 
considered as one clinical entity, it has more recently been classified as acute 
chorioamnionitis and chronic chorioamnionitis 23.  Acute chorioamnionitis is a less strong 
risk factor for HIV MTCT compared to chronic chorioamnionitis, and chronic 
chorioamnionitis may be of particular importance for IU transmission 23. 
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Other sexually transmitted infections (STI) 24, in particular maternal syphilis co-
infection 25, are associated with a higher risk of HIV MTCT of HIV.  Older maternal age 
has been associated with the risk of HIV MTCT of HIV 18 but it is unclear if age is a 
proxy of other risk factors, such as complications during pregnancy for older mothers.  
Maternal behaviors such as smoking 26-28 and illicit drug use 21; 29, and infant drug 
withdrawal symptoms 30 are associated with an increased risk of HIV MTCT. 
Maternal nutritional factors play a role in transmission risk and may have the 
strongest impact on HIV MTCT in developing countries.  Low maternal serum retinol, 
resulting from maternal vitamin A deficiency, has been associated with the risk of HIV 
MTCT 13; 31.  However, a clinical trial in a predominantly breastfeeding group of mother-
infant pairs found that supplemental doses of vitamin A did not affect postnatal HIV 
MTCT.  The trial also found that supplemental vitamin A prolonged survival among 
infants HIV-positive before 6 weeks, but increased the risk of death among infants 
infected after 6 weeks 32, suggesting that the effect of vitamin A on the risk of HIV 
MTCT and the progression to AIDS may be influenced by other factors.  Maternal 
nutrition may also influence low infant birth weight as well as intrauterine growth 
restriction (IUGR) and/or preterm delivery (PTD), considered as separate phenotypic 
entities. 
 The mode of delivery (vaginal, emergency caesarian, or elective caesarian) has 
been associated with the risk of HIV MTCT, where elective caesarian sections decrease 
the risk of transmission 1; 13, although this is controversial 33.  The use of elective 
caesarians may be impractical in the developing world for a variety of reasons including 
stigma and access to adequate health care facilities.  Emergency caesarians may increase 
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the risk of transmission, possibly through contact with infectious fluids during surgery, or 
possibly due to tissue trauma and membrane rupture that may have necessitated the 
emergency actions. 
 As previously noted, one of the strongest risk factors for HIV MTCT is maternal 
HIV viral load (MVL), which often is negatively correlated with maternal CD4 count, 
both serving as indicators of maternal immunosuppression.  The use of antiretroviral 
treatment results in a reduction in MVL, thereby reducing the risk of HIV MTCT.  Single 
dose nevirapine, which can dramatically reduce MVL during labor and delivery 34-36, 
reducing the risk of transmission to the newborn, in particular for intrapartum 
transmission.  However, some conflicting results have been reported 37.  MVL may also 
modify the effect of genetic factors on HIV MTCT 38; 39. 
1.5 Genetic Risk Factors for HIV MTCT 
 Because HIV is an infectious disease, traditional heritability or linkage studies to 
understand genetic risk factors disease susceptibility have not been thoroughly 
conducted, as has been done for many chronic diseases.  Furthermore, because HIV 
infection requires behavioral or environmental exposures such as sexual contact, 
intravenous drug use, or other means of contact with body fluids, understanding the 
genetic susceptibility to infection has not been at the forefront of HIV prevention efforts.  
This was changed in the mid 1990’s, through discoveries related to chemokines, 
chemokine receptors, and the risk of HIV infection or progression to AIDS.  Specifically, 
the chemokine receptor called CCR5 was identified as a key player in susceptibility to 
HIV infection.  With these findings, additional investigations into genetic factors of HIV 
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This section will describe genes and relevant biology that are associated with the 
risk of HIV MTCT.  The focus will be placed on a chemokine co-receptor gene (CCR5) 
and two Heparan Sulfate genes (HS3ST3A1 and HS3ST3B1) for their role in viral 
infection.  This discussion is directly related to the dissertation aims 2 and 3. 
1.5.1 Chemokines and Chemokine Receptors 
Chemokines are the largest family of cytokines or signaling molecules, which are 
proteins secreted by cells 40.  Chemokines induce directed chemotaxis from nearby cells 
40
.  Proinflammatory chemokines control chemotaxis for specific types of leukocytes 41 as 
part of an inflammatory immune response, for example, recruiting cells to the site of an 
infection.  Other types of chemokines are involved in the normal migration of cells, such 
as homeostatic chemokines 40.    
The three-dimensional structure of a chemokine can vary, depending on the 
spacing of two cysteine residues.   There are four structurallt specific types of 
chemokines: 1) CC chemokines (also known as β chemokines), which have two cysteine 
residues side by side; 2) CXC chemokines, which have two cysteine residues separated 
by one amino acid; 3) C chemokines, which have one cysteine at the N terminus and 
another downstream; and 4) CX3C chemokines, which have two cysteine residues 
separated by three amino acids 42.  The CC chemokines, RANTES, MIP (Macrophage 
Inflammatory Proteins) 1α, and 1β, are also referred to as CCL5, CCL3, and CCL4, 
respectively.  These chemokines are produced by CD8+ T cells and have been noted to 
suppress HIV-1 infection and progression to AIDS, as indicated by the observation of a 
lower risk of infection/progression to AIDS corresponding to higher concentrations of the 
CCL5, CCL3, and CCL4 ligands 43. 
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Understanding how these ligands suppress HIV infection and progression requires 
a description of key chemokine receptors.  Receptors for chemokines are located on the 
surface of leukocytes and there are multiple receptors for each family of chemokines.  
For example, there are eight known receptors for CC chemokines 41 and nineteen 
chemokine receptors described to date 44.   Of interest for HIV research is the chemokine 
(CC motif) receptor 5 (CCR5), a co-receptor of the CD4 receptor, used by macrophage-
tropic (R5) HIV-1 for cell entry.  CCR5 can bind to the CCL5, CCL3 and CCL4 ligands.  
These ligands can then compete with R5 strains of HIV for binding with the CCR5 
receptor, thereby preventing HIV from entering the cell and replicating 45-50.  Genes that 
regulate ligands for chemokine receptor genes are associated with the risk of HIV 
infection, including CCL2 (MCP-1) and CCL3L1 (MIP-1α).  These genes will not be 
discussed in great detail here but are briefly described in Table 1.1. 
1.5.2 CCR5 
An additional step forwards in the understanding of chemokines, chemokine 
receptors and HIV infection/progression to AIDS was that the CCR5 protein is 
genetically regulated by the CCR5 gene 50.  Studies of HIV-exposed but uninfected 
individuals revealed that resistance to infection was not completely explained by levels of 
CCL5 or other competing ligands for the CCR5 receptor.  Rather, a 32-basepair deletion 
in the open reading frame the CCR5 gene (CCR5 ∆32) was identified in these individuals, 
where homozygosity for the ∆32 mutation frame conferred almost complete resistance to 
infection by R5 strains 47-49; 51; 52.  The loss of receptor expression was a direct result of 
this mutation 53, as the 32-basepair deletion introduces as premature stop codon in the 
CCR5 chemokine receptor locus, abolishing receptor expression.  Single nucleotide 
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polymorphism (SNP)s have been observed within the promoter region of the CCR5 gene, 
and demonstrate variable associations with susceptibility to HIV transmission and/or 
disease progression 54-57 as well as decreased susceptibility to infection in vitro 58; 59.   
The associations between CCR5 and the risk of sexual transmission for HIV are not 
replicated for HIV MTCT.  A recent meta-analysis indicated that the CCR5∆32 mutation 
does not significantly change the susceptibility to maternal infection among infants 60.  
The rarity of the ∆32 mutation in African populations, where HIV MTCT is more 
common, may account for this lack of association.  However, other risk factors for HIV 
MTCT may also need to be addressed. One study found that MVL modified the 
association between CCR5∆32 and HIV MTCT 39.  Another study of promoter 
polymorphisms of CCR5 observed that CCR5-2459G (alternative names, Table 1.2) was 
associated with a reduced risk of HIV MTCT but only in the context of low MVL 38.  
These studies highlight the importance of accounting for key risk factors (i.e. MVL) in 
HIV MTCT when attempting to understand the genetic etiology.  
1.5.3 CXCR4 
Depending on the viral strain, HIV can also use the CXC chemokine receptor 4 
(CXCR4) as a co-receptor for CD4 for cell entry.  Typically, CXCR4 is used by T-cell 
trophic strains of HIV and the CCR5 co-receptor is used by macrophage (M)–trophic 
strains of HIV 61, although some variations of this model may exist.  Strains of HIV that 
use CCR5 as a co-receptor can be referred to a CCR5-using, R5-targetting, or R5 strains 
of HIV.  Similarly, strains that use CXCR4 as a co-receptor can be referred to as CXCR4-
using, X4-targetting, or X4 strains of HIV. 
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Like CCR5, CXCR4 binds to endogenous ligands which, when bound to the 
receptor, inhibit HIV-1 binding and cell entry 62; 63.  The natural ligand for CXCR4 is the 
stromal cell-derived factor 1 (SDF1) 64-66, genetically regulated by the gene, SDF1 (also 
called CXCL12).  Studies have identified a common GA transition at position 801 in 
the 3’ untranslated region of the β transcript of SDF1, to be associated with a reduced risk 
of HIV-1 infection 62; 63.  However, these findings could not be replicated in other studies 
which found an association between this variant and delayed HIV progression to AIDS 67; 
68
.  Whether this is a reflection of varying strains of HIV, genetic heterogeneity (when a 
phenotype can be caused by multiple genetic causal components), or pleiotropy (when 
multiple phenotypes can result from a single genetic variant) across study populations 
remains speculative. 
Although CXCR4-using HIV can be transmitted from mother to child, the majority 
of such transmission operates through the CCR5 co-receptor 69.  CCR2 64I has not 
demonstrated association with the risk of MTCT of HIV in studies of both African and 
non-African infants 70; 71. 
1.5.4 CCR2 
Another chemokine co-receptor gene variant associated with HIV progression to 
AIDS is the valine to isoleucine substitution at codon 64 in the chemokine co-receptor 2b 
gene (CCR2 V64I, alternative names, Table 1.2) whose natural ligand is CCL2 (MCP-1), 
which also binds to the CCR4 receptor.  The CCR2 gene demonstrates linkage 
disequilibrium with the CCR5 promoter region 72.  The CCR2 V64I polymorphism has 
been associated with delayed disease progression in adults but these findings have not 
been consistently replicated 72-75.  It is suggested that the CCR2 V64I  polymorphism may 
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inhibit HIV progression to AIDS by forming heterodimers with the CCR5 and CXCR4 
receptors, reducing receptor expression levels, and thereby preventing HIV from 
successfully infecting cells 76.   
Unlike the role for CCR2 V64I in disease progression, the CCR2 gene appears to 
play little to no role in susceptibility to infection.  For example, a study of female sex 
workers in Africa found no association between CCR2 variants and HIV infection 77, 
consistent with findings by others 73; 78.  In contrast to the CCR5 ∆32 mutation, CCR2 
V64I is most common among populations of African descent 72; 79; 80.  It is possible that 
the CCR2 gene does not individually influence HIV progression to AIDS, but rather acts 
in combination with other gene polymorphisms such as variants of CCR5, CXCR4, and 
possibly HLA (Human Leukocyte Antigen) gene variants 81 in promoting or preventing 
infection.  
1.5.5 CX3CR1 
The chemokine (C-X3-C motif) receptor 1 (CX3CR1) is part of a family of G-
coupled receptors, is a leukocyte chemotactic, and an adhesion receptor for its natural 
ligand fractalkine (CX3CL1) 82.  CX3CR1 and CX3CL1 play a role in the protection of 
hippocampal neurons from the neurotoxicity of HIV-1 envelope protein gp120.  
Nonsynonymous polymorphisms in the coding region of CXCL1 (V/I249 and T/M280) 
have been found to be associated with more rapid disease progression in adults 83 and 
immunological impairment 84.  Other variants have been associated with the risk of CNS 
impairment in children, independent of CD4+ lymphocytes, plasma HIV RNA load, 
CCR5-wt/∆32, CCR5-2459G/A, and CXC2CR1-T/M280 polymorphisms85.  The role for 
CXCR1 variants in the risk of HIV MTCT has not been established. 
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1.5.6 DCSIGN 
Dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN) and DI-SIGN-
related molecule (DC-SIGNR), are HIV-binding lectins 86.  DC-SIGN is also called 
CD209 molecule and DC-SIGNR, C-type lectin domain family 4, member M 
(CLEC4M).  Lectins are sugar-binding proteins sometimes used by pathogens for 
attachment to cells in the host during infection.  DC-SIGN is a C-type lectin (C-type 
lectins are a large family of Ca++ -dependent lectins) expressed on human dendritic cells 
and CD4+ macrophages in the placenta and in the lung 87., which efficiently bind to HIV-
1, HIV-2, and SIV 88.  Cells expressing these lectins are able to absorb the virus and 
contribute to a higher efficiency of HIV infection in other cell types.  The DC-SIGN gene 
regulates DC-SIGN, which when in cis with CD4 and a coreceptor, facilitates more 
efficient entry of HIV and SIV, an effect more notable when the CD4 or coreceptors are 
limited 89.  DC-SIGN has also allowed infection of cells via CD4 using an alternate 
coreceptor, STRL33, which is not usually an efficient mechanism of infection 90.  
Although less studied than other variants, researchers have demonstrated a more rapid 
progression to AIDS for the gene variant DC-SIGN -139C among Japanese hemophiliacs 
91
.   
It is likely that variants of DCSIGN play a role in the risk of MTCT of HIV.  High 
levels of DC-SIGN mRNA are present in the human placenta 88 and it has been shown 
that DC-SIGN is expressed on both maternal and fetal cells of myeloid lineage within the 
placenta, likely to be Hofbauer cells, which also express CCR5 and CXCR4 88.  However, 
the significance of these findings depends on the contact between Hofbauer cells and 
maternal virus, as DC-SIGN+ Hofbauer cells are separated from maternal blood by the 
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trophoblast layer.  If barrier breaches occur during pregnancy, cell-associated HIV 
infection could result between adult DC-SIGN+ decidual macrophages and fetal DC-
SIGN cells.  This cell-associated transmission mechanisms may explain why in utero 
transmission can occur despite low maternal viral load 88, and offers one possible 
explanation for why HIV MTCT is higher than expected in the context of antiretroviral 
treatment.  
1.5.7 HLA Class I 
The Human Leukocyte Antigen (HLA) system is the name for the major 
histocompatibility complex (MHC) in humans and includes many genes crucial for 
human immunity, including genes encoding cell-surface antigen-presenting proteins.  
There are two different classes of HLA specific to different mechanisms of antigen 
presentation.  Class I (HLA-A, B, and C) presents peptides (i.e. viral peptides) from 
inside the cell.  Class II (HLA-DR, DP, and DQ), presents antigens from outside the cell 
to T-lymphocytes.  A study employing genome wide association methodology identified 
HLA-B*5701 as well as a variant in HLA-C to be associated with HIV viral set point 92, 
which is the point at which HIV viral load stabilizes, following acute HIV infection.  
Another study of the risk of HIV infection found that men who were carriers of the HLA-
Bw4 variant were less likely to transmit HIV to their female partners 93.   
Other HLA variants have been noted to play a role in the risk of HIV MTCT, in 
particular when describing HLA variants in both the mother and the infant.  During 
pregnancy, the infant shares MHC genes with the mother and the mother tolerates the 
paternally derived fetal histocompatibility molecules 94.  HLA class I alleles play a role in 
HIV MTCT because they are involved in determining maternal-infant compatibility as 
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well as regulation of the CD8 T-cell surveillance of HIV-infected cells 95. In the mother, 
the virus has already been exposed to the maternal immune response defined in some 
ways by her HLA-I genes, allowing the fast replicating virus to evolve in vivo.  Maternal-
fetal polymorphism mismatches have demonstrated association with HIV MTCT, where 
mismatches between the mother and infant HLA variants are protective from 
transmission.  One study of maternal HLA-B alleles found that mothers with specific 
HLA-B variants (*1302, *3501, *3503, *4402, *5001) transmitted HIV to their infant 
even in the context of low viral loads whereas mothers with other variants (*4901, 
*5301) did not transmit the virus despite high viral loads 94.  The infant HLA-B genotypes 
in this study were not associated with HIV MTCT.  Another study found that discordant 
HLA-G variants between mother and infant for variants C3743T was associated with a 
decreased risk of HIV MTCT-1 compared to mother-child pairs concordant for this allele 
96
.  The same study also determined that dissimilarities in the variants C634G and 
714insG/G were associated with transmission 96. 
1.5.8 KIR-HLA Interactions 
Natural killer (NK) cells are another important part of the innate host immune 
response, acting as the first line of defense to infections through cytokine activation and 
cytotoxic activity 97; 98.  Regulation of NK cell activity is controlled by inhibitory and 
activating killer immunoglobulin-like receptors (KIR) 99.  These receptors are expressed 
on the cell surface in NK cells 100 as well as on a subset of T cells that recognize MHC 
class I molecules 101.  The receptors contains three external Ig-like domains (2D, 3D) that 
have long (2DL, 3DL) or short (2DS, 3DS) cytoplasmic tails.  These tails determine the 
inhibitory or activating functions of the receptors 102.  KIR contain activating or 
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inhibitory receptors that recognize ligands on cells that are potential targets for HIV 
infection 103.  The receptors are encoded by a family of genes (the KIR family) located on 
chromosome 19q13.4.  This region of DNA has undergone expansion and contraction 
over time, possibly from unequal crossing over 104, resulting in a diversity of KIR genes 
and gene variants. 
HLA class I act as ligands for KIR 105.  Both KIR and HLA are highly polymorphic 
and exhibit interlocus linkage disequilibrium 106, and both KIR and HLA ligands must be 
present for NK regulation 104; 107.  Interesting interactions between HLA-B and KIR gene 
variants have been observed, including an epistatic interaction between the variants 
KIR3DS1 and HLA-Bw4 alleles with an isoleucine at position 80 (HLA-B Bw4-80I or -
80Ile), associated with a protection from rapid progression to AIDS 104; 108.  HIV-infected 
cells expressing HLA-B Bw4-80Ile molecules bind specifically with KIR3DS1 and are 
therefore more prone to the resulting NK-cell activity, resulting in cell lysis and 
ultimately, a reduction in viral load 104.  A pleiotropic effect of the KIR3DS1/HLA-B 
Bw4-80I haplotype was found to be associated with a reduced risk of AIDS-defining 
illnesses (Kaposi’s sarcoma and AIDS lymphoma) and diseases caused by opportunistic 
infections (pneumocystic carnii pneumonia, cytomegalovirus retinitis, and 
mycobacterium avium complex), but not with AIDS-defining malignancies 108.  In the 
absence of KIR3DS1, the HLA-B Bw4-80I variant was not associated with the measured 
AIDS outcomes.  However, in the absence of HLA-B Bw4-80I, KIR3DS1 was associated 
with a more rapid progression to AIDS 104.   
The relationship between KIR-HLA interactions and the risk of HIV MTCT has not 
been thoroughly studied.  One study in 2004 found that among mothers with low viral 
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loads, the ability of the HLA-B molecule to bind and signal strongly through KIR3DL1 
was associated with a reduced risk of HIV MTCT 94.  However, replicating and relevant 
work is warranted. 
1.5.9 IL-4 
Interleukin-4 (IL-4) regulates CXCR4 and CCR5 coreceptors – increasing 
CXCR4 receptors but decreasing CCR5 receptors on CD4+ T-lymphocytes.  The IL4-
589C/T variant has been associated with increased rates of STI acquisition of HIV-1 
infected Japanese individuals 109.  However, one study of the association between this 
variant and the risk of HIV MTCT observed no significant association 110.   Other 
variants of IL-4 have not been investigated for association with HIV MTCT or with the 
risk of HIV infection through other mechanisms.  
1.5.10 MBL2 
The MBL2 gene encodes the mannose-binding lectin (MBL) protein, which plays 
a role in innate immune responses to infection 111-114.  MBL binds to mannose residues on 
bacteria, yeast, viruses, and parasites, which activates a sequence of events leading to 
opsonization of pathogens, chemotaxis, activation of leukocytes, and subsequent 
pathogen killing 115.  A variety of polymorphisms in the MBL2 gene result in MBL 
deficiency, which results in immunological impairment in children 85; 116; 117. It is also 
detrimental to children in the context of a weakened maternal immune system 111.  
Unsurprisingly, MBL deficiency has been associated with increased risk of HIV MTCT 
118
.
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1.5.11 APOBEC3G 
Apolipoprotein B mRNA Editing Catalytic Polypeptide 3g (APOBEC3G), also 
known as CEM15, is an endogenous inhibitor of HIV-1 replication 119.  It limits HIV 
propagation by packaging the virus during assembly.  During normal infection, 
APOBEC3G becomes incorporated in nascent viral particles, mediating deoxycytidine-
to-deoxyuridine deamination of the minus (first)-strand reverse transcripts in target cells 
85
.  This leads to guanine-to-adenine hypermutation of the viral plus (sense) coding strand 
and premature cDNA degradation and ultimately, antiviral activity of APOBEC3G. 
Functionally significant variants of the APOBEC3G gene can alter this antiviral 
activity and have been associated with disease progression.  This includes an Arg to His 
amino acid substitution at position 186 identified in African Americans, associated with a 
declined in CD4+ cells and more rapid progression to AIDS 120.  Other variants have been 
associated with a more rapid disease progression in children 85 but the association 
between APOBEC3G variants in the risk of HIV MTCT has not been established.   
Other variants not described that may be associated with the risk of HIV MTCT 
include IL-10, IL-6, IFN-γ, and TNF-α.  Current literature does not adequately explain a 
role for variants of these genes in the risk of HIV MTCT. 
 
  
19 
Table 1.1 Summary of genes/variants associated with HIV transmission and progression to AIDS 
Category Allele 
Study Design 
(Ethnicity/ 
Demography) Observations Reference 
CCR5 ∆32 In vitro CCR5/ccr5Delta32 heterodimerization as a molecular explanation for the delayed onset of AIDS in CCR5/ccr5Delta32 individuals Benkirane et al., 1997 
53
 
CCR5 Study of 
receptor In vitro CCR5 noted as a fusion cofactor for macrophage-tropic HIV-1 strains. Alkhatib et al., 1996 
45
 
CCR5 Study of 
receptor In vitro 
CCR5 and CCR3 receptors are able to support the early stages of HIV-1 
infection Choe et al., 1996 
46
 
CCR5 Study of 
receptor In vitro 
CCR5 is the principal cofactor for entry mediated by the envelope 
glycoproteins of primary macrophage-tropic strains of HIV-1. Deng et al., 1996 
47
 
CCR5 Study of 
receptor In vitro CCR5 serves as a cofactor for M-tropic HIV viruses Doranz et al., 1996 
48
 
CCR5 Study of 
receptor In vitro CCR5 is a second receptor for NSI primary viruses Dragic et al., 1996 
49
 
CCR5 ∆32 Cohort (Caucasians) 
∆32 heterozygous individuals experience partial resistance to HIV-1 
infection. Samson et al., 1996 
121
 
CCR5 ∆32 Cohort (Various) 
∆32 common in Caucasians, less common in other North American racial 
groups, and not detected in West Africans or Tamil Indians; ∆32 
heterozygous seroconvertors had a 52.6% lower risk of developing AIDS 
than homozygous wild-type seroconvertors 
Zimmerman et al., 1997  
52
 
CCR5 
59029A 
(2459A),59353
C (2135C) 
Cohort 
(Caucasians) 
Individuals lacking the CCR5 59029A/CCR5 59353C homozygous 
genotype likely to progress more slowly towards AIDS and/or death Clegg et al., 2000 
54
 
CCR5 59029A (2459A), 
Cohort 
(Caucasians) 
2459A/A individuals experience faster progression towards death 
compared to A/G individuals (P = 0.03), taking ∆32 and CCR2I into 
account 
Knudsen et al., 2001 55 
CCR5 
59353C 
(2135C), 
59356T 
(2132T), 
59402G 
(2086G), ∆32, 
CCR2-64I 
(Caucasians, 
African 
Americans, 
Hispanics) 
2132T common in African-Americans (20.6%) and rare in Caucasians 
(3.4%) and Hispanics (5.6%).  Homozygosity for CCR5-59356-T is 
strongly associated with an increased rate of perinatal HIV-1 
transmission. RR=5.9, 95% CI=2.3, 5.3). 
Kostrikis et al., 1999 56 
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Table 1.1, continued 
Category Allele 
Study Design 
(Ethnicity/ 
Demography) Observations Reference 
CCR5 
59029A 
(2459A), ∆32, 
CCR2-64I 
In vitro and 
Cohort 
(Various) 
In-vitro promoter activity for 59029-G was 45% lower compared to 
59029-A (p=0.05). Among HIV-1 seroconvertors lacking both CCR5 ∆32 
and CCR2-64I, 59029-G/G individuals progressed to AIDS on average 
3.8 years more slowly than 59029-A/A individuals (p=0.004). 
McDermott et al., 1998 57 
 
CCR5 
59029A 
(2459A), ∆32, 
CCR2-64I 
Case control 
(Caucasians) 
The -2459G allele significantly enriched in HIV exposed seronegative 
men with persistent high risk behavior compared to low-risk control men 
(P = 0.02). No protective influence of the CCR2-64I allele observed. The 
haplotypes CCR5 ORF delta32/CCR5 -2459A (in complete linkage 
disequilibrium) and CCR5 ORF wt/CCR5 -2459G had a cumulative 
negative effect on the expression of CCR5 on T-helper cells and are 
associated with resistance to sexual HIV-1 transmission. 
Hladik et al., 2005 58 
CCR5 ∆32 Meta-analysis Clarifies that perinatal infection is not significantly altered by heterozygosity for CCR5-Delta32 in the child. 
Contopoulos-Ioannidis et 
al., 2003 60 
CCR5 ∆32 
Case control 
(Various, from 
Europe) 
CCR5 delta32 heterozygosity exerts a protective effect against perinatal 
transmission in children exposed to a low maternal viral burden of an R5-
type isolate. 
Ometto et al., 2000 39 
CCR5 59029A (2459A) 
In vitro 
(Caucasian 
blood donors) 
CCR5 -2459 (A/G) promoter polymorphism determines CCR5 expression 
and predicts the magnitude of HIV-1 propagation in vitro, where higher 
propagation observed for A allele.  
Salkowitz et al., 2003 59 
CXCR4/ 
CXCL12 SDF-1 In vitro 
SDF-1 inhibited infection by T-tropic HIV-1 of HeLa-CD4 cells, CXCR-4 
transfectants, and peripheral blood mononuclear cells (PBMCs), but did 
not affect CCR-5-mediated infection by macrophage-tropic (M-tropic) 
and dual-tropic primary HIV-1. 
Bleul et al. 1996 62 
CXCR4/ 
CXCL12 
SDF-1, 
Y7A/Y12A, 
D193A, D262A, 
D97N 
In vitro 
Iidentification of CXCR4 residues involved in the interaction with both 
SDF-1 and HIV-1 may account for the signaling activity of gp120 and has 
implications for the development of antiviral compounds. 
Brelot et al., 2000 65 
CXCR4/ 
CXCL12 SDF-1 In vitro 
The ability of the SDF-1 analogs to block HIV-1 entry via CXCR4, which 
is a HIV-1 coreceptor for the virus in addition to being the receptor for 
SDF-1, correlated with their affinity for CXCR4. Activation of the 
receptor is not required for HIV-1 inhibition. 
Crump et al. 1997 66 
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Table 1.1, continued 
Category Allele 
Study Design 
(Ethnicity/ 
Demography) Observations Reference 
CXCR4/ 
CXCL12 SDF-1 
Cohort (African 
mother-infant 
pairs, Kenya) 
maternal heterozygous SDF1 genotype (SDF1 3'A/wt) is associated with 
perinatal transmission of HIV-1 (risk ratio [RR], 1.8; 95% confidence 
interval [CI], 1.0 to 3.3) and particularly postnatal breastmilk transmission 
(RR, 3.1; 95% CI, 1.1 to 8.6). In contrast, the infant SDF1 genotype had 
no effect on mother-to-infant transmission 
John et al. 2000 122 
 
CXCR4/ 
CXCL12 
SDF-1-3'A, 
CCR2-64I,  
Case control 
(Polish) 
No significant association between SDF-1-3'A allelic frequency an HIV-1 
infection (allele frequency of 15.3% (HIV-) vs. 16.5% (HIV+),  p = 0.77).  Wasik et al. 
123
 
CXCR4/ 
CXCL12 SDF1-3'A 
Combined 
Cohorts 
(Caucasian) 
SDF1-3'A/3'A associated with delayed progression to AIDS, more 
pronounced effects than CCR5 and CCR2 chemokine receptor variants in 
this study population. 
Winker et al. 1998 67 
CXCR4/ 
CXCL12 64I 
Cohort 
(Caucasians) 
SDF1-3'A/3'A genotype associated with slower progression to AIDS, but  
overshadowed by the protective effects of CCR5 ∆32. Hendel et al. 1998 
124
 
CXCR4/ 
CXCL12 64I 
Cohort 
(Various) 
SDF1-3'-A/A variant was associated with more-rapid disease progression 
but present in less than 2% of study population. Singh et al., 2003 
125
 
CCR2 64I 
Cohort (African 
women,  Cote 
d'Ivoire) 
No association between 64I mutation and HIV-1 plasma viral load or 
markers of immune activation; no association with risk of HIV infection. Adje et al. 2001 
77
 
CCR2 64I Cohort (African 
women, Kenya) 64I allele associated with delayed progression to AIDS in African women. Anzala et al. 1998 
73
 
CCR2 64I Cohort (Danish 
men) 
No association between 64I allele on development to AIDS, overall 
survival, and annual CD4 T-cell decline. 
Eugen-Olsen et al. 1998 
126
 
CCR2 64I 
Chicago 
Multicenter 
AIDS Cohort 
(Various) 
V64I is protective against disease progression and in complete linkage 
disequilibrium with a point mutation in the CCR5 regulatory region. Kostrikis et al. 1998 
72
 
CCR2 64I 
Cohort 
(Caucasians, 
Amsterdam) 
No association between CCR5 delta32/+ and CCR2b 64I/+ and risk of 
HIV progression among injecting drug users Schinkel et al. 1999 
75
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Table 1.1, continued 
Category Allele 
Study Design 
(Ethnicity/ 
Demography) Observations Reference 
CCR2 64I 
Case control 
(African 
mother-infant 
pairs, Malawi) 
No association with the risk of mother-to-child transmission of HIV Pedersen et al., 2007  
 
CCR2 64I 
Cohort (African 
and non-
African) 
CCR2B-64I not associated with the risk of mother-to-child transmission 
of HIV or progression to disease, regardless of ethnicity.  Teglas et al, 1999 
71
 
CX3CR1 249I, 280T/M 
Retrospective 
study 
(Caucasians) 
No association between CX3CR1 SNPs and time to virological success or 
time to virological/immunological failure (P > 0.1). Trend of earlier 
immunological failure in individuals with the CX3CR1 249I 
polymorphism (P = 0.02), and after adjusting for baseline age, sex, pVL, 
CD4 cell count, type of therapy, and adherence ( P < or = 0.05).  
Brumme et al. 2003 84 
CX3CR1 CX3CR1-I249 M280 
Cohort 
(Caucasians) 
CX3CR1-I249 M280 homozygotes associated with more rapid 
progression to AIDS. Faure et al. 2000 
83
 
CX3CR1 V/I249 and T/M280 
Collection of 
cohorts 
(Various) 
V249-T280 haplotype associated with  less disease progression (RH, 0.42 
[95% CI, 0.24-0.73]; P=.002) and central nervous system impairment 
(RH, 0.39 [95% CI, 0.39-0.22]; P=.001). 
Singh et al. 2005 82 
DC-SIGN 139C 
Case control 
(Japanese 
hemophiliacs) 
DC-SIGN promoter -139C associated with faster progression to AIDS (p 
= 0.040, OR=1.95, 95% CI=1.039, 3.677) Koizumi et al., 2007 
91
 
DC-SIGN DC-SIGN 
expression In vitro 
Expression of DC-SIGN on target cells enhanced viral infection and is 
coexpressed and colocalized with CD4 and CCR5 on alveolar 
macrophages. 
Lee et al., 2001 89 
DC-SIGN DC-SIGN 
expression In vitro 
Placental expression of DC-SIGN on a variety of cells targeted by HIV 
for infection, including Hofbauer cells which co-express CD4, CCR5, and 
CXCR4.  
Soilleux et al., 2001 88 
DC-SIGN DC-SIGN 
expression In vitro 
DC-SIGN can be up-regulated on monocyte-derived macrophages upon 
exposure to the Th2 cytokine, IL-13. Soilleux et al., 2002 
87
 
DC-SIGN DC-SIGN 
expression In vitro 
DC-SIGN is coexpressed with CD4 and CCR5 on dendritic 
cells/macrophages in human foreskin Soilleux et al., 2004 
127
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Table 1.1, continued 
Category Allele 
Study Design 
(Ethnicity/ 
Demography) Observations Reference 
HLA Class I Bw4, Bw6 Cohort (Various) 
HLA-Bw4 vs. Bw6 associated with decreased risk of heterosexual HIV-1 
transmission. 
Welzel et al., 2007 93 
 
HLA Class I 
HLA-B*5701 in 
LD with HCP5-
rs2395029, 
HLA-C 
rs9264942 
Collection of 
cohorts, 
genome wide 
association 
study (Various) 
HLA-B and –C variants associated with viral set point. Fellay et al. 2007 92 
HLA Class I 
HLA-B*1302, 
B*3501, 
B*3503, 
B*4402, or 
B*5001 
Cohort 
(Various) 
HLA-B*1302, B*3501, B*3503, B*4402, and B*5001 associated with 
higher risk of mother-to-child transmission of HIV, despite low viral load.  
B*4901 and B*5301 associated with lower risk of transmission despite 
high viral load (P=0.003). 
Winchester et al., 2004 94 
HLA Class I 
HLA-G 
T3742A, 
C3743T, 
G3777C, 
C634G, 714 
insT/G 
Nested case 
control 
(primarily 
African 
American and 
Hispanic) 
T3742A, C3743T, G3777C associated with HI V HIV MTCT (P = 0.001). 
C3743T allele associated with decreased risk of HIV MTCT (OR=0.02, 
95% CI= 0.00-0.15, P = 0.00001). C634G and 714 insT/G associated with 
lower risk of transmission compared to C634C, 714insG/G. 
Aikhionbare et al., 2006 96 
KIR-HLA  Bw4-80Ile 
Collection of 
cohorts 
(Various) 
KIR3DS1+HLA-B Bw4-80Ile associated with delayed progression to 
AIDS.  HLA-B Bw4-80Ile alone not associated with any AIDS outcomes.  
KIR3DS1 alone associated with more rapid progression to AIDS. 
Suggests epistatic interaction between the two loci.  
Martin et al., 2002 104 
KIR-HLA Bw4-80Ile 
Collection of 
cohorts 
(Various) 
KIR3DS1/HLA-B Bw4-80I confers slower progression to AIDS 
containment of HIV viral load, and defense against opportunistic 
infections, but not AIDS-related malignancies. 
Qi et al. 2006 108 
CCL3L1 
(MIP-1α) Copy number 
Collection of 
cohorts 
(Various) 
Higher number of copies of CCL3L1 associated with reduced 
susceptibility to HIV infection. Gonzalez et al. 2005 
128
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Table 1.1, continued  
Category Allele 
Study Design 
(Ethnicity/ 
Demography) Observations Reference 
CCL3L1 
(MIP-1α) Copy number 
Nested case 
control (African 
mother-infant 
pairs, South 
Africa) 
Higher numbers of infant, but not maternal, CCL3L1 gene copies were 
associated with reduced HIV transmission (P = 0.004) overall, but the 
association was attenuated if mothers took single-dose nevirapine or if the 
maternal viral load was low. 
Kuhn et al. 2007 129 
 
CCL2 
(MCP-1) 
MCP-1-2136T, -
1385A 
Collection of 
cohorts 
(Caucasians) 
Three SNPs (-2136T located in the MCP-1 promoter region, 767G in 
intron 1 of MCP-1, and -1385A in the Eotaxin promoter) associated with 
reduced risk of HIV infection (OR=0.6; P = 0.005-0.01) despite high risk  
Modi et al., 2003 130 
CCL2 
(MCP-1) 2518GG 
Cohort 
(Spanish) 
Homozygosity for the variant CCL2-2518GG genotype is overrepresented 
in HIV-1- infected subjects. Vilades et al. 2006 
131
 
MBL2 “Allele 0” 
Cohort 
(Brazilians of 
Various 
ancestry) 
MBL2 allele (allele 0) associated with higher risk of HIV-1 infection in 
perinatally exposed children and more rapid progression to death. Boniotto et al., 2003 
132
 
MBL2 -550, -328  
Case control 
(Italian 
children) 
A polymorphism at position -550 in the promoter region and 6 bp deletion 
at position -328 associated with risk of perinatal infection. Boniotto et al., 2000 
118
 
MBL2 Various Review Multiple phenotypic outcomes from MBL genetic variants. Garred et al., 2006 133 
APOBEC3G 
(CEM15) H186R 
Cohort (African 
Americans) 
Arg to His amino acid substitution at position 186 associated with decline 
in CD4+ cells and more rapid progression to AIDS. Sheehy et al. 2003 
120
 
APOBEC3G 
(CEM15) H186R, F119F 
Cohort 
(Unpublished) 
H186R associated with more rapid HIV progression, F119F associated 
with moderate protection against HIV disease progression. 
Referenced in  
Singh et al., 2009 85 
IL-4 -589CT 
Cohort 
(Caucasians, 
France) 
IL-4-589T associated with protection from HIV-1 disease progression by 
reducing viral load. Nakayama et al. 2002 
109
 
IL-4 -589CT Cohort (Various) 
Lack of protective effects of IL-4-589T against HIV-1 disease progression 
and CNS impairment in children.  Singh et al., 2004
110
 
†
 This table and background section highlights key findings and is not intended to represent a comprehensive literature review. 
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Table 1.2 CCR2/CCR5 variants and alternative names 
Commonly used 
NCBI Ref 
Sequence # 
Genbank  
U95626 # 
Mummidi et al. 1997 
134
,Genbank  AF031236, 
AF031237 # 
CCR2-64VI rs1799864 46295  
CCR5-2733AG rs2856758 58755 29 
CCR5-2554GT rs2734648 58934 208 
CCR5-2459AG rs1799987 59029 303 
CCR5-2135CT rs1799988 59353 627 
CCR5-2132CT  59356 630 
CCR5-2086AG rs1800023 59402 676 
CCR5-1835CT  59653 927 
CCR5-∆32  62036  
 
 
1.6 Syndecans 
Syndecans are transmembrane domain proteins that act as coreceptors, in particular 
for G-coupled receptors.  The core proteins attach to heparan sulfate and chondroitin 
sulfate, which can interact with a variety of ligands.  The combination of a syndecan 
protein with an attached heparan sulfate or chondroitin sulfate polysaccharide chain is 
referred to as a proteoglycan. 
Specific syndecans are genetically encoded by genes in the syndecan proteoglycan 
family and include SDC-1, 2, 3, and 4.  Research related to whether and how the HIV-1 
virus binds to syndecans is recent and growing.  One study demonstrated that a conserved 
area of the V3 region of gp120 is involved in HIV-1 binding to syndecans and that this 
binding specifically utilizes the 6-O-sulfated form of heparan sulfate 135.  Another in vitro 
study demonstrated that both cell-associated chondroitin sulfate proteoglycans and 
heparan sulfate proteoglycans facilitate infective entry of HIV-1 into human brain 
microvascular endothelial cells 136.  Yet another in vitro study demonstrated that HIV-1 
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exploits both syndecans and chemokine receptors to facilitate cell-free transport through 
the genital epithelium 137.   
Syndecans-3 (SDC-3) stablizes captured HIV virus, enhancing dendritic cell (DC) 
infection in cis, and facilitating transmission to cells 138.  The use of heparinase III to 
silence syndecans-3 using siRNA was found to partially impaired HIV-1 transmission to 
immature DCs.  Additional silencing of DC-SIGN completely abrogated HIV-1 
transmission 139.  Evidence for an interaction between chemokine receptors and 
syndecans includes the finding that a syndecans-4 (SDC-4)/CXCR4 complex binds with 
SDF-1 140.  SDF-1 is the natural ligand for CXCR4 which can inhibit X4-using HIV 
infection.  Furthermore, syndecans-2 (SDC-2) has been noted to play a role in hepatitis C 
viral entry 141.  To date, no associations between syndecans and HIV MTCT or between 
variants of syndecan genes and HIV MTCT have been reported. 
1.7 Heparan Sulfate and Viral Infection 
Understanding the role of proteoglycans and viral infection allows us to speculate 
what associations may exist for HIV MTCT.  However, the structural specificity of 
heparan sulfate has not been thoroughly investigated for association with HIV infection 
or disease progression.  This section aims to define heparan sulfate, why it is an 
important component of our study and to place it into context for studying the genetics of 
HIV MTCT. 
1.7.1 Heparan Sulfate Structure and Function 
Heparan sulfate (HS) is a highly sulfated polysaccharide in the form of a 
proteoglycan, made up of glucosamine and glucuronic/iduronic acid repeating 
disaccharide units.   HS is ubiquitous in animals 142 and located on the surface of 
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endothelial and surrounding tissues 143.  HS is involved in many processes, including fetal 
development 142; 144, blood coagulation, inflammation, and cell differentiation 143.  An 
analog of HS, heparin, is a commonly used anticoagulant drug 143.   
HS proteoglycan biosynthesis consists of three stages: 1) the formation of a primed 
protein core, 2) the assembly on the primed protein of a non-sulfated polysaccharide, and 
3) the modification of the polysaccharide by the addition of sulfate groups and 
epimerization of some glucuronosyl units 142. Of interest for this project is the third 
process, where significant modification of the HS structure takes place.   
HS biosynthetic enzymes are genetically regulated by multiple genes across 
different chromosomes.  This includes, but is not limited to, the genes HS (glucosamine) 
3-O-sulfotransferase 3A1 (HS3ST3A1), HS (glucosamine) 3-O-sulfotransferase 4 
(HS3ST4), HS 6-O-sulfotransferase 1 (HS6ST1), and HS proteoglycan 2 (HSPG2).  
HS3ST3A1 codes for a rate-limiting enzyme (3-OST-3) that converts nonanticoagulant 
HS to anticoagulant HS, acting as a D-glucosaminyl 3-O-sulfotransferase 145; 146.  More 
specifically, the 3-OST-3 enzyme transfers sulfate to the 3-OH position of a glucosamine 
unit (GlcNH2±6S) that is linked to a 2-O-sulfo iduronic acid unit (IdoUA2S).  The result 
of this transfer is the formation of the 3-O-sulfated HS containing IdoUA2S-
GlcNH23S±6S 147 (Figure 1.1).  The specific functions of HS are determined by the 
unique sulfated saccharide structure, which vary by tissue, making HS function likely to 
be tissue-specific.  HS genes are also variably expressed by tissue type.  For example 
HS3ST3A1 is most expressed in the liver and placenta 138.  The application of tissue-
specific HS structure and corresponding gene expression to HIV research have not been 
thoroughly investigated.  
 28 
 
Figure 1.1 Biosynthesis and modification of Heparan Sulfate† 
 
 
 
 
 
 
3-O-sulfated Heparan Sulfate: 
† 148 
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1.7.2 Heparan Sulfate and HSV 
The 3-O-sulfated glucosamine is a rare form of HS and displays critical binding for 
antithrombin 149, growth factor reception 150, and fibroblast growth factor 151.   A clear 
example of HS structural  specificity and susceptibility to viral infection has been 
demonstrated for herpes virus type 1 (HSV-1) infection 152.  HS is typically located on the 
cell surface and in the extracellular matrix, where cell interactions with virus occur 143.  
For HSV-1 and HSV-2, the virus binds to cells through interactions of specific envelope 
glycoproteins (gB and gC) and cell surface HS 152.  After viral binding to the cell surface, 
HS then interacts with the glycoprotein gD for viral entry by fusion of the virion 
envelope with a cell membrane 152.  This also involves other glycoproteins, gB, gH, and 
gL 152.  Receptors used by gD include TNFRSF14, a member of the TNF receptor family 
and two members of immunoglobulin superfamily related to the poliovirus receptors 152-
155
.  In addition to these receptors, a different kind of gD receptor has been identified, the 
specific 3-O-sulfated form of HS. This receptor has demonstrated site-specific binding to 
gD and is used by HSV-1 for cell entry 152; 156.  This was shown in vitro using Chinese 
hamster ovary (CHO) cells starting with wild-type CHO cells resistant to HSV-1 entry 
157
.  Transfection with plasmids with 3-OST enzymes, expected to produce 3-O-sulfated 
HS, revealed that plasmids expressing 3-OST-3s became susceptible to HSV-1 entry 152.  
Knowing that HSV-1 entry correlated with 3-OST-3 enzymatic activity, it was 
demonstrated that entry activity depended on the presence of cell surface HS that could 
be modified by 3-OST-3, by investigating mutant cell lines defective of different steps in 
the assembly and modification of HS 152.  The specific 3-O-sulfated form of HS 
correlated to the 3-OST-3 enzyme activity and this form of HS was associated with 
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susceptibility to HSV-1 infection 152.  These studies were ground breaking for 
understanding the role of HS structure specificity and viral infection. 
1.7.3 Heparan Sulfate and HIV 
HS proteoglycans have also been found to be involved in HIV-1 gp120 attachment 
to specific human host cells for binding and infection.  One study found that a CD4 
receptor epitope is targeted by size-defined HS-derived oligosaccharides, playing a role 
in HIV virus-cell attachment.  Overall, these findings indicated that HS targets the HIV-1 
envelope glycoprotein gp120 coreceptor binding site, possibly aiding late stage virus-cell 
attachment 158.  A study of HIV MTCT found similar results, where HS was used by 
HIV-1 to bind to and infect trophoblasts, cells lining the placental tissue barrier 22.   
No studies to date have specifically studied the 3-O-sulfated form of HS or the 3-
OST-3 enzyme in relation to HIV infection in general or specifically for HIV MTCT.  
And although 3-OST-3 enzymes, responsible for production of 3-O-sulfated HS, are 
genetically regulated, no studies of the genetics of HS and HIV infection have been 
conducted.  It is plausible that a polymorphism disrupting gene expression could reduce 
enzymatic activity and subsequent production of structure-specific HS.  This could be 
detected through a genetic association between the variant and the risk of HIV infection.  
The effect of altered gene expression could be most relevant in tissues with high gene 
expression (i.e. placenta and liver for H3ST3A1).  
1.8 Drug Developments related to CD4 co-receptor research 
The examination of chemokines and of the receptors for chemokines used by HIV 
led to the design of chemokine-derived antagonists to be used for HIV therapeutic 
regimens 41.  A variety of studies have developed antagonists for the CD4 coreceptors 
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CCR5 and/or CXCR4, typically characterized as small molecules that bind to the receptor 
or a part of the receptor in order to prevent binding of the HIV-1 glycoprotein gp120. 
Such antagonists include but are not limited to AMD3100, acting as a CXCR4 antagonist 
that also blocks dual-tropic viruses (both R5 and X4 strains) 159, and the small molecule 
inhibitor, ALX40-4C, which inhibits HIV-1 envelope (Env)-mediated membrane fusion 
and viral entry for the CXCR4 but not the CCR5 co-receptors 61.  It has also been 
demonstrated that anti-CCR5 mAb can efficiently prevent HIV-1 infection by inducing 
receptor dimerization 76.  Chemokine receptor antagonists corresponded to a reduction in 
HIV infection and/or disease progression in some but not all studies 160-163, presented 
some undesirable side effects 164, and overall, were not as successful as anticipated 165.  A 
current drug now Food and Drug Administration (FDA) approved for use in the U.S. is 
the CCR5 antagonist Maraviroc 166 which thus far is effective, although expensive and 
not to be used by HIV-positive pregnant women to prevent transmission to their infants. 
1.9 Methodological Considerations for Genetic Epidemiology 
There are many statistical issues that must be understood in order to conduct an 
appropriate genetic epidemiology investigation with adequate external generalizability.  
Some of these issues are described in this section. It is important to understand the 
different strategies used in genetic epidemiology research: 1) Linkage analysis and 
heritability studies, 2) Candidate gene studies, and 3) Genome wide association studies.  
Each design has its strengths and weaknesses and each may be more or less appropriate 
for HIV research compared to common chronic diseases.
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1.9.1 Linkage Analysis 
Genetic linkage occurs when genetic loci or alleles are jointly inherited.  If loci 
are close in location they are more likely to be linked and transmitted together during 
meiosis.  Linkage analysis is typically conducted when data is available on various 
markers in family studies.  It operates on three key principles: 1) that genes on different 
chromosomes segregate independently, indicating no linkage between them, 2) that the 
probability of recombination between two loci on the same chromosome increases with 
increasing physical distance between the loci, eventually reaching a value of 1/2, and 3) 
that if a marker is found to have low recombination rate with a disease gene, the disease 
gene must be close to that marker 167.  These principles are applied to identify markers 
genotyped in families that are linked or close in location to true disease locus or loci.  
Statistical details of linkage analysis are beyond the scope of this project and will not be 
discussed. 
Linkage analysis works well for identifying rare genetic variants with high 
penetrance and has helped identify variants associated with cancer, cardiovascular 
disease, and other inherited and common disorders.  It can be very informative when 
applied to large families or a collection of sibling pairs (often called sib-pair analysis).  
However, if data on only a few families are obtained or missing family members exist in 
the dataset, the study may not have power to identify genetic loci.  Furthermore, linkage 
analysis typically identifies a broad region of a chromosome and additional fine mapping 
is required to identify the specific genetic variants influencing disease.   
Susceptibility to infectious disease is not commonly viewed as an inherited 
disorder, but rather an indicator of behavioral or environmental risk factors. Thus, linkage 
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analysis studies have not been performed to investigate susceptibility to HIV MTCT, 
with the exception of transmission disequilibrium test (TDT) if genetic information on 
both the mother and infant are available. 
1.9.2 Candidate Gene Studies 
One way to follow-up on key findings from linkage analysis is to conduct a 
candidate gene study.  For example, linkage analysis may identify a region on a 
chromosome where a disease gene or genes may lie.  A closer look at this region may 
identify genes that have biological properties in line with disease etiology.  An 
investigator can then select “candidate” genes based on their biological properties, 
location within the region of interest, or for other reasons, and genotype specific SNPs or 
other variations within or nearby such genes.  One can then determine whether such 
variations are distributed equally between individuals with the disease (cases) compared 
to individuals without the disease (controls).  The gene CCR5 is a good example of a 
candidate gene for studies of HIV infectivity and progression to AIDS.  However, as 
described previously, the selection for this candidate gene was not based on linkage 
analyses, but rather, on in vitro understanding of the co-receptor’s role in HIV infection.   
Although candidate gene studies offer more specific information about a region of 
interest and disease susceptibility, they can be limited by issues such as genetic 
heterogeneity, linkage disequilibrium, population stratification, and/or knowledge of the 
gene function (discussed below).  
1.9.3 Genome Wide Association Studies 
Genome wide association studies (GWAS) is an approach for gene discovery that 
can be used for both chronic and infectious disease gene finding.  GWA was made 
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possible with advances in genotyping technology and statistical genetics.  It involves 
large scale genotyping, i.e., over 1 million SNPs genotyped across the genome of each 
individual study participant, in a case-control association design which compares 
genotypes in each SNP between cases and controls.  SNPs can be selected based on low p 
value using models such as a general association test (Chi-Square), logistic regression, or 
another type of analysis.   
 Unlike candidate gene studies, GWAS search thousands to millions of SNPs 
across the genome, but are not a hypothesis-generating tool.  Limitations are the multiple 
testing (which can be corrected using the Bonferroni or other methods) and requirements 
for a larger sample sizes than are required for candidate gene studies.  It has incorporated 
extensive international projects such as the Hap Map Project 168 and has been enhanced 
by advancements in genotyping and statistical analysis tools.    
 A variety of genotyping platforms have been developed, including BeadChips 
genotyping 500,000 to up to 1 million SNPs by the Illumina and Affymetrix companies. 
One platform is Illumina’s HumanHap BeadChip 169, which provides data on thousands 
to over a million SNPs across an individual genome.  Through cooperation of the 
HapMap Project 168 BeadChips can be ordered specific for a population or ethnic group 
of interest.  For populations of African descent, the HumanHap 650Y BeadChip can be 
used, which selects over 650,000 tagSNPs based on data from the Nigerian Yoruban 
HapMap Population.    
 Although there is evidence for infant genetic susceptibility to maternal HIV 
transmission, to our knowledge, a genome-wide analysis of this phenotype has not been 
published.  It is essential that the applications of this genomic revolution apply to all 
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populations and all diseases, including the HIV MTCT in populations most afflicted by 
the disease. 
1.9.4 Linkage Disequilibrium 
 Correlation between variants or polymorphisms is known as linkage 
disequilibrium (LD).  Variants in LD can serve as proxy to another variant with a causal 
role.  LD is strongest between SNPs close in physical location on a chromosome, and the 
correlation typically decays with increasing physical distance between loci.  With regards 
to genetic epidemiology methodology, it is always important to measure and report LD, 
in particular for GWA studies. 
 
1.9.5 Genetic Heterogeneity 
 The variability of findings for genes or SNPs associated with an outcome can 
often be attributed to genetic heterogeneity, which occurs when a particular phenotype 
(i.e. disease) is caused by more than one gene 170.  In addition, allelic heterogeneity 
occurs when more than one allele at a specific gene locus causes the same phenotype 170.  
Both of these types of heterogeneity may explain the lack of generalizability for some 
candidate gene studies, as the allele frequencies may vary by study population ancestry 
and admixture.  For example, variable findings for the association between CCR2 64I and 
HIV transmission or progression to AIDS were reported from  a study in London 74, to a 
study in Denmark 126, a study in Kenya 73, and a study among African Americans in the 
United States 72.  Because allele frequencies for CCR5 and CCR2 SNPs may be different 
in frequency by geographic region and corresponding ethnic group 171-174, the inconsistent 
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findings may be an artifact of the allelic variation, and make identification of the true 
deleterious variant(s) more difficult. 
 Another study in South Africa demonstrated that the allele frequencies of the 
CCR5 variants found to be protective for HIV infection and progression to AIDS were 
less common in the South African Black population relative to Caucasians.  The opposite 
was observed for  CCR2-64I  (higher frequency) 80, thus limiting the ability to compare 
genetics findings across ethnic or geographic groups.  However, understanding genetic 
heterogeneity may help to cater interventions to specific populations. 
1.9.6 Population Stratification 
 Similar to genetic heterogeneity, where allele frequencies may vary by study 
population, allele frequencies may also vary in subgroups within a study population.  
This phenomenon is known as population stratification or population substructure, and 
often is a consequence of admixture or the presence of subgroups of individuals with 
unique ancestries.  Population stratification is a confounder in the association between 
genotypes and the phenotype, and needs to be properly accounted for in the analysis.  
Statistical methods can be used to determine if population substructure is present.  To 
correct for population stratification one can use principal components analysis (PCA), or 
model-based clustering.  PCA, related to factor analysis, transforms a number of 
correlated variables into a smaller subset of uncorrelated variables. PCA can be applied to 
genetic data in order to infer continuous axes of genetic variation, as is done by the 
software program EIGENSTRAT 175.  Then genotype data can then be continuously 
adjusted by amounts attributable to ancestry, thereby removing ancestry correlations 175.  
Another method to adjust for population stratification is to use model-based clustering 
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which can be implemented using the software program STRUCTURE 176.  This method 
uses multilocus genotype data to infer population substructure and assign individuals to 
populations, which each population is characterized by a range of allele frequencies at 
specific loci 176.  This method can be useful for studying admixture and to determine 
whether or not one should stratify data by sub-populations. 
1.10 Background Summary 
 Several genetic variants have been associated with HIV MTCT, including but not 
limited to variants of CCR5, CXCR4, CCR2, CX3CR1, DCSIGN, HLA Class I, KIR-HLA 
interactions, IL-4, MBL2, and APOBEC3G.  This is likely just the beginning of our 
understanding of the genetics of HIV MTCT.  A more comprehensive genomic approach 
is necessary in order to identify novel genes/SNPs.  As technology advances, future 
research may incorporate multiples of millions rather than thousands to 1 million SNPs or 
sequence data, increasing the need for larger sample size and enhanced computational 
resources.  In order to obtain a more comprehensive understanding of infant genetic 
susceptibility to maternal HIV infection, it will be pertinent to follow-up variant-disease 
associations with investigations at the gene expression and protein level of the human 
system.  This dissertation addresses the genotypic and gene expression levels, with the 
goal of stimulating additional and related research, and ultimately, pharmaceutical 
advancements to protect infants from infection. 
CHAPTER 2 SPECIFIC AIMS 
2.1 Summary 
 The overall hypothesis for this proposal is as follows: There are variations in 
the human genome that differentially predict individual susceptibility to Mother-
To-Child Transmission of HIV (HIV MTCT).  This hypothesis is tested with a genome 
wide association study followed by placental gene expression studies.  This chapter lists 
each specific aim, the corresponding overview, and rationale for each one. 
2.2 Specific Aim 1.  Identify variants associated with HIV MTCT using a genome 
wide approach for association in mother-infant pairs from Malawi. 
2.2.1 Overview 
 The Malaria and HIV in Pregnancy (MHP) cohort study was conducted in 
Blantyre, Malawi, between 2000 and 2004.  The goals of MHP included a clearer 
description of the interaction between malaria during pregnancy and HIV MTCT and to 
better understand the mechanisms of HIV MTCT in general.  In order to study human 
genetic susceptibility to HIV MTCT, we obtained DNA samples from infants at birth and 
at 6 and 12 weeks post delivery.  For this aim, we selected samples from infants of HIV 
positive mothers who delivered at Queen Elizabeth Hospital in Blantyre. 
 To determine the association between infant genomic variants and the risk of HIV 
MTCT, over 650,000 SNPs dispersed across infant genomes were genotyped using the 
Illumina HumanHap 650Y BeadChip.  Infants of HIV(+) mothers were designated as 
cases (HIV transmission occurred) or controls (HIV transmission did not occur), 
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depending on their HIV status measured through follow-up.  HIV transmission events 
were classified as occurring during pregnancy (intrauterine transmission, IU), during 
labor (intrapartum transmission, IP), or through breastfeeding (postpartum transmission, 
PP).  This aim focuses on an African population in Malawi, and results may generalize to 
other populations in Africa and to populations throughout the world. 
2.2.2 Rationale 
 In this Malawian study population, nevirapine was administered to both HIV 
positive mothers during labor and to their infants following delivery.  However, the rate 
of transmission was much higher than expected.  Such rates indicate the need for more 
adequate treatment in an African setting but also suggest that some infants may have 
varying susceptibility to infection and/or drug resistance.   Because the mechanisms of 
HIV MTCT are not yet clearly elucidated, a more comprehensive description of infant 
genetic susceptibility to HIV MTCT is warranted, particularly in African populations 
where the burden of HIV is high.  Understanding an infant’s genomic profile in the 
context of treatment and HIV exposure is essential in order to broaden the current view of 
the mechanisms of HIV MTCT.  This specific aim will serve to identify novel variants 
associated with HIV MTCT, for use in future studies.   
2.3 Specific Aim 2.  Quantify placental expression of the gene HS3ST3A1 and 
evaluate the association between expression and the risk of HIV MTCT 
2.3.1 Overview 
 Preliminary GWA work from specific aim 1 identified a SNP, rs8069770, intronic 
to the gene, heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 (HS3ST3A1) (Odds 
Ratio=0.27, p=0.0000379).  Although the rs8069770 GA transition has no known 
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alteration of HS3ST3A1 expression, it may serve as a marker for another variant that 
alters gene expression, with ultimate significance at the functional level.  Substantial 
functional information for HS3ST3A1 is known, specifically in relation to blood 
coagulation and viral entry.  HS3ST3A1 codes for an enzyme, heparan sulfate 
glucosamine 3-O-sulfotransferase 3A (3-OST-3) whose activity is 3-O-sulfation of 
glucosamine in restricted domains, leading to the 3-O-sulfated form of heparan sulfate 
(HS) 177.  HS is a polysaccharide in the form of a proteoglycan, located close to the cell 
surface or extracellular matrix proteins, and involved in the regulation of many biological 
activities, including developmental processes 142; 144.  The goal of this aim will be to 
quantify HS3ST3A1 in placental tissue of mother-infant pairs of variable HIV status and 
determine how this expression associates with the risk of HIV MTCT. 
2.3.2 Rationale 
 The 3-O-sulfated form of HS is used by herpes simplex virus 1 (HSV-1) 
glycoprotein gD for viral entry 147; 178.  Studies have also demonstrated a role of HS in the 
attachment of gp120 of HIV-1 for to cell entry 22; 158, and the use of HS by HIV-1 for 
infection of trophoblasts, cells lining the maternal-fetal placental barrier 22.  A more 
thorough investigation of the role of HS3ST3A1 expression in placental tissue is an 
important piece to understanding how the genetic regulation of 3-O-sulfated HS relates to 
HIV MTCT.  HS3ST3A1 is highly expressed in placental tissue, further necessitating the 
need to describe its expression in placental tissue from our study population.   
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2.4 Specific Aim 3.  Quantify placental expression of the gene CCR5 and evaluate 
the association between expression and the risk of HIV MTCT 
2.4.1 Overview 
 Multiple studies of the CCR5 gene have demonstrated its role in the risk of HIV 
infection, including studies of HIV MTCT.  The illustrious ∆32 mutation has provided 
some of the strongest evidence for susceptibility to infectious disease, leading to R5-
targeting microbicides and antiretroviral therapy.  Up regulation of CCR5 expression in 
the placenta has also been associated with vertical transmission 179 but this has not yet 
been replicated in populations of African descent.  Employing identical methodology to 
aim 2, we aim to describe CCR5 expression in placental tissue for our MHP cohort. 
2.4.2 Rationale 
 Previous work in the MHP cohort determined that infants who were carriers of the 
variant CCR5-2459G had a decreased risk of HIV MTCT, at low levels of maternal HIV 
viral load 38.  Given our finding that CCR5 plays a role in HIV MTCT susceptibility in 
this cohort, it is important to follow these genotypic findings with expression data.  And 
as inflammatory responses such as chemokines (i.e.MIP-1β) and cytokines (i.e. IL-
2,3,4,5,7,8,12) depend on binding to HS 177, and because CCR5 plays a role in these 
inflammatory immune responses, characterization of CCR5 expression in relation to 
HS3ST3A1 expression and evaluation of epistatic effects is imperative. 
2.5 Summary 
 To our knowledge, this project will be the first study to capture an extensive view 
of the genomes of HIV-1-exposed infants in relation to susceptibility to HIV MTCT.  
This is also the only study to investigate known and novel mutations associated with fetal 
 42 
 
susceptibility to HIV MTCT and to follow up findings with extensive expression 
analysis. 
CHAPTER 3 RESEARCH DESIGN AND METHODS 
3.1 Summary 
This chapter describes in detail the laboratory and statistical methodology applied 
to each specific aim.  The methods for aim 1 include information about the original 
Malawi study population, the classification of exposure and outcome, subject 
identification and sampling, reproducibility, power calculations, and genotyping.  The 
remainder of aim 1 methodology is more statistically involved, including quality control 
and statistical procedures specific to the genome wide association analysis.  These 
methods deviate slightly from general epidemiological techniques as over 650,000 
genetic exposures are initially assessed, raising a list of additional methodological issues 
as discussed in chapter 1.   
The methods of aims 2 and 3 apply to the same study population and original 
collection of study subjects.  However, these methods include more detail of the 
laboratory-based data collection, and are followed by statistical methodology that is more 
in-tune to classical epidemiologic analyses.   
3.2 METHODS FOR AIM 1 
3.2.1 Source Population 
 The data included in this part of the study comes from the Malaria and HIV in 
Pregnancy (MHP) cohort study conducted from 2000 to 2004, resulting in 3,825 
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consenting pregnant women admitted to Queen Elizabeth Central Hospital, Blantyre, 
Malawi.  HIV testing was performed at delivery and patients were followed up at 6 and 
12 weeks post delivery.  A total of 1157 women tested positive for HIV, 884 of which 
delivered at Queen Elizabeth Central Hospital resulting in 807 singleton live births.  At 
delivery, 751 infants were tested for HIV, identifying 65 HIV positive infants at birth.  Of 
the 668 HIV negative infants, 179 were lost to follow-up.  507 infants were tested for 
HIV at 6 or 12 weeks, resulting in 89 additional HIV positive infants (Figure 3.1).  
Figure 3.1 MHP study profile, as previously published † 
† Mwapasa et a. 2004 180
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3.2.2 Study Population and Study Design 
The study design for this aim was a nested case-control, nested within the MHP 
Cohort.  This cohort was closed at the time of this study, preventing any additional 
ascertainment of subjects, sample collection, or follow-up collection of demographic data 
from the subjects.  However, it was not restricted from ongoing data analysis and 
laboratory work on stored samples.  This allowed for the ability to complete genotyping 
and analysis of existing stored infant DNA samples.  The study did not have Internal 
Review Board (IRB) approval for genotyping in maternal DNA samples, so a comparison 
of mother and child genotyping profiles was not an option. 
3.2.3 Classification of Exposure 
All infants selected for genotyping had an HIV positive mother who delivered at 
Queen Elizabeth Hospital in Blantyre, Malawi.  The genetic exposures of interest 
consisted of each SNP for which a valid genotype was obtained.  After initial quality 
control, there were approximately 638,000 SNP exposures for each HIV-exposed infant 
(details provided later). 
3.2.4 Classification of Outcome 
The outcome of interest was transmission of HIV from the HIV positive mother to 
the HIV exposed infant.  Maternal HIV status was measured with the Determine HIV-1/2 
Rapid Test (Abbott Laboratories, Illinois, USA) and the SeroCard HIV-1/2 Rapid Test 
(Trinity Biotech, Co Wicklow, Eire), as described in the original publication for the 
cohort 180.  Infant HIV status was determined at birth, 6, and 12 weeks using real time 
PCR 180.  
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3.2.5 Measurement Characteristics and Reproducibility 
Use of the Illumina HumanHap BeadChip allows for an easily reproducible 
technique for the genotyping.  The less reproducible aspect of this work is the collection 
of subjects from Blantyre, Malawi enrolled in the original MHP cohort, especially with 
regards to treatment during pregnancy and at delivery.  All HIV-infected women and 
their infants received a single dose (200 mg) of nevirapine at delivery in the MHP cohort.  
Other studies of mother-to-child transmission of HIV may include additional 
antiretrovirals and multiple treatments through pregnancy, especially as treatment 
regimens change over time. 
3.2.6 Sample Collection for Cases and Controls 
 The original allocation of the GWA MHP cases were collected by using unique 
subject identification number (ID) corresponding to the time the subject was enrolled in 
the cohort.  A corresponding control sample was chosen by selecting the very next ID of 
an HIV negative infant of an HIV positive mother delivering at the clinic.  For example, 
for case ID 100, a potential control sample was an HIV negative infant with an ID of 101 
or greater.  The first ID greater than 100 identified as an adequate control, and with a 
DNA sample of sufficient concentration, was selected.  In this manner, the cases and 
controls were selected in an approximately 1:1 unmatched case to control ratio, with 
similar distribution through time of enrollment.  Because the control status of subjects 
were designated at the beginning of sample selection for the nested case control, this 
study can be considered a case-cohort study and analyzed accordingly 181.
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3.2.7 Genotyping 
 The GWA genotyping was completed for 114 HIV-exposed, infected infants and 
132 exposed, uninfected infants.  Additional cases were not available because DNA 
samples were either not available, of poor quality, or had a very low concentration of 
DNA.  As previously mentioned, mothers of infants could not be genotyped as the 
original IRB approval did not include this.  It was not possible to return to study 
participants in order to obtain informed consent for maternal genotyping.  Thus, no test of 
transmission disequilibrium or analyses involving mother-infant pairs could be 
conducted.  The study focus was infant genomic susceptibility to HIV infection, given an 
HIV positive mother. 
 The genotyping was performed at Duke University Genotyping Core 
Laboratories, by using Illumina’s HumanHap650Y Genotyping BeadChip.  This 
BeadChip enables whole-genome genotyping of over 655,000 tagSNPs derived from the 
International HapMap Project 168 and over 100,000 tag SNPs selected based on the 
Yoruban Nigerian HapMap Population.  The BeadChip contains over 4,300 SNPs with 
copy number polymorphism regions of the genome, 8,000 non-synonymous SNPs 
(nsSNPs), 1,800 tag SNPs in the Major Histocompatibility Complex (MHC) important 
for immunological significance, 177 mitochondrial SNPs, and 11 Y-chromosome SNPs. 
3.2.8 Data Management and Quality Control 
3.2.9 Genotyping Error 
The quality control for genotyping error was performed at Duke University 
Genomic Laboratories and has been described previously 92.  Briefly, all samples were 
brought into a BeadStudio data file using an Illuminum cluster file and clustering of 
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samples was evaluated in order to determine random clustering of SNPs.  Samples with 
very low call rates (<95%) were excluded.  Subsequent reclustering of undeleted SNPs 
and additional exclusion by call rate was performed 92.  SNPs with a heterozygosity value 
between -1.0 to -0.1 and 0.1 to 1.0 were evaluated to determine if raw and normalized 
data indicated clean calls for the genotypes 92.   
3.2.10 Missing Data 
Individuals missing more than 10% of marker data were excluded in initial data 
cleaning.  Missing maternal HIV viral load was previously determined to be missing at 
random in the MHP cohort 38.  However, it was re-evaluated for association with the 
outcome (Table 3.1).  This evaluation was applied to aims 2 and 3 statistical analysis 
assumptions. 
Table 3.1 Association between missingness of MVL and HIV MTCT 
 HIV - Infants HIV+ Infants Total 
MVL Not Missing 43 84 127 
MVL Missing 8 19 27 
Total 51 103 154 
Pearson’s χ2 = 0.18, p=0.672 
 
Based on the Pearson’s χ2
 
results MVL was determined not to be associated with 
the outcome, HIV MTCT. 
3.2.11 Hardy-Weinberg Equilibrium 
SNPs were tested for Hardy-Weinberg Equilibrium (HWE) overall and separately 
by case/control status.  SNPs out of HWE (p< 0.001) among the control group were 
excluded from initial analyses.  Analysis was performed including all SNPs and again 
after excluding SNPs out of HWE in the control group in order to determine how the 
results compared.
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3.2.12 Gender Verification 
Gender verification was completed for all subjects to ensure that gender recorded 
in the covariate dataset matched with gender based on genetic data.  For mismatched 
gender, PLINK was used to impute gender based on the X chromosome.  The statistical 
quality control for aim 1 was conducted in PLINK version 1.05 182 unless otherwise 
specified.   
3.2.13 Power Calculations 
Power was calculated based on a Genome Wide scan of 587,055 SNPs, needing a p 
value of 1x10-8 in order to meet statistical significance after Bonferroni correction for 
multiple comparisons.  The Software Quanto 183 was used.  Per specifications of this 
software, power was computed using a log-additive model, allele frequency of 10%, a 
baseline risk of 25% (to approximate the proportion of infants that became infected with 
HIV from HIV positive mothers in the GWAS study population), a case to control ratio 
of 1:1, and an alpha of 1x10-8 to account for multiple testing of over 587,055 SNPs.  Plots 
were created for varying relative risks (1.25 to 3.25). 
These analyses estimated that, depending on the effect estimate, at least 1000 cases 
are needed in order to have 80% power to detect a p value of 1x10-8 and a baseline risk of 
25% (Figure 3.2).  This implies that our current GWA dataset with a sample size of 231 
for the MHP population is underpowered.
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Figure 3.2 Power curves with varying disease allele frequencies† 
 
 
† 1:1 case:control ratio, log-additive genetic model, 0.01 allele frequency, 25% baseline 
risk 
 
3.2.14 Logistic Regression for Genome Wide Association Analysis in PLINK 
 Assuming an additive genetic model, logistic regression was performed where the 
outcome of interest was HIV status of the infant [(+)/(-)] of an HIV infected mother.  
HIV positive infants of HIV positive mothers were designated as cases and HIV negative 
infants of HIV positive mothers were designated as HIV exposed controls.  The 
dichotomous outcome was coded as 1 for a case and 0 for a control.  The primary 
exposure of interest was infant SNP genotype.  The baseline (reduced) model was 
specified as: 
logit[p(Y=1)] = β0 + β1(SNP) 
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 Where P(Y=1) represents the probability of mother-to-child transmission of HIV, 
β0 represents the y intercept, and β1 is the coefficient for the SNP of interest.  For the 
additive model, the SNP variable was coded as 0, 1, and 2, corresponding to homozygous 
wild type, heterozygous, and homozygous variant genotypes, and treated as a continuous 
variable.  The null hypothesis for this model was that the SNP of interest was not 
associated with HIV MTCT: Ho: β1=0, compared to the alterative hypothesis, that the 
SNP was associated with HIV MTCT: Ha: β1 ≠ 0.  All SNPs were assumed to be 
independent, and Bonferroni correction was used to adjust for multiple testing.  The 
Bonferroni adjusted p value corresponding to genome-wide statistical significance in this 
dataset was 0.05/587,055 SNPs=8.5x10-8.  These statistical analyses were conducted in 
PLINK version 1.05 182 and the results were visualized in WGAViewer 184.   
3.2.15 Evaluation of Effect Measure Modification and Confounding for GWA data 
In GWAS, because over 600,000 exposures are evaluated for association with the 
outcome of interest, the techniques for assessing effect measure modification (EMM) and 
confounding differ from standard epidemiological methodology.  In the situation of a 
single exposure and a single outcome of interest, each covariate is tested for EMM and 
confounding (if no EMM).  This can be repeated for multiple covariates, even if 10, 20, 
or more, are necessary to test.  However, for GWAS, one would have to test each 
covariate for each of the 600,000+ SNPs, which is computationally intensive. 
For the purposes of this GWA study, we first ran an unadjusted scan of SNPs 
associated with HIV MTCT.  Then the most significant SNPs (i.e. the top 10) were 
included in evaluation of EMM and confounding for covariates of interest evaluated in 
the DAG (Table 3.2, Figure 3.3).  Covariates were also tested for association with the 
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outcome, HIV MTCT, among the unexposed (referent allele).  Covariates associated with 
the outcome with an effect estimate lower than an Odds Ratio of 2.0 were not considered 
to be strongly associated with the outcome and were not investigated further for 
confounding.   
Exposures of known biological significance for the risk of HIV MTCT (Figure 
3.3) were evaluated for association with HIV MTCT in this study population.  Of 
particular interest was maternal HIV viral load (MVL), as peripheral MVL is an indicator 
of HIV disease severity in mothers and is frequently used as a covariate in HIV MTCT 
peer-reviewed publications.   
3.2.16 Evaluation of Effect Measure Modification and using top SNP of interest as 
main exposure 
 Potential effect measure modifiers (EMMs) were first assessed with directed 
acyclic graph (DAG, Figure 3.3) using a selected SNP (rs8069770) from unadjusted 
analyses as the exposure of interest for association with MTCT of HIV.  Unblocked 
backdoor pathways were only observed for MVL and CD4 count.  MVL was considered 
for additional testing for EMM because 1) CD4 count and MVL are typically correlated 
and may introduce collinearity if both terms are included in a model, and 2) MVL is more 
consistently used in the literature, and is a more accurate measure of HIV exposure 
experienced by the infant. 
 A categorical variable for carrying the A allele vs. the G allele for rs8069770 was 
used as the exposure variable.  The EMM by MVL was tested for the association between 
rs8069770 genotypes and HIV MTCT using a Breslow-Day Test in PLINK 182.  This test 
resulted in a Chi-Square value of 0.476 and a P value of 0.49.  Thus, MVL was not a 
 53 
 
significant effect measure modifier of the association between rs8069770 and HIV 
MTCT. 
  
 
54 
Figure 3.3 Directed Acyclic Graph (DAG) for SNP association with HIV MTCT † 
 
† Dotted lines represent hypothesized associations where the direction of association has not been 
established in the literature. 
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Table 3.2 Covariate description and relevance to this study 
Key Covariates  Relevance 
 
Maternal Malaria 
 
 
Mwapasa et al. 2004 found that co-infection with malaria was not 
associated with the risk of HIV MTCT 180.  
 
Maternal Syphilis 
 
Maternal co-infection with syphilis was associated with a higher 
risk of HIV MTCT 5; 25.  Maternal syphilis is also 
immunosuppressive, decreasing CD4 count. 
 
Infant birth weight 
 
Low infant birth weight is associated with intrauterine 
transmission of HIV-1 185 but association with genetic exposures is 
unknown. 
 
Maternal HIV viral 
load/ Maternal CD4 
count 
 
Higher levels of maternal viral load and lower maternal CD4 
count, have both been associated with HIV MTCT 185.  The two 
variables are often correlated. 
 
 
Maternal anemia 
 
An association between maternal anemia and HIV MTCT has been 
noted 186 but finding vary and anemia may be a proxy for other 
nutritional factors influencing the risk of HIV MTCT. 
 
Maternal age 
 
Older mothers are more likely to have infants with adverse health 
outcomes, suggesting a greater risk of HIV MTCT, although 
association between age and HIV MTCT has not been 
demonstrated. 
 
Mode of delivery 
 
Emergency caesarians increase the risk of HIV MTCT whereas 
elective caesarians decrease the risk, although results vary 33; 187.  
No association between mode of delivery and HIV MTCT was 
observed in previous work with the MHP cohort 38. 
 
PLAP 
 
Placental microtransfusions, detected by the maternal enzyme 
placental alkaline phosphatase (PLAP), are a risk factor for HIV 
MTCT 5. 
 
Episiotomy, dose of 
sulfadoxine 
pyrimethamine, 
gravidity 
 
No associations with HIV MTCT observed in previous work with 
the MHP cohort 38. 
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3.2.17 Evaluation of Confounding using top SNP of interest as main exposure 
 As MVL was not an EMM, it was then evaluated for confounding.  First, MVL 
must be associated with both the exposure and the outcome, where an odds ratio (OR) 
above 3.0 or below 0.5 is evidence of a strong association, an OR between 0.05 and 0.90 
or between 1.2 and 2.9 was considered to be a weak association.  The change in estimate 
criterion was also employed in order to evaluate confounding. 
 The association between MVL and dichotomous HIV MTCT was not strong 
(OR=1.67, 95% CI=0.29, 9.70).  Odds ratios for other categorizations of MVL varied 
(medium tertile: OR=1.40, 95% CI=0.14, 13.57; high tertile OR=1.75, 95% CI=0.22, 
14.23; medium quartile: OR=0.50, 95% CI=0.04, 7.45; medium-high quartile OR=0.83, 
95% CI=0.05, 13.63; high quartile OR=1.50, 95% CI=0.17, 13.22).  These odds ratios 
were imprecise and corresponded to very large confidence intervals.  The association 
between MVL and categorical carrier variable for rs8069770 was also weak and 
imprecise (OR= 0.75, 0.30, 1.88, p=0.546).   
 To determine the change in effect estimate, the crude OR (OR=0.71, 95% 
CI=0.065, 7.66) was compared with the MVL adjusted OR (OR=0.61, 95% CI=0.054, 
6.76).  The lnCoRR= |ln(0.71)–ln(0.61)| * 100 = 15%.  Although this value was larger 
than 10%, suggesting that it may be a necessary confounder, the confidence intervals for 
the estimates of the odds ratios were very wide and therefore imprecise.  However, both 
unadjusted and adjusted by MVL analyses were presented for the GWA analysis.  Note 
that these analyses were conducted in STATA version 10 188and the effect estimates varied 
slightly from the GWAS affect estimates calculated by PLINK 182. 
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3.2.18 Combination of Malawi GWAS data with HapMap Data 
 Although not initially indicated as a specific aim, the GWA data offered an 
opportunity to investigate genetic variation in African subpopulations.  With more of a 
population genetics or anthropological focus, the goal was to compare genetic variation 
in the Malawi population to that of other populations in Africa.  Data on African 
populations as well as populations of other ancestry was obtained from the International 
HapMap Project189, which offers an extraordinary amount of publically available 
information on SNPs genotyped across the human genome for populations across the 
world 190.  
 The HapMap Project originally obtained 269 DNA samples from four 
populations: Han Chinese from Bejing, China (CHB), Japanese from Tokyo, Japan (JPT), 
Caucasians from Utah, USA, with northern and Western European ancestry (CEU), and 
Yoruban of Ibadan, Nigeria (YRI) 189.  Subsequently, the project has introduced seven 
additional populations: Individuals of African ancestry in the Southwest USA (ASW), 
Chinese in Metropolitan Denver, Colorado (CHD), Gujarati Indians in Houston, Texas 
(GIH), Luhya in Webuye, Kenya (LWK), individuals of Mexican ancestry in Los 
Angeles, California (MEX), Maasai in Kinyawa, Kenya (MKK), and Toscans in Italy 
(TSI).  
 The allele and genotype frequencies from the GWA data of the Malawi 
population were compared to genome wide data from 11 HapMap populations, including 
4 populations of African ancestry (AFA).  In these analyses, the study population 
recruited from Malawi was referred to as “Individuals of various self-reported ethnic 
group in Blantyre, Malawi” (BMW).  All HapMap populations with available data at the 
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time of this study (through May, 2009) were included (Phases 1-3).  HapMap data was 
downloaded in PLINK format from the International HapMap Project website189.  
Populations were limited to unrelated individuals and processed through identical 
statistical quality control as completed for the Malawi population with the exception of 
gender verification.  HapMap populations were then merged into one file, adding one 
population at a time. This file was then merged with the Malawi population.  Due to 
strand differences between the Malawi population and the HapMap populations, some 
Malawi strands were flipped and the files were remerged.  One monomorphic variant of 
the Malawi population was excluded as strand flipping did not change the allele 
(rs17759134).  Population-specific files were re-created from the combined file in order 
to ensure that all population-specific files consisted of the same SNPs, that all SNPs were 
on the same strand, and that individuals of the subsets were included in the combined 
population file.   
 Four analytic methods were conducted in order to compare genetic variation 
between populations: 1) the correlation of allele frequencies across the genome, 2) the 
correlation of adjacent SNP-SNP linkage disequilibrium (LD) across the genome, 3) 
allelic-based chi-square tests to evaluate the association between population and SNPs, 
and 4) principal component analysis to evaluate population substructure.  Each HapMap 
population was individually compared to the Malawi population and within Malawi; the 
self-reported ethnic groups were compared.  It is important to note that the information 
on self-reported ethnic group was maternal self-reported ethnic group.  Because paternal 
ancestry was not available, maternal ancestry represents a proxy for the ethnic group with 
which a study subject may identify.  A categorical variable was created base on 
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frequency of individuals in each group and evaluated for association with population 
substructure.  Information relevant to each group is reported in Table 3.3.  In all analyses, 
comparisons were only made between SNPs with minor allele frequency (MAF) > 0.05 
in each included population sample. 
3.2.19 Comparison of Allele Frequencies and Adjacent Linkage Disequilibrium 
 Allele frequencies were computed for each population using PLINK version 1.05 
182
.  Each allele frequency file was formatted and imported into STATA version 10 188.  In 
order to compare allele frequencies across populations, a generic coded allele was set for 
each SNP, using alphabetical hierarchy (A<C<T<G).  For example, if the alleles were A 
and G for a particular SNP, the coded allele would be designated as A and the non-coded 
allele as G, regardless of the observed allele frequency in a population. Spearman’s 
correlation coefficient was computed for each pair of populations (i.e. BMW vs. ASW, 
BMW vs. YRI, etc.) using all SNPs with MAF > 0.05 in both populations.  Adjacent 
linkage disequilibrium (LD) was estimated by calculating the standard r2 value for all 
pairs of adjacent SNPs using PLINK version 1.05 182.  For each pair of populations, 
Spearman’s correlation coefficient was calculated using all adjacent SNP pair r2 
estimates.  
3.2.20 Association with Population Membership 
Allelic-based (1 df) chi-square tests were systematically computed to identify SNPs 
with significantly different allele frequencies between the Malawi population and each 
HapMap population containing subjects of African ancestry. Specifically, we defined a 
dichotomous outcome variable, with value of ‘1’ assigned to the BMW population and 
value of ‘2’ assigned to the comparison population (ASW, LWK, MKK, or YRI).  Two 
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measures of the genomic inflation factor, based on the median and mean chi-square 
statistic over all SNP comparisons, were computed for each genome-wide association 
analysis using PLINK version 1.05 182. Because chi-square statistics are affected by 
sample size under the alternative hypothesis, analyses were also performed using a 
random selection of 42 individuals from each HapMap comparison group to facilitate 
more direct comparison of the results across the HapMap populations.  The value of 42 
was used as it represented the smallest group (ASW, N=42).  
3.2.21 Population Substructure 
 As discussed in chapter 1, it is important to appropriately capture population 
stratification in this study as genetic substructure can lead to false positive findings.  v 
Population substructure was evaluated with principal components (PC) analysis 
separately in the Malawi population and then in the combined subset of the HapMap 
populations of African ancestry (ASW, LWK, MKK, YRI) plus the Malawi population. 
The PC analyses were conducted using EIGENSOFT version 2.0 191. SNP inclusion in the 
PC analysis was restricted to autosomal SNPs that had MAF > 0.05 and observed 
genotype frequencies consistent with Hardy-Weinberg equilibrium expected proportions 
(p > 0.001) in each participating individual population.  Strict SNP pruning based on 
pair-wise SNP-SNP LD was conducted to identify a subset of independent SNPs for 
inclusion in PC analysis.  Specifically, we calculated pair-wise SNP-SNP LD, measured 
by r2, between all SNP pairs within 500 kb in the BMW sample using PLINK.  A custom 
computer program was used to select the largest number of SNPs from each chromosome 
such that each selected SNPs had no other selected SNPs within 500 kb that were in LD 
with it (defined by r2 > 0.01).  Based on these selection rules, we identified 23,612 and 
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18,481 SNPs for use in the PC analyses of the Malawi and combined African HapMap 
and Malawi samples, respectively. 
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Table 3.3 Self-Reported ethnic group in Malawi study population; historical, cultural, and geographic notes† 
Self- 
Reported 
Tribe N Lineage 
Residential 
Tradition‡ Similar Groups Geography 
Geographic History for Malawi  
& Other Comments 
       
Tumbuka 14 Patrilineal Virilocal  North Have lived in Malawi for hundreds of 
years, conquered by Ngoni, but 
reasserted ethnic identity at the end of 
British rule in the 20th century. 
 
Likoma 1 Patrilineal Virilocal Tonga North Similar to Tumbuka. 
Tonga 1 Patrilineal Virilocal Likoma North Similar to Tumbuka. 
 
Nkhonde 1 Patrilineal Virilocal Also called Nkonde, 
Ngonde 
North Small group, still speak Nkhonde 
dialect in district. 
 
Ngoni 63 Patrilineal Virilocal in the North, 
Uxorilocal in Central  
Malawi 
 
Integrated within  
Tumbuka in the  
North or Chewa  
in Central Malawi 
North or 
Central 
Migrated north to Malawi in the mid-
1800s, conquering and assimilating 
with various groups in Malawi, 
including the Tumbuka and the Tonga. 
Ngoni is a branch of the Zulu ethnic 
group of South Africa.  Only about 1% 
of the population in Malawi still 
speaks Ngoni. 
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Table 3.3, continued 
Self- 
Reported 
Tribe N Lineage 
Residential 
Tradition‡ Similar Groups Geography 
Geographic History for Malawi  
& Other Comments 
       
Chewa 18 Matrilineal Uxirolocal Nyanja, Mang’Anja Central Have been in Malawi for over 500 
years, separate group from Nyanja for 
over 200 years.  Referred to as Maravi 
by early Portuguese. 
 
Nyanja or 
Mang'Anja 
15 Matrilineal Uxirolocal Chewa South Similar to Chewa, have been in 
Malawi for over 500 years, separate 
group from Chewa for over 200 years. 
Referred to as Maravi by early 
Portuguese. 
 
Lomwe 59 Matrilineal Uxorilocal Khokhola South Have been migrating to Malawi from 
Mozambique since the late 1800s.  
Settled peacefully among the Yao and 
Nyanja. 
 
Khokhola 4 Matrilineal Uxorilocal A sub-group of  
the Lomwe 
South Khokhola language similar to Lomwe, 
considered a subset of the Lomwe. 
 
Yao 32 Matrilineal Uxirolocal  South Began migrating to Malawi in mid-
19th century Islam. Slave trade 
reportedly found the Yaos already in 
Malawi. 
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Table 3.3, continued 
Self- 
Reported 
Tribe N Lineage 
Residential 
Tradition‡ Similar Groups Geography 
Geographic History for Malawi  
& Other Comments 
       
Sena 13 Patrilineal Virilocal Similar to Nyungwi 
or Nyungwe 
Far South Sena is a generic term for a number of 
related groups in eastern Malawi, 
arriving from the Sena province in 
Mozambique in the early 20th century. 
 
Missing 5 NA    NA 
† References: 192; 193 and oral interviews and email correspondence with Dr. Adamson Muula, a Malawian doctor studying 
Epidemiology at UNC Chapel Hill. ‡ Virilocal: Tradition is for a married woman to move to and live in her husband’s village; 
Uxirolocal: A married man moves to and lives in his wife’s village.  In cities such as Blantyre, these labels are less in practice, and 
rather an indicator of the cultures within households. 
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3.3 METHODS FOR AIMS 2 & 3 
 This sub-section will describe the laboratory and statistical methods for aims 2 
and 3 of the dissertation.  The laboratory methods for aims 2 and 3 were conducted 
simultaneously and the statistical methods varied slightly but followed a similar protocol.  
The same source population was used as described for aim 1 methods.  Depending on 
sample availability, it was intended for subject overlap to exist between the individuals 
with GWAS data and the individuals with gene expression data. 
3.3.1 Study Subjects and Sample Collection 
 Fresh placental tissue samples from the MHP cohort were obtained from 
consenting study participants at delivery and immediately frozen at –4 degrees Celsius 
(0C).  Samples stored at the University of North Carolina at Chapel Hill (UNC) were 
catalogued and demographic information per subject was stored in an electronic de-
identified STATA database.  Study numbers were assigned to each individual and are 
unlinked to any names, addresses, or identifying data.  Placental tissue samples stored at 
UNC were available for 723 HIV positive mothers and 419 HIV negative mothers.  Of 
the HIV positive mothers, a total of 411 samples had data on transmission status of the 
infant (Table 3.4).  Preliminary testing of assays was completed among the HIV negative 
mother-infant pairs. 
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Table 3.4 Transmission outcomes for infants of HIV positive mothers 
Transmission†  
All MHP Subjects 
N (%)  
MHP Subjects with 
Placental Sample‡ 
N (%) 
HIV(-) at birth 
HIV(+) at birth  
713 (90.7) 
73 (9.3)  
577 (92.0) 
50 (8.0) 
HIV(-) at 6 weeks 
HIV(+) at 6 weeks  
458 (81.1) 
107 (18.9)  
354 (82.1) 
77 (17.9) 
HIV(-) at 12 weeks 
HIV(+) at 12 weeks  
377 (77.6) 
109 (22.4)  
288 (77.6) 
83 (22.4) 
Total HIV(-) 
Total HIV(+)  
370 (68.7) 
169 (31.4)  
284 (69.1) 
127 (30.9) 
† Infant HIV status of HIV positive mothers was collected at birth, 6 weeks, and 12 
weeks although some infants were lost to follow-up.  Once an infant tested positive for 
HIV, they remained noted as HIV(+) in the database for subsequent time points, even if 
lost to follow-up.  
‡
 Frozen placental tissue samples stored at UNC. 
 
3.3.2 RNA Extraction 
 The AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA) was initially used for 
RNA and DNA extraction from placental tissue.  However, the RNA yield was quite low, 
resulting in concentrations far below 100 ng/ul.  Because only RNA was needed for this 
study and because placental tissue can be considered to be lipid rich, the RNeasy Lipid 
Tissue Kit (Qiagen, Valencia, CA) was used for all remaining RNA extractions, resulting 
in a total of 232 samples with adequate concentration of RNA for cDNA synthesis.  Prior 
to beginning an experiment, the workbench area was decontaminated using 70% ethanol 
followed by RNAseZap (Ambion, Austin, TX) solution to minimize RNA degradation.  
All work was conducted under the hood in a separate room from the main laboratory.  
Approximately 5 µg of tissue was excised from each placental tissue sample.  Samples 
were physically homogenized by chopping with scissors, placing the sample into Buffer 
RLT Plus containing Beta-Mercaptoethanol (β-ME), pipetting up and down in solution, 
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and then running that solution through a Qiashreddder (Qiagen, Valencia, CA).  Thick 
rubber gloves were worn to minimize the opportunity for self-punctures while 
homogenizing the samples.  The RNA extraction protocol continued according to the 
Qiagen RNeasy Lipid Tissue Kit (Qiagen, Valencia, CA).  Genomic DNA from initial 
extractions was stored at -400C and RNA was stored at -800C. 
3.3.3 Reverse Transcriptase for cDNA Synthesis 
 The Qiagen QuantiTect Reverse Transcriptase Protocol (Qiagen, Valencia, CA) 
was followed to create cDNA libraries from RNA samples.  As live virus was eliminated 
during the RNA extraction protocol, samples were no longer considered to be infectious 
and work was conducted in the main laboratory area, at a work bench designated for 
working with RNA.  The workbench area was sprayed with 70% ethanol followed by 
RNAaseZap (Qiagen, Valencia, CA).  RNA samples were thawed on ice.  Genomic DNA 
was eliminated from samples using the gDNA Wipeout Buffer.  Reverse transcriptase 
master mix was prepared and added to samples followed by incubation for 30 minutes at 
420C and then for 3 minutes at 950C to inactivate the Quantiscript Reverse Transcriptase 
(Qiagen, Valencia, CA).  Samples were then stored at -40C. 
3.3.4 SYBR Green Real-Time PCR 
 The initial assay for quantifying gene expression employed the Qiagen 
QuantiTect SYBR Green Real Time PCR protocol (Qiagen, Valencia, CA).  Qiagen 
QuantiTect SYBR Green PCR Master Mix and QuantiTect SYBR Green primers were 
used to amplify the target genes HS3ST3A1 and CCR5, as well as for the house keeping 
gene, GAPDH, which provided a baseline measurement of the cDNA in each sample. 
Aims 2 and 3 differ in this part of the laboratory protocol only with regards to the target 
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gene (HS3ST3A1 for aim 2, CCR5 for aim 3).  In addition to subject samples, FirstChoice 
PCR-Ready Human Placenta cDNA (Ambion, Austin, TX) was used as a control sample 
in test PCRs as well as to determine primer efficiency.  A 96-well plate was used to load 
the master mixes and non template controls (NTC) using water as well as the cDNA 
samples of interest.  Each well of the plate contained 20 µL of master mix including 
primers and 5 µL of cDNA or water (NTC).  Real-time PCR amplications were 
performed in a 96-well plate using the ABI Prism 7300 Real Time PCR System. Cycling 
conditions were as follows: 2 minutes at 500C, 15 minutes at 950C, 15 seconds at 940C 
(denaturation), 30 seconds at 550C (annealing), and 30 seconds at 720C (extension), 
followed by a dissociation stage.  A total of 40 cycles was completed. 
 Data from the real time PCR is sigmoidal in shape, where the number of cycles is 
plotted against fluorescence (Figure 3.4).  The threshold cycle (Ct) is the starting 
template amount for each sample and represents the cycle where there is first detectable 
increase in fluorescence, where fluorescence represents gene transcription.  Laboratory 
safety and biohazards safety courses were completed as required by UNC. 
3.3.5 Taqman Real Time PCR 
 The results from the SYBR green primers and PCR protocol were unsatisfactory, 
particularly for the HS3ST3A1 gene.  Samples that did not provide adequate results were 
selected for re-evaluation using Taqman master mix and self-designed primers and probe.  
Such samples required re-synthesis of cDNA, which was performed using the same 
protocol as previously described.  The primary reason for redesigning the real-time PCR 
assay was due to the high cycle threshold (Ct) values.  However, Taqman real-time PCR 
results were also unsatisfactory. It was speculated that the primers were not efficient for 
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this particular population, possibly due to the presence of polymorphisms in the area 
where the primers bind.  Contamination with human genomic DNA was also an issue as 
the samples being processed were from human tissue.  Rather than redesigning primers 
and probes and/or changing in-lab protocol, assistance from an on-campus core facility 
was sought for replication of existing data and generation of data for trouble samples.  
This approach was also the least expensive and time consuming option compared to other 
protocols.   
3.3.6 Repeat Real-Time PCR 
Replication work was conducted at the UNC Chapel Hill Animal Chemistry and 
Gene Expression Core Facility located on campus. Multiplex real-time PCR 
amplification could be completed using RNA rather than cDNA, which dramatically 
reduced the possibility of human genomic DNA contamination.  Stock and 1:100 diluted 
RNA samples extracted for each mother-infant pair were sent to the facility. Real-time 
RT-PCR amplifications were performed in a 96-well plate in the ABI Prism 7700 
sequence detector (PE Biosystems).  A total volume of 30 µl was used, which included 
10 µl of RNA and 20µl reaction mixture 194.  The cycle conditions were 30 min at 48°C 
for the RT reaction, then 10 min at 94°C, followed by a total of 40 temperature cycles (15 
sec at 94°C and 1 min at 60°C).  
Investigation of the HS3ST3A1 region revealed the existence of a nearby gene, 
HS3ST3B1, located approximately 700kb downstream from HS3ST3A1 on chromosome 
17.  Because these genes are identical in function, both encoding the heparan 3-O-sulfo-
transferase enzyme, it was viewed necessary to also capture HS3ST3B1 expression in the 
placenta.  Following all laboratory procedures, real-time PCRs quantified the expression 
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of the housekeeping gene, GAPDH, and the target genes, HS3ST3A1, HS3ST3B1, and 
CCR5.  
3.3.7 Relative Quantification 
Relative quantification was performed relative to an endogenous placental RNA 
control sample, where each 96-well plate was normalized to the control sample.  
Negative control samples (water) were used to eliminate the presence of genomic DNA 
contamination.  The difference in Ct value between GAPDH and target gene was 
obtained for each sample (∆Ct).  That value was subtracted from the ∆Ct value of the 
endogenous control sample (∆∆Ct).  This value was then transformed to a percent change 
in gene expression between GAPDH and the target gene for each sample.   
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Figure 3.4 Typical amplication plot for real time PCR † 
 
† (Qiagen QuantiTect Primer Assay Handbook www.qiagen.com). Amplification plots 
indicate increases in fluorescence from 2 samples (A and B). Sample A contains a higher 
amount of starting template than sample B. 
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3.3.8 Power and Sample Size 
 Sample size was computed in STATA v.9 using “powerreg.” Specifying 80% 
power, an alpha of 0.05, four predictor variables in a linear regression model, with 
varying correlation coefficients for the model, it was determined that a  total sample size 
of 200 ensured a power greater than 80%.  This power held when only two predictor 
variables were included in the model.  
3.3.9 Quality Control 
 Subjects were excluded if placental tissue samples were missing, if RNA yield 
was poor (<100 ng/ul), or if the sample was poor in quality for other reasons.  For 
example, some samples were missing the cap of the tube in which the placental biopsy 
was placed, and other samples were poor in appearance such as discoloration.   The total 
number of samples with such characteristics was less than 10 and our analysis was blind 
to the sample ID, phenotype, and other demographic information throughout all 
laboratory procedures. 
3.3.10 Missing Data 
As mentioned in Aim 1 methods, maternal HIV viral load was previously 
determined to be missing at random in the MHP cohort 38.  MVL missingness was also 
not associated with the outcome in aim 1.  However, it was re-evaluated for association 
with the outcomes of interest for aims 2 and 3 (Table 3.5).  This evaluation was applied 
to aims 2 and 3 statistical analysis assumptions. 
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Table 3.5 Association between missingness of expression, covariates, & HIV MTCT 
Outcome MVL HIV - Infants HIV+ Infants χ2 (P) 
HIV MTCT Not Missing 36 13 1.70 (0.192) Missing 64 38 
Maternal Syphilis Not Missing 49 0 NA Missing 102 0 
 
 Low 
Expression 
High 
Expression  
HS3ST3A1 high vs. 
low expression 
Not Missing 85 22 0.40 (0.525) Missing 87 18 
HS3ST3B1 high vs. 
low expression 
Not Missing 76 16 0.20 (0.652) Missing 72 18 
CCR5 high vs. low 
expression 
Not Missing 83 19 0.018 (0.894) Missing 78 17 
† Analyses conducted in the gene expression dataset, N=211, MVL: Maternal HIV 
Viral Load, χ2: Chi-Square statistic, P: p-value. 
 
 Each covariate was also assessed for the association between covariate 
missingness and the linear outcome (gene expression) of interest by using Kruskal-Wallis 
Test of equality-of-populations rank test, which is quantified by a chi-square statistic (χ2) 
and p value. For MVL, the correlations with HS3ST3A1 expression, HS3ST3B1 
expression, and CCR5 expression were 2.36 (0.124), 0.18 (0.676), and 0.42 (0.516), 
respectively.  For maternal syphilis, these correlations were 4.0 (0.044), 2.3 (0.127), and 
3.3 (0.068), respectively. 
Based on the Pearson’s χ2 test and Kruskal-Wallis tests, the missingness of  MVL 
and maternal syphilis were determined not to be associated with the outcomes, HIV 
MTCT, placental expression of HS3ST3A1, placental expression of HS3ST3B1, or 
placental expression of CCR5. 
3.3.11 SNP data for CCR5, HS3ST3A1, and HS3ST3B1 
Previous work allowed collected data on infant genotypes of promoter SNPs of 
the CCR5 gene.  The genotyping was determined using multiplex ligase detection 
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reaction (LDR) based method with flow cytometric technology as previously described 
195
.  The association between these SNPs and the risk of HIV MTCT has been previously 
published 38.  Data on CCR5 SNPs were merged into CCR5 expression data to evaluate 
the association between infant CCR5 polymorphisms and placental expression of CCR5. 
The GWA dataset was also combined with gene expression data in order to obtain 
information on polymorphisms within the HS3ST3A1 and HS3ST3B1 genes and to 
evaluate the association between these infant polymorphisms and placental expression of 
HS3ST3A1 and HS3ST3B1. 
3.3.12 Missing Data, Outlier Data, and other Exclusions  
 As discussed in a previous publication from the MHP cohort 38, maternal HIV 
viral load was determined to be missing at random.  MVL was also investigated for 
implausible outliers, which were set to missing.  Duplicate samples were also removed. 
3.3.13 Statistical Analysis 
Four key statistical exercises were performed: 1) the association between gene 
expression and risk of HIV-1 HIV MTCT, 2) the association between placental 
expression of one gene and placental expression of another gene (gene expression 
interplay), 3) the association between placental gene expression and relevant gene 
polymorphisms (SNP) or haplotypes, and 4) a replication of previous findings for the 
association between HIV-1 HIV MTCT and gene polymorphisms or haplotypes 38.  The 
gene expression variables were log-transformed to approximate normality.  As previously 
mentioned, because the control status of subjects were designated at the beginning of 
sample selection for the nested case control, this study can be considered a case-cohort 
study 181.  The case-cohort study does not require the rare disease assumption in order for 
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the odds ratio to approximate the risk ratio.  Thus, for dichotomous outcomes, logistic 
regression was performed and the odds ratios are viewed to represent the risk ratios. 
The association between placental gene expression and the risk of HIV-1 HIV 
MTCT was evaluated using logistic regression, where transmission from mother to child 
was coded as 1 (transmission occurred) vs. 0 (no transmission).  All infants included in 
this analysis were from HIV positive mothers.  The unadjusted models are as follows: 
Model 1: logit[p(HIV MTCT =1)] = β0 + β1(HS3ST3A1 expression) 
Model 2: logit[p(HIV MTCT =1)]  = β0 + β1(HS3ST3B1 expression) 
Model 3: logit[p(HIV MTCT =1)] = β0 + β1(CCR5 expression) 
 Where P(HIV MTCT =1) represents the probability of mother-to-child 
transmission of HIV, β0 represents the y intercept, β1 is the coefficient for the expression 
of the target gene. 
In order to assess a potential interplay between the placental expression of CCR5, 
HS3ST3A1, and HS3ST3B1, separate linear regression models were evaluated for each 
gene by gene comparison and correspond to models 4, 5, and 6.  The exposure expression 
variables were log-transformed continuous variables. 
Model 4: ln(HS3ST3A1 expression) = β0 + β1(HS3ST3B1 expression) 
Model 5: ln(HS3ST3A1 expression) = β0 + β1(CCR5 expression) 
Model 6: ln(HS3ST3B1 expression) = β0 + β1(CCR5 expression) 
Each gene expression variable was then categorized into tertiles representing low, 
medium, and high expression.  Fisher’s exact test was used to describe the general 
association between CCR5 expression tertile and CCR5 SNP carrier status or genotype.  
Carriers were determined as individuals who had one or two variants of the SNP of 
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interest (dominant model).  For example, the genotypes AG and GG would be compared 
to AA, where G is the variant of interest and A is the wild type or more common allele, 
used as the referent allele.  CCR5 haplotypes were also assessed after categorized as 
carriers (having one or two copies of the haplotype vs. no copies).   The association 
between CCR5 variants and expression was estimated using linear regression models, 
where gene expression was a log-transformed continuous outcome.  Each SNP and 
haplotype was tested separately. Identical analyses were carried out for the association 
between HS3ST3A1 SNPs and placental expression of HS3ST3A1 and for the association 
between HS3ST3B1 SNPs and placental expression of HS3ST3B1.   
 Model 7: ln(CCR5 expression) = β0 + β1(CCR5 SNP/haplotype) 
Model 8: ln(HS3ST3A1 expression) = β0 + β1(HS3ST3A1 SNP) 
Model 9: ln(HS3ST3B1 expression) = β0 + β1(HS3ST3B1 SNP 
A final set of analyses was conducted in order to replicate previous findings from 
this cohort, in the subset of samples included in this study.  This was to determine if the 
association between CCR5 SNPs and the risk of HIV-1 HIV MTCT held in this cohort.  
Logistic regression was used where HIV-1 HIV MTCT was the outcome of interest and 
CCR5 SNP carrier and haplotype variables were the exposures of interest.  
Model 10: logit[p(HIV MTCT =1)]  = β0 + β1(CCR5 SNP) 
 Where P(HIV MTCT =1) represents the probability of mother-to-child 
transmission of HIV, β0 represents the y intercept, and β1 is the coefficient for the SNP or 
haplotype variables.  Unless stated as otherwise, all SNP and haplotype variables were 
evaluated as carriers of the variant allele verses non carriers in all relevant analyses.  
Diplotypes were also constructed and investigated in the models mentioned haplotypes.  
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However, these analyses were not pursued due to small cell sizes.  With the exception of 
the CCR5 SNPs, models that were run for multiple SNPs or haplotypes were adjusted for 
multiple comparisons by using the Bonferrroni correction (alpha/number of SNPs tested 
and alpha/number of haplotypes tested).  For the CCR5 SNPs, variable linkage 
disequilibrium was present, making Bonferroni correction inappropriate for this region of 
closely correlated SNPs.  For the HS3ST3A1 SNPs, the alpha level of significance was 
conservatively set to 0.05/38=0.0013.  For the HS3ST3B1 SNPs, the alpha level of 
significance was set to 0.05/14=0.0036. 
3.3.14 Evaluation of Effect Measure Modification 
All of the above models were evaluated for effect measure modification by the 
covariates described in Figure 3.3 and Table 3.2.  Only covariates involved in unblocked 
backdoor pathways in the DAG (Figure 3.3) were considered potential modifiers.   The 
relationship between covariates and the gene expression exposures was viewed to be 
slightly different from that between the covariates and the genetic polymorphism 
exposures.  Thus, the DAG differed slightly for the gene expression variables (Figure 3.5) 
with regards to maternal syphilis infection and MVL, where both of these variables were 
expected to affect gene expression but not SNP genotype.  Unblocked backdoor pathways 
were assessed and the minimal adjustment set was observed to be MVL and maternal 
syphilis.  Thus, these two covariates were considered for EMM and confounding.  For the 
models evaluating the association between SNPs and expression, only MVL was assessed 
as there is unlikely to be an association between maternal syphilis and the SNPs of 
interest. 
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For the logistic regression models, effect measure modification was evaluated by 
calculating the crude odds ratio (OR), 95% confidence intervals (CI) and a p value 
corresponding to the Mantel-Haenszel test of homogeneity of the odds ratios across 
covariate strata.  For the continuous expression exposures, tertiles were used and the ORs 
were computed for each tertile of each covariate category.  If the test of homogeneity p 
value≤0.10, in both tertiles, the covariate was designated as a strong EMM. However, if 
the p value was only significant in one tertile and not the other, the covariate was 
determined to be a weak EMM.  For models 4-6, which use continuous exposures and 
outcomes, EMM was evaluated by using a dichotomous (high/low) expression outcome 
and tertile expression exposures so that the Mantel-Haenszel test of heterogeneity could 
be estimated.  Similarly, for model 10, a dichotomous outcome of high/low CCR5 
expression was used. 
If covariates that presented evidence of EMM, additive and multiplicative EMM 
were assessed.  In order to assess EMM on the additive scale, the crude association of 
interest was stratified by a dichotomous categorization of the covariate of interest.  The 
strata-specific ORs, 95% CIs, and the interaction contrast ratio (ICR) were calculated.  
For an ICR=1, EMM was not considered to be present.  An ICR<1 is suggestive of 
antagonistic EMM and an ICR>1 suggests synergistic EMM 181.   
In order to assess EMM on the multiplicative scale, a likelihood ratio test was 
performed for models stratified by a covariate of interest.  Specifically, the reduced 
model with the main exposure-disease relationship is   compared to the same model with 
the addition of a covariate of interest (full model).  An example if used for model 1: 
Reduced Model: logit[p(Y=1)] = β0 + β1(HS3ST3A1 expression) + covariate 
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Full Model: logit[p(Y=1)] = β0 + β1(HS3ST3A1 expression) + β2(covariate)  
+ β3(HS3ST3A1*covariate) 
LR χ22df  =[-2logL(Full)] – [2-logL(reduced)] 
For a LR p value<0.20, the interaction term was determined not to modify the 
association of interest.  If the LR p value was ≥0.20, the interaction term was determined 
not to modify the association of interest. 
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Figure 3.5 Directed Acyclic Graph (DAG) for gene expression association with HIV MTCT † 
 
† Dotted lines represent hypothesized associations where the direction of association has not been  
established in the literature. 
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3.3.15 Evaluation of Confounding 
Covariates determined not to be EMMs were subsequently tested for confounding 
in each model.   Each covariate was subjected to three tests: 1) association with the 
outcome of interest among the unexposed, 2) association with the exposure of interest 
among the controls, and 3) creating a percent change in estimate >10%.  For tests 1 and 2, 
an OR above 3.0 or below 0.5 was considered a strong association.  An OR between 0.50 
and 0.80 or between 1.2 and 2.9 was considered a moderate association.  Other ORs were 
considered to be weak associations.  If strong associations were observed for both the 
covariate-exposure and covariate-outcome analyses, the covariate was considered to be a 
strong confounder.  If a combination of strong and weak associations or two weak 
associations were observed, the covariate was classified as a weak confounder.. 
A greater emphasis was placed on the percent change in estimate criterion and 
this served as a resolution for borderline strong/weak confounders.  The difference 
between the crude OR and the adjusted by covariate OR were evaluated as lnCoRR= 
|ln(0.71)–ln(0.61)| * 100. A value greater than 10% was considered evidence of 
confounding and the covariate was planned for inclusion in multivariate models. 
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3.3.16 Additional Tables for Aims 2 & 3 Statistical Analysis: Crude Models and 
Evaluation of EMM 
The crude results for each model described for aims 2 and 3 are shown below.  
For models 8 and 9 (heparan sulfate gene SNPs vs. heparan sulfate gene expression), 
small sample size and low minor allele frequencies proposed a statistical issue, resulting 
in difficulties with convergence for some models. This was particularly the case of 
HS3ST3B1 SNPs vs. HS3ST3B1expression.  Thus, the crude results for model 9 are not 
presented and not further evaluated for EMM/confounding.  Furthermore, convergence 
and sample size were an issue for both model 8 in the evaluation of EMM/confounding, 
so the results of those analyses are not presented.  
EMM and confounding for model 10 (CCR5 SNPs. vs. CCR5 expression) were 
not evaluated in this dissertation as these results have already been published 38.  The 
crude model 10 was intended to determine whether this subset of individuals replicated 
previous results.  Thus, EMM and confounding was evaluated for models 1-7, but not for 
models 8-10.   
In order to evaluate EMM by covariates for Models 4-6, a logistic regression 
using high vs. low gene expression was used as the outcome and expression tertiles were 
used as the exposures of interest. This was done so that odds ratios could be calculated 
and compared across expression tertile strata. 
  
 
83 
Table 3.6 Crude associations for Models 1-3: Association of placental gene expression with HIV MTCT 
Exposure† Crude OR (95% CI) P 
HS3ST3A1 expression (N=150) 
Medium vs. low 
High vs. low 
0.66 (0.29, 1.51) 
0.99 (0.41, 2.34) 0.328 
HS3ST3B1 expression (N=132) 
Medium vs. low 
High vs. low 
2.02 (0.81, 5.02) 
1.56 (0.63, 3.84) 0.129 
CCR5 expression (N=141) 
Medium vs. low 
High vs. low 
1.31 (0.55, 3.11) 
1.38 (0.55, 3.43) 0.540 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome,  
HIV MTCT (yes/no); OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value 
 
Table 3.7 Crude associations for Models 4-6: Placental gene expression associations 
Comparison† β (95% CI) P 
HS3ST3A1 vs. HS3ST3B1 expression (N=177) 0.37 (0.12, 0.61) 0.004 
HS3ST3A1 vs. CCR5 expression (N=194) 0.29 (0.20, 0.38) <0.0001 
HS3ST3B1 vs. CCR5 expression (N=176) 0.11 (0.06, 0.18) <0.0001 
† Placental expression variables compared via linear regression; β: Beta coefficient; 95% CI: 95% Confidence  
Interval; P: P value 
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Table 3.8 Crude associations for Model 7: Association of CCR5 SNPs and haplotypes 
with CCR5 expression† 
SNP/Haplotype Genotype/Copies£ β (95% CI)† P 
CCR2-64VI VI/II vs. VV -0.05 (-0.65, 0.55) 0.872 
CCR5-2733AG AG/GG vs. AA -0.03 (-1.01, 0.96) 0.952 
CCR5-2554GT GT/TT vs. GG -0.08 (-0.66, -0.49) 0.778 
CCR5-2459AG AG/GG vs. AA -0.59 (-1.24, 0.06) 0.074 
CCR5-2135CT CT/TT vs. CC -0.63 (-1.27, 0.02) 0.057 
CCR5-2132CT CT/TT vs. CC -0.33 (-0.92, -0.25) 0.256 
CCR5-2086AG AG/GG vs. AA 0.57 (-0.27, 1.40) 0.184 
CCR5-1835CT CT/TT vs. CC -0.12 (-0.70, 0.47) 0.696 
Haplotype A (VAGGTCAC) +-/++ vs. -- 0.57 (-0.005, 1.14) 0.052 
Haplotype B (VATGTCAC) +-/++ vs. -- 0.84 (-0.80, 2.50) 0.313 
Haplotype C (VATGTCGC) +-/++ vs. -- 0.57 (-0.27, 1.41) 0.180 
Haplotype D (VATGTTAC) +-/++ vs. -- -0.49 (-1.09, -0.11) 0.108 
Haplotype E (VAGACCAC) +-/++ vs. -- -0.62 (-1.22, -0.02) 0.044 
Haplotype F1 (VAGACCAT) +-/++ vs. -- -0.03 (-1.27, 1.21) 0.957 
Haplotype F2 (IAGACCAT) +-/++ vs. -- -0.26 (-0.63, 0.58) 0.933 
Haplotype G1 (VGGACCAC) +-/++ vs. -- -0.03 (-1.01, 0.96) 0.952 
† Linear regression using a continuous outcome of placental expression, SNPs and 
haplotypes grouped as carriers vs. non carriers using carriers of each SNP variant or 
haplotype as the exposure of interest. β: Beta coefficient; 95% CI: 95% Confidence 
Interval for Beta coefficient; P: P value. Sample size ranged by model (192-194) 
£ Copies: Number of copies of haplotype: 0 (--), 1 (-+/+-), or 2 (++) per subject.  
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Table 3.9 Crude associations for Model 8: Association of HS3ST3A1 SNPs with 
HS3ST3A1 expression 
SNP Sample Size Position β (95% CI)† P 
rs9896557 31 13376273 -0.04 (-1.24, 1.16) 0.944 
rs9916623 153 13384523 -0.26 (-0.99, 0.47) 0.481 
rs7224721 133 13385098 -0.46 (-1.10, 0.19) 0.167 
rs16948063 49 13385406 -0.06 (-1.08, 0.96) 0.906 
rs10521225 78 13392090 -0.08 (-2.30, 2.13) 0.941 
rs9941385 26 13392537 0.36 (-1.0, 1.73) 0.585 
rs10521226 121 13392554 -0.08 (-0.80, 0.65) 0.837 
rs1981629 152 13393581 -0.16 (-0.90, 0.58) 0.662 
rs10521227 43 13394685 0.14 (-0.79, 1.08) 0.758 
rs4399565 161 13407619 -0.14 (-0.92, 0.63) 0.713 
rs2098026 127 13411022 -0.67 (-3.48, 2.14) 0.639 
rs16948136 158 13417625 -0.17 (-0.97, 0.64) 0.684 
rs8069770 66 13417891 -0.18 (-1.10, 0.74) 0.696 
† Linear regression for the association between HS3ST3A1 SNPs and HS3ST3A1 
expression: continuous outcome of placental expression, SNPs grouped as carriers vs. 
non carriers.  β: Beta coefficient; 95% CI: 95% Confidence Interval for the Beta 
coefficient; P: P value. Effect estimates were undetermined for the following SNPs, due 
to small sample size: rs11078161, rs9909849, rs1029682, rs6502269, rs1860068, 
rs3785710, rs8073109, rs9897001, rs11651136, rs12941565, rs8082242, rs3785705, 
rs3785702, rs9303081, rs7212673, rs6502282, rs3785697, rs2098026, rs4588021, 
rs8082581, rs12952904, rs11078168, rs3785690, rs726799, rs8074072. 
 
 
Note that Model 9 is not presented due to sample size and convergence issues.   
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Table 3.10 Crude associations for Model 10: Association of CCR5 SNPs and haplotypes with HIV MTCT 
SNP/Haplotype Genotype/Copies£ OR (95% CI) ‡ P 
CCR2-64VI VI/II vs. VV  1.17 (0.57, 2.41) 0.663 
CCR5-2733AG AG/GG vs. AA 0.29 (0.10, 0.82) 0.019 
CCR5-2554GT GT/TT vs. GG 1.30 (0.66, 2.57) 0.454 
CCR5-2459AG AG/GG vs. AA 0.64 (0.28, 1.44) 0.279 
CCR5-2135CT CT/TT vs. CC 0.72 (0.32, 1.60) 0.417 
CCR5-2132CT CT/TT vs. CC 1.44 (0.71, 2.90) 0.307 
CCR5-2086AG AG/GG vs. AA 0.87 (0.30, 2.50) 0.790 
CCR5-1835CT CT/TT vs. CC 1.02 (0.50, 2.07) 0.951 
Haplotype A (VAGGTCAC) +-/++ vs. -- 1.38 (0.69, 2.79) 0.364 
Haplotype B (VATGTCAC) +-/++ vs. -- 1.47 (0.15, 14.50) 0.742 
Haplotype C (VATGTCGC) +-/++ vs. -- 0.88 (0.30, 2.53) 0.806 
Haplotype D (VATGTTAC) +-/++ vs. -- 1.35 (0.66, 2.77) 0.410 
Haplotype E (VAGACCAC) +-/++ vs. -- 0.91 (0.45, 1.86) 0.803 
Haplotype F1 (VAGACCAT) +-/++ vs. -- 0.47 (0.06, 3.47) 0.463 
Haplotype F2 (IAGACCAT) +-/++ vs. -- 1.19 (0.58, 2.45) 0.633 
Haplotype G1 (VGGACCAC) +-/++ vs. -- 0.29 (0.10, 0.82) 0.019 
‡  Logistic regression for association between CCR5 SNPs/haplotypes and HIV MTCT (yes/no).  OR: Odds ratio;  
95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. £ Copies: Number of copies of haplotype:  
0 (--), 1 (-+/+-), or 2 (++) per subject. N=~150 for each model. 
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Table 3.11 Evaluation of EMM by MVL of the association of placental gene expression with HIV MTCT: Models 1-3 
Exposure† 
Crude OR (95% 
CI) 
Low MVL 
OR (95% CI) 
High MVL 
OR (95% CI) 
ORM-H  
(95% CI) 
Mantel-Haenszel  
χ
2
 
(P) EMM? 
HS3ST3A1 
expression  
Medium vs. low 
High vs. low 
0.66 (0.29, 1.51) 
0.99 (0.41, 2.34) 
0.45 (0.12, 1.67) 
2.0 (0.50, 7.86) 
0.94 (0.30, 2.91) 
1.08 (0.33, 3.51) 
0.68 (0.29, 1.63) 
1.40 (0.56, 3.55) 
0.72 (0.396) 
0.52 (0.469) No 
HS3ST3B1 
expression  
Medium vs. low 
High vs. low 
2.02 (0.81, 5.02) 
1.56 (0.63, 3.84) 
1.75 (0.37, 7.98) 
0.71 (0.16, 3.22) 
3.64 (0.79, NA) 
0.67 (0.19, 2.21) 
2.59 (0.84, 7.98) 
0.68 (0.26, 1.81) 
2.77 (0.096) 
0.57 (0.45) No 
CCR5 expression  
Medium vs. low 
High vs. low 
1.31 (0.55, 3.11) 
1.38 (0.55, 3.43) 
1.11 (0.28, 4.31) 
0.42 (0.09, 2.05) 
0.74 (0.23, 2.33) 
1.56 (0.44, 5.41) 
0.88 (0.36, 2.15) 
0.96 (0.36, 2.60) 
0.08 (0.776) 
0.01 (0.941) No 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome, HIV MTCT (yes/no); 
OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. EMM: Effect measure modification. ORM-H: 
Mantel-Haenszel Combined Odds Ratio, χ2: Mantel-Haenszel Chi-Square Statistic. 
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Table 3.12 Evaluation of EMM by maternal syphilis of the association of placental gene expression with HIV MTCT: Models 1-3 
Exposure† Crude OR (95% CI) 
No Maternal 
Syphilis 
OR (95% CI) 
Yes Maternal 
Syphilis 
OR (95% CI) 
ORM-H  
(95% CI) 
Mantel-Haenszel  
χ
2
 
(P) EMM? 
HS3ST3A1 expression  
Medium vs. low 
High vs. low 
0.66 (0.29, 1.51) 
0.99 (0.41, 2.34) 
0.69 (0.33, 1.46) 
1.20 (0.56, 2.55) 
0 (0, 1.80) 
NA (0.121, NA) 
0.62 (0.30, 1.28) 
1.27 (0.60, 2.70) 
1.68 (0.194) 
0.38 (0.536) No 
HS3ST3B1 expression  
Medium vs. low 
High vs. low 
2.02 (0.81, 5.02) 
1.56 (0.63, 3.84) 
1.30 (0.56, 3.02) 
1.20 (0.53, 2.75) 
NA (0.84, NA) 
NA (0, NA) 
1.55 (0.68, 3.54) 
1.24 (0.54, 2.85) 
1.11 (0.292) 
0.25 (0.618) No 
CCR5 expression  
Medium vs. low 
High vs. low 
1.31 (0.55, 3.11) 
1.38 (0.55, 3.43) 
0.97 (0.45, 2.09) 
1.29 (0.58, 2.86) 
NA (0.40, NA) 
NA (0, NA) 
1.10 (0.52, 2.34) 
1.32 (0.59, 2.94) 
0.06 (0.801) 
0.45 (0.502) No 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome, HIV MTCT (yes/no); 
OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. EMM: Effect measure modification. ORM-H: 
Mantel-Haenszel Combined Odds Ratio, χ2: Mantel-Haenszel Chi-Square Statistic. 
 
Table 3.13 Evaluation of EMM by MVL of the associations of placental gene expression: Models 4-6 
Exposure† 
Crude  
OR (95% CI) 
Low MVL 
OR (95% CI) 
High MVL 
OR (95% CI) 
ORM-H  
(95% CI) 
Mantel-Haenszel  
χ
2
 
(P) EMM? 
HS3ST3B1 vs. HS3ST3A1  
Medium vs. low 
High vs. low 
0.95 (0.45, 1.97) 
3.78 (1.75, 8.15) 
1.08 (0.25, 4.83) 
2.67 (0.58, 0.90) 
0.51 (0.15, 1.69) 
17.50 (4.21, 71.03) 
0.68 (0.26, 1.76) 
7.56 (2.71, 21.08) 
0.64 (0.425) 
17.19 (<0.001) Maybe 
HS3ST3A1 vs. CCR5  
Medium vs. low 
High vs. low 
1.54 (0.76, 3.14) 
4.30 (2.07, 8.92) 
0.90 (0.23, 3.56) 
1.39 (0.34, 5.67) 
0.90 (0.29, 2.81) 
9.33 (2.38, 35.74) 
0.90 (0.37, 2.20) 
3.83 (1.49, 9.57) 
0.05 (0.82) 
8.33 (0.004) Maybe 
HS3ST3B1 vs. CCR5  
Medium vs. low 
High vs. low 
2.35 (1.12, 4.95) 
4.44 (2.05, 9.62) 
1.08 (0.25, 4.83) 
5.33 (1.06, 26.40) 
0.41 (0.12, 1.36) 
13.0 (3.23, 51.06) 
0.59 (0.23, 1.54) 
9.08 (3.09, 26.62) 
1.15 (0.284) 
18.31 (<0.001) Maybe 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome, high/low expression of 
the gene of interest; OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. EMM: Effect measure 
modification. ORM-H: Mantel-Haenszel Combined Odds Ratio, χ2: Mantel-Haenszel Chi-Square Statistic. 
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Table 3.14 Evaluation of EMM by maternal syphilis of the associations of placental gene expression: Models 4-6 
Exposure† 
Crude  
OR (95% CI) 
No Maternal 
Syphilis 
OR (95% CI) 
Yes Maternal 
Syphilis 
OR (95% CI) 
ORM-H  
(95% CI) 
Mantel-Haenszel  
χ
2
 
(P) EMM? 
HS3ST3B1 vs. HS3ST3A1  
Medium vs. low 
High vs. low 
0.95 (0.45, 1.97) 
3.78 (1.75, 8.15) 
0.54 (0.28, 11.60) 
3.41 (1.71, 6.80) 
0.60 (0.062, 5.56) 
NA (0, NA) 
0.55 (0.29, 1.05) 
3.56 (1.78, 7.11) 
3.31 (0.069) 
13.67 (0.0002) No* 
HS3ST3A1 vs. CCR5 
Medium vs. low 
High vs. low 
1.54 (0.76, 3.14) 
4.30 (2.07, 8.92) 
0.83 (0.44, 1.56) 
3.99 (2.05, 7.78) 
0.53 (0.067, 4.33) 
0 (0, 1.07) 
0.80 (0.43, 1.48) 
3.21 (1.70, 6.05) 
0.51 (0.474) 
13.70 (0.002) No* 
HS3ST3B1 vs. CCR5  
Medium vs. low 
High vs. low 
2.35 (1.12, 4.95) 
4.44 (2.05, 9.62) 
1.10 (0.57, 2.14) 
2.59 (1.32, 5.10) 
5.33 (0.46, NA) 
NA (0, NA) 
1.22 (0.65, 2.32) 
2.71 (1.38, 5.32) 
0.40 (0.527) 
8.56 (0.003) No* 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome, high/low expression 
of the gene of interest; OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. EMM: Effect measure 
modification. ORM-H: Mantel-Haenszel Combined Odds Ratio, χ2: Mantel-Haenszel Chi-Square Statistic. 
*EMM by Maternal Syphilis was determined not to be present due to small sample size in stratified analyses
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Table 3.15 Evaluation of EMM by MVL of the association of SNPs and haplotypes with CCR5 placental expression:  Model 7 
Variable 
Crude  
OR (95% CI) 
Low MVL 
OR (95% CI) 
High MVL 
OR (95% CI) 
ORM-H 
(95% CI) 
Mantel-Haenszel 
χ
2
 
(P) EMM? 
CCR2-64VI 0.83 (0.46, 1.51) 0.80 (0.19, 3.34) 1.14 (0.39, 3.29) 1.00 (0.42, 2.39) 0.00 (0.993) No 
CCR5-2733AG 0.80 (0.30, 2.12) 0.35 (0, 2.79) 0.37 (0, 2.83) 0.36 (0.07, 1.87) 1.53 (0.217) No 
CCR5-2554GT 1.34 (0.76, 2.36) 0.83 (0.21, 3.31) 1.04 (0.37, 2.92) 0.96 (0.42, 2.23) 0.01 (0.928) No 
CCR5-2459AG 0.40 (0.20, 0.78) 0.38 (0.08, 1.87) 0.33 (0.09, 1.22) 0.35 (0.12, 1.0) 3.96 (0.047) Yes 
CCR5-2135CT 0.38 (0.19, 0.75) 0.27 (0.06, 1.30) 0.33 (0.09, 1.22) 0.31 (0.11, 0.87) 5.14 (0.023) Yes 
CCR5-2132CT 0.99 (0.56, 1.76) 0.83 (0.21, 3.31) 1.16 (0.41, 3.31) 1.03 (0.44, 2.40) 0.00 (0.947) No 
CCR5-2086AG 2.10 (0.89, 4.99) 0 (0, NA) 1.21 (0.20, 7.40) 0.82 (0.13, 5.27) 0.04 (0.836) No 
CCR5-1835CT 0.86 (0.48, 1.52) 0.80 (0.19, 3.34) 0.99 (0.34, 2.84) 0.92 (0.39, 2.18) 0.04 (0.850) No 
Haplotype A 1.66 (0.93, 2.94) 1.71 (0.43, 6.87) 1.85 (0.65, 5.25) 1.79 (0.77, 4.20) 1.82 (0.180) No 
Haplotype B 5.33 (0.61, 46.53) NA NA NA NA NA 
Haplotype C 2.13 (0.90, 5.05) 0 (0, NA) 1.21 (0.20, 7.40) 0.83 (0.13, 5.38) 0.04 (0.849) No 
Haplotype D 0.82 (0.45, 1.48) 1.02 (0.26, 4.08) 0.84 (0.29, 2.44) 0.90 (0.38, 2.13) 0.06 (0.811) No 
Haplotype E 0.44 (0.24, 0.82) 0.49 (0.12, 2.02) 0.56 (0.20, 1.63) 0.54 (0.23, 1.27) 1.98 (0.160) No 
Haplotype F1 1.24 (0.37, 4.21) NA (NA, NA) 1.20 (0, NA) 1.20 (0.07, 20.17) 0.02 (0.900) No 
Haplotype F2 0.86 (0.47, 1.56) 0.89 (0.21, 3.77) 1.14 (0.39, 3.30) 1.04 (0.44, 2.50) 0.01 (0.925) No 
Haplotype G1 0.80 (0.30, 2.12) 0.35 (0, 2.79) 0.37 (0, 2.83) 0.36 (0.07, 1.87) 1.53 (0.217) No 
† Logistic regression for the association between CCR5 high/low expression and CCR5 variants: SNPs and haplotypes grouped as carriers vs. non carriers.  
OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. EMM: Effect measure modification. ORM-H: Mantel-Haenszel Combined 
Odds Ratio, χ2: Mantel-Haenszel Chi-Square Statistic. 
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Table 3.16 Evaluation of EMM by maternal syphilis of the association of SNPs and haplotypes with CCR5 placental expression: Model 7 
Variable 
Crude  
OR (95% CI) 
Low PLAP 
OR (95% CI) 
High PLAP 
OR (95% CI) 
ORM-H 
(95% CI) 
Mantel-Haenszel 
χ
2
 
(P) EMM? 
CCR2-64VI 0.83 (0.46, 1.51) 0.87 (0.47, 1.62) 0.31 (0, 3.26) 0.82 (0.45, 1.49) 0.42 (0.518) No 
CCR5-2733AG 0.80 (0.30, 2.12) 0.78 (0.30, 2.02) NA 0.78 (0.29 (2.07) 0.25 (0.619) No 
CCR5-2554GT 1.34 (0.76, 2.36) 1.38 (0.76, 2.48) 1.20 (0.15, 9.35) 1.36 (0.77, 2.41) 1.11 0.291) No 
CCR5-2459AG 0.40 (0.20, 0.78) 0.38 (0.19, 0.76) 1.14 (0.10, NA) 0.41 (0.21, 0.80) 6.89 (0.009) Yes 
CCR5-2135CT 0.38 (0.19, 0.75) 0.36 (0.18, 0.72) 1.14 (0.10, NA) 0.39 (0.20, 0.76) 7.68 (0.006) Yes 
CCR5-2132CT 0.99 (0.56, 1.76) 1.10 (0.60, 2.01) 0.53 (0.07, 4.33) 1.05 (0.58, 1.87) 0.02 (0.883) No 
CCR5-2086AG 2.10 (0.89, 4.99) 2.03 (0.83, 4.94) 2.0 (0, NA) 2.02 (0.84, 4.86) 2.54 (0.111) No 
CCR5-1835CT 0.86 (0.48, 1.52) 0.89 (0.49, 1.63) 0.31 (0, 3.27) 0.84 (0. 47, 1.50) 0.34 (0.558) No 
Haplotype A 1.66 (0.93, 2.94) 1.59 (0.87, 2.88) 1.33 (0.17, 11.37) 1.57 (0.88, 2.80) 2.32 (0.128) No 
Haplotype B 5.33 (0.61, 46.53) 5.24 (0.79, NA) NA 5.24 (0.60, 45.81) 2.75 (0.098) No* 
Haplotype C 2.13 (0.90, 5.05) 2.05 (0.84, 5.01) 2.0 (0, NA) 2.05 (0.85, 4.92) 2.63 (0.105) No 
Haplotype D 0.82 (0.45, 1.48) 0.86 (0.46, 1.60) 0.83 (0.11, 6.81) 0.86 (0.47, 1.56) 0.25 (0.618) No 
Haplotype E 0.44 (0.24, 0.82) 0.41 (0.22, 0.78) 1.88 (0.23, 14.80) 0.47 (0.25, 0.86) 5.97 (0.015) Yes 
Haplotype F1 1.24 (0.37, 4.21) 1.21 (0.38, 3.90) NA 1.21 (0.36, 4.14) 0.10 (0.756) No 
Haplotype F2 0.86 (0.47, 1.56) 0.90 (0.49, 1.69) 0.31 0, 3.27) 0.85 (0.46, 1.54) 0.30 (0.589) No 
Haplotype G1 0.80 (0.30, 2.12) 0.78 (0.30, 2.02) NA 0.78 (0.29, 2.08) 0.25 (0.619) No 
† Logistic regression for the association between CCR5 high/low expression and CCR5 variants: SNPs and haplotypes grouped as carriers vs. non carriers.  
OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. EMM: Effect measure modification. ORM-H: Mantel-Haenszel Combined 
Odds Ratio, χ2: Mantel-Haenszel Chi-Square Statistic. * EMM determined not to be present despite p value <0.10 if small sample size. 
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3.3.17 Conclusions from EMM & Evaluation of Confounding 
Maternal viral load and maternal syphilis were not strong effect measure 
modifiers for models 1-3.  For models 4-6, maternal viral load appeared to modify the 
effect in the highest expression tertile.  However, the confidence intervals were very wide 
suggesting that stratified analysis was underpowered and imprecise.  Thus, MVL was 
considered to be a weak EMM and was considered for confounding in models 4-6.  
Maternal syphilis was not a strong EMM for any models, and the sample size was small.  
Model 7 results varied for EMM of each covariate, depending on the SNP/haplotype.  
Model 7 also had issues with small sample size, making stratification or inclusion of 
interaction terms in the model less valuable.  Because of the inconsistency of EMM and 
issue of sample size for most models, none of the covariates were included as EMMs in 
the final analysis.  All covariates were evaluated for confounding. 
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Table 3.17 Evaluation of confounding of the association of gene expression with HIV MTCT: Models 1-3 
Covariate Exposure† 
Crude 
OR (95% CI) 
Outcome-Covariate 
association among 
the Unexposed‡ 
OR (95% CI) 
Exposure-Covariate 
association among the 
Controls 
OR (95% CI) 
Covariate 
Adjusted 
OR (95% CI) Ln|CoRR| 
MVL 
HS3ST3A1 expression  
Medium vs. low 
High vs. low 
 
0.66 (0.29, 1.51) 
0.99 (0.41, 2.34) 
 
1.46 (0.47, 4.56) 
 
0.71 (0.35, 1.48) 
0.68 (0.36, 1.29) 
 
0.73 (0.28, 1.94) 
1.12 (0.40, 3.19) 
 
0.10 
0.12 
HS3ST3B1 expression  
Medium vs. low 
High vs. low 
 
2.02 (0.81, 5.02) 
1.56 (0.63, 3.84) 
 
1.91 (0.58, 6.25) 
 
1.10 (0.55, 2.21) 
1.11 (0.56, 2.21) 
 
2.63 (0.78, 8.96) 
0.99 (0.34, 2.90) 
 
0.26 
0.45 
CCR5 expression  
Medium vs. low 
High vs. low 
 
1.31 (0.55, 3.11) 
1.38 (0.55, 3.43) 
 
1.78 (0.61, 5.23) 
 
0.98 (0.51, 1.88) 
1.75 (0.81, 3.75) 
 
0.83 (0.29, 2.34) 
0.83 0.26, 2.66) 
 
0.46 
0.51 
Maternal 
Syphilis 
HS3ST3A1 expression  
Medium vs. low 
High vs. low 
 
0.66 (0.29, 1.51) 
0.99 (0.41, 2.34) 
 
NA 
 
2.10 (0.75, 5.85) 
0.67 (0.21, 2.15) 
 
0.62 (0.27, 1.43) 
0.98 (0.42, 2.38) 
 
0.06 
0.01 
HS3ST3B1 expression  
Medium vs. low 
High vs. low 
 
2.02 (0.81, 5.02) 
1.56 (0.63, 3.84) 
 
0.59 (0.08, 4.55) 
 
3.10 (0.94, 10.24) 
0.18 (0.02, 1.43) 
 
1.92 (0.77, 4.81) 
1.62 (0.66, 4.02) 
 
0.05 
0.04 
CCR5 expression  
Medium vs. low 
High vs. low 
 
1.31 (0.55, 3.11) 
1.38 (0.55, 3.43) 
 
1.35 (0.23, 7.98) 
 
1.48 (0.49, 4.45) 
0.15 (0.02, 1.18) 
 
1.38 (0.57, 3.30) 
1.57 (0.62, 3.96) 
 
0.05 
0.13 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome, HIV MTCT (yes/no); OR: Odds 
Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value; Ln|CoRR|: Change in estimate, CoRR=difference in crude and adjusted 
OR. ‡ Unexposed for expression variable set to the lowest tertile/referent group.  
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Table 3.18 Evaluation of confounding of the associations of placental gene expression: Models 4-6 
Covariate Comparison† 
Crude  
OR (95% CI) 
Outcome-Covariate 
association among the 
Unexposed‡ 
OR (95% CI) 
Exposure-Covariate 
association among the 
Controls 
OR (95% CI) 
Covariate Adjusted 
OR (95% CI) Ln|CoRR| 
MVL 
HS3ST3B1 tertile vs. 
HS3ST3A1 high/low expression 
Medium vs. low 
High vs. low 
 
0.95 (0.45, 1.97) 
3.78 (1.75, 8.15) 
 
0.53 (0.09, 3.18) 
 
0.56 (0.10, 3.10) 
 
2.30 (0.69, 7.63) 
12.34 (3.59, 42.52) 
 
0.88 
1.18 
HS3ST3A1 tertile vs. CCR5 
high/low expression 
Medium vs. low 
High vs. low 
 
1.54 (0.76, 3.14) 
4.30 (2.07, 8.92) 
 
0.55 (0.12, 2.56) 
 
0.19 (0.04, 0.94) 
 
1.94 (0.68, 5.57) 
5.47 (1.83, 16.40) 
 
0.23 
0.24 
HS3ST3B1 tertile vs. CCR5 
high/low expression 
Medium vs. low 
High vs. low 
 
2.35 (1.12, 4.95) 
4.44 (2.05, 9.62) 
 
1.67 (0.27, 10.33) 
 
2.0 (0.30, 13.3) 
 
1.90 (0.59, 6.10) 
12.48 (3.62, 43.04) 
 
0.21 
1.03 
Maternal 
Syphilis 
HS3ST3B1 tertile vs. 
HS3ST3A1 high/low expression 
Medium vs. low 
High vs. low 
 
0.95 (0.45, 1.97) 
3.78 (1.75, 8.15) 
 
0.46 (0.04, 4.68) 
 
NA 
 
0.97 (0.46, 2.03) 
3.53 (1.62, 7.66) 
 
0.02 
0.07 
HS3ST3A1 tertile vs. CCR5 
high/low expression 
Medium vs. low 
High vs. low 
 
1.54 (0.76, 3.14) 
4.30 (2.07, 8.92) 
 
6.30 (0.62, 64.43) 
 
2.53 (0.52, 12.45) 
 
1.58 (0.77, 3.25) 
4.10 (1.97, 8.54) 
 
0.03 
0.05 
HS3ST3B1 tertile vs. CCR5 
high/low expression 
Medium vs. low 
High vs. low 
 
2.35 (1.12, 4.95) 
4.44 (2.05, 9.62) 
 
NA 
 
0.41 (0.04, 3.93) 
 
2.39 (1.13, 5.05) 
4.16 (1.91, 9.06) 
 
0.02 
0.07 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the outcome, high/low expression of the gene of interest; OR: 
Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value; Ln|CoRR|: Change in estimate, CoRR=difference in crude and adjusted OR. 
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Table 3.19 Evaluation of confounding of the associations of CCR5 SNPs and haplotypes with CCR5 placental expression: Model 7 
Covariate Variable 
Crude  
OR (95% CI) 
Outcome-Covariate 
association among 
the 
Unexposed 
OR (95% CI) 
Exposure-Covariate 
association among the 
Controls 
OR (95% CI) 
Covariate 
Adjusted 
OR (95% CI) Ln|CoRR| 
MVL 
CCR2-64VI 0.83 (0.46, 1.51) 1.12 (0.39, 3.18) 1.10 (0.34, 3.54) 1.00 (0.42, 2.39) 0.19 
CCR5-2733AG 0.80 (0.30, 2.12) 1.26 (0.51, 3.16) 0.46 (0.09, 2.29) 0.36 (0.07, 1.87) 0.80 
CCR5-2554GT 1.34 (0.76, 2.36) 1.24 (0.39, 3.86) 1.10 (0.36, 3.36) 0.96 (0.42, 2.23) 0.33 
CCR5-2459AG 0.40 (0.20, 0.78) 1.50 (0.22, 10.22) 1.13 (0.22, 5.64) 0.35 (0.12, 1.0) 0.13 
CCR5-2135CT 0.38 (0.19, 0.75) 1.20 (0.19, 7.78) 1.13 (0.22, 5.64) 0.30 (0.11, 0.87) 0.24 
CCR5-2132CT 0.99 (0.56, 1.76) 1.18 (0.39, 3.64) 0.84 (0.27, 2.60) 1.03 (0.44, 2.40) 0.04 
CCR5-2086AG 2.10 (0.89, 4.99) 1.18 (0.49, 2.83) 1.38 (0.12, 16.26) 0.82 (0.13, 5.21) 0.94 
CCR5-1835CT 0.86 (0.48, 1.52) 1.18 (0.41, 3.37) 1.26 (0.40, 4.03) 0.92 (0.39, 2.18) 0.07 
Haplotype A 1.66 (0.93, 2.94) 1.26 (0.40, 4.03) 1/26 (0.40, 4.03) 1.80 (0.77, 4.20) 0.08 
Haplotype B 5.33 (0.61, 46.53) 1.30 (0.55, 3.11) NA 1.30 (0.55, 3.11) 1.41 
Haplotype C 2.13 (0.90, 5.05) 1.27 (0.53, 3.08) 1.38 (0.12, 16.26) 0.83 (0.13, 5.30) 0.94 
Haplotype D 0.82 (0.45, 1.48) 1.45 (0.49, 4.36) 1.03 (0.33, 3.21) 0.90 (0.38, 2.13) 0.09 
Haplotype E 0.44 (0.24, 0.82) 1.30 (0.43, 3.96) 1.03 (0.34, 3.13) 0.54 (0.23, 1.27) 0.20 
Haplotype F1 1.24 (0.37, 4.21) 1.35 (0.56, 3.22) NA 1.20 (0.07, 20.17) 0.03 
Haplotype F2 0.86 (0.47, 1.56) 1.24 (0.43, 3.61) 1,10 (0.34, 3.54) 1.04 (0.44, 2.50) 0.19 
Haplotype G1 0.80 (0.30, 2.12) 1.26 (0.51, 3.16) 0.46 (0.09, 2.29) 0.36 (0.07, 1.87) 0.80 
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Table 3.19, continued 
Covariate Variable 
Crude  
OR (95% CI) 
Outcome-Covariate 
association among 
the 
Unexposed 
OR (95% CI) 
Exposure-Covariate 
association among the 
Controls 
OR (95% CI) 
Covariate 
Adjusted 
OR (95% CI) Ln|CoRR| 
Maternal 
Syphilis 
CCR2-64VI 0.83 (0.46, 1.51) 0.75 (0.19, 2.92) 1.47 (0.37, 5.88) 0.82 (0.45, 1.49) 0.01 
CCR5-2733AG 0.80 (0.30, 2.12) 0.54 (0.17, 1.69) NA 0.78 (0.29, 2.08) 0.03 
CCR5-2554GT 1.34 (0.76, 2.36) 0.59 (0.10, 3.38) 1.43 (0.36, 5.70) 1.36 (0.77, 2.42) 0.01 
CCR5-2459AG 0.40 (0.20, 0.78) 0.24 (0.02, 2.88) 0.72 (0.14, 3.81) 0.41 (0.21, 0.80) 0.02 
CCR5-2135CT 0.38 (0.19, 0.75) 0.23 (0.02, 2.79) 0.72 (0.14, 3.81) 0.39 (0.20, 0.76) 0.03 
CCR5-2132CT 0.99 (0.56, 1.76) 0.78 (0.17, 3.65) 1.99 (0.50, 7.91) 1.05 (0.58, 1.87) 0.06 
CCR5-2086AG 2.10 (0.89, 4.99) 0.54 (0.16, 1.87) .125 (0.14, 11.31) 2.02 (0.84, 4.86) 0.04 
CCR5-1835CT 0.86 (0.48, 1.52) 0.76 (0.19, 2.97) 1.16 (0.29, 4.60) 0.84 (0.47, 1.50) 0.02 
Haplotype A 1.66 (0.93, 2.94) 0.61 (0.15, 2.59) 0.79 (0.19, 3.39) 1.57 (0.88, 2.80) 0.06 
Haplotype B 5.33 (0.61, 46.53) 0.58 (0.19, 1.81) NA 5.24 (0.60, 45.80) 0.02 
Haplotype C 2.13 (0.90, 5.05) 0.55 (0.16, 1.90) 1.25 (0.14, 11.31) 2.05 (0.85, 4.92) 0.04 
Haplotype D 0.82 (0.45, 1.48) 0.57 (0.12, 2.50) 1.40 (0.35, 5.59) 0.86 (0.47, 1.56) 0.05 
Haplotype E 0.44 (0.24, 0.82) 0.30 (0.06, 1.60) 1.05 (0.26, 4.19) 0.46 (0.25, 0.86) 0.04 
Haplotype F1 1.24 (0.37, 4.21) 0.56 (0.18, 1.74) NA 1.21 (0.36, 4.14) 0.02 
Haplotype F2 0.86 (0.47, 1.56) 0.77 (0.20, 3.02) 1.47 (0.37, 5.88) 0.85 (0.46, 1.54) 0.01 
Haplotype G1 0.80 (0.30, 2.12) 0.54 (0.17, 1.69) NA 0.78 (0.29, 2.08) 0.03 
† Logistic regression for the association between CCR5 high/low expression and CCR5 variants: SNPs and haplotypes grouped as carriers vs. non carriers.   
OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value; Ln|CoRR|: Change in estimate, CoRR=difference in crude and adjusted OR. 
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3.3.18 Conclusions from Confounding 
MVL was a strong confounder for models 1-3.  Because the effect measure 
modification of these variables varied by expression tertile whereas the confounding was 
consistent across tertiles, MVL was used as a confounder of interest in the final models 1-
3.  Maternal syphilis was not a strong confounder so was not included as a covariate in 
final models. 
For models 4-6, MVL was a strong confounder in all three models and will be 
used as a continuous covariate in the final models 4-6.  Maternal syphilis was not a strong 
confounder. 
For model 7, confounding by MVL varied by SNP/Haplotype whereas 
confounding by maternal syphilis was absent.  Model 7 was summarized for both crude 
and MVL-adjusted results. 
3.3.19 Evaluation of Linearity 
For logistic regression models (1-3), the continuous covariate (MVL) was tested 
for the assumption of linearity in order to determine whether the variable could be used 
as continuous variable in the adjusted models.  This involved categorizing MVL into 
indicator terms and evaluating the OR for each indicator term and the dichotomous 
outcome. If an incremental increase, decrease, or a constant OR was observed across 
covariate strata, the variables were determined to meet the assumption of linearity.  This 
was also done for the gene expression variables, which were log10-transformed to 
approximate normal distribution.   
MVL and the gene expression variables did not meet the assumption of linearity 
of the logit for the HIV MTCT outcome (Models 1-3). Thus, gene expression tertiles 
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(low, medium, and high expression) were used as the exposure variables and a quartile 
variable (very low, low/medium, medium/high, and high viral load) was used for MVL in 
adjusted models.  For the models evaluating the continuous gene expression outcomes, 
(Models 4-7), gene expression exposure variables and MVL were left in the log-
transformed continuous form.   
3.3.20 Adjusted Models 
The adjusted model results are presented in the tables below.  Note that the 
models chosen for presentation in the third manuscript (Chapter 6) may vary from the 
more comprehensive list of models described in this chapter. 
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Table 3.20 Adjusted by MVL associations for Models 1-3: Placental gene expression association with 
HIV MTCT 
Exposure† Adjusted by MVL OR (95% CI) 
HS3ST3A1 expression (N=100) 
Medium vs. low 
High vs. low 
0.77 (0.29, 2.08) 
1.12 (0.39, 3.24) 
HS3ST3B1 expression (N=85) 
Medium vs. low 
High vs. low 
2.52 (0.73, 8.73) 
0.96 (0.33, 2.88) 
CCR5 expression (N=92) 
Medium vs. low 
High vs. low 
0.78 (0.27, 2.25) 
0.77 (0.24, 2.49) 
† Expression variables were evaluated as log %change tertiles and evaluated for association with the 
outcome, HIV MTCT (yes/no); OR: Odds Ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; 
P: P value; MVL: Maternal HIV Viral Load 
 
 
Table 3.21 Adjusted by MVL associations for Models 4-6: Placental gene expression associations 
Comparison† 
Adjusted by MVL β  
(95% CI) P 
HS3ST3A1 vs. HS3ST3B1 expression (N=85) 0.57 (0.32, 0.81) <0.0001 
HS3ST3A1 vs. CCR5 expression (N=92) 0.22 (0.12, 0.32) <0.0001 
HS3ST3B1 vs. CCR5 expression (N=85) 0.19 (0.11, 0.27) <0.0001 
† Placental expression variables compared via linear regression; β: Beta coefficient; 95% CI: 95% 
Confidence Interval;  P: P value; MVL: Maternal HIV Viral Load 
 
.
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Table 3.22 Adjusted associations for Model 7: Association of CCR5 SNPs and haplotypes with CCR5 expression† 
SNP/Haplotype Genotype/Copies£ 
Adjusted by MVL  
β (95% CI)† P 
CCR2-64VI VI/II vs. VV 0.08 (-0.79, 0.96) 0.853 
CCR5-2733AG AG/GG vs. AA -0.31 (-1.78, 1.16) 0.677 
CCR5-2554GT GT/TT vs. GG -0.56 (-1.39, 0.28) 0.189 
CCR5-2459AG AG/GG vs. AA -0.33 (-1.36, 0.70) 0.527 
CCR5-2135CT CT/TT vs. CC -0.43 (-1.43, 0.58) 0.402 
CCR5-2132CT CT/TT vs. CC -0.31 (-1.16, 0.54) 0.465 
CCR5-2086AG AG/GG vs. AA -0.68 (-2.52, 1.15) 0.464 
CCR5-1835CT CT/TT vs. CC -0.01 (-0.87, 0.86) 0.987 
Haplotype A (VAGGTCAC) +-/++ vs. -- 0.59 (-0.25, 1.43) 0.167 
Haplotype B (VATGTCAC) +-/++ vs. -- 1.32 (-2.72, 5.36) 0.518 
Haplotype C (VATGTCGC) +-/++ vs. -- -0.67 (-2.52, 1.17) 0.469 
Haplotype D (VATGTTAC) +-/++ vs. -- -0.50 (-1.36, 0.36) 0.252 
Haplotype E (VAGACCAC) +-/++ vs. -- -0.19 (-1.05, 0.66) 0.654 
Haplotype F1 (VAGACCAT) +-/++ vs. -- 0.64 (-2.23, 3.52) 0.660 
Haplotype F2 (IAGACCAT) +-/++ vs. -- 0.11 (-0.77, 0.99) 0.800 
Haplotype G1 (VGGACCAC) +-/++ vs. -- -0.31 (-1.78, 1.16) 0.677 
† Linear regression using a continuous outcome of placental expression, SNPs and haplotypes grouped as carriers vs. 
non carriers using carriers of each SNP variant or Haplotype as the exposure of interest. β: Beta coefficient; 95% CI: 
95% Confidence Interval for Beta coefficient; P: P value; MVL: Maternal HIV Viral Load. Sample size ranged by 
model (91-94). 
£ Copies: Number of copies of haplotype: 0 (--), 1 (-+/+-), or 2 (++) per subject. 
 
  
 
CHAPTER 4 RESULTS MANUSCRIPT 1: Comparison of Genome Wide Variation 
between Malawians and African Ancestry HapMap Populations 
4.1 Summary 
This chapter is more methodological in nature compared to chapters 5 and 6.  It 
does not assess an exposure-disease relationship, but rather, aims to assess genetic 
diversity within Malawi and across populations of the International HapMap Project.  
The HapMap data included in this work is publically available for free download and 
offers no restrictions on publication other than cited rules on the HapMap Project 
website. This series of analyses is relevant to pharmacogenomic research, as differences 
in allele frequencies and linkage disequilibrium patterns across populations are important 
to consider for assessing drug and vaccine efficacy.  Genetic differences across 
populations may also provide clues about recent selective pressure due to infectious 
disease, lifestyle, or other distinguishing characteristics across populations.   
4.2 Abstract 
The International HapMap Project has supported our understanding of common 
genetic variation across the world, with applications to the research of genetics and 
disease. The purpose of our study was to compare genetic variation and substructure 
between Malawians andfour HapMap populations (N=376) of African Ancestry (AFA).  
The Malawian population sample consisted of 226 unrelated infants receiving antenatal 
care in Blantyre, Malawi.  Allele frequencies and adjacent linkage disequilibrium were 
measured for 617,715 single nucleotide polymorphisms (SNPs), genotyped across the 
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genomes of Malawian infants and of individuals within each HapMap population. Allele 
frequencies in the Malawian population were highly correlated with allele frequencies in 
AFA HapMap populations, namely Yoruban in Ibadan, Nigeria (Spearman’s r2=0.97), 
Luhya in Webuye, Kenya (r2=0.97), African Americans in the southwest United States (r2 
= 0.94), and Maasai in Kinyawa, Kenya (r2 = 0.91).  The correlation of allele frequency 
estimates were much lower between Malawians and other ancestry populations (r2<0.51).  
The correlations of marker-marker linkage disequilibrium for adjacent SNPs between 
Malawians and HapMap populations were stronger for the populations of African 
ancestry than for the other HapMap populations. (AFA Spearman’s r2>0.80, other 
ancestries r2<0.54). Principal components analyses revealed little evidence for population 
substructure within our Malawi sample but provided clear distinction between our 
Malawi sample and the AFA HapMap populations.  In total, our results show that our 
Malawian sample was genetically most similar to the HapMap samples from the Yoruba 
and the Luhya.  Interestingly, five SNPs within the lactase gene (LCT) were found to 
have substantially different allele frequencies between the Malawi population and Maasai 
in Kenyawa, Kenya (rs3769013, rs730005, rs3769012, rs2304370; Bonferroni adjusted p 
values <1x10-33).  
4.3 Introduction 
The International HapMap Project 189 has offered an extraordinary amount of 
information on common genetic variation across the human genome, leading to publicly 
available data including more than one million single nucleotide polymorphisms (SNPs) 
genotyped in populations across the world 190.  The project originally obtained 269 DNA 
samples from four populations: Han Chinese from Bejing, China (CHB), Japanese from 
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Tokyo, Japan (JPT), Caucasians from Utah, USA, with northern and Western European 
ancestry (CEU), and Yoruban of Ibadan, Nigeria (YRI) 189.  Subsequently, the project has 
introduced seven additional populations: Individuals of African ancestry in the Southwest 
USA (ASW), Chinese in Metropolitan Denver, Colorado (CHD), Gujarati Indians in 
Houston, Texas (GIH), Luhya in Webuye, Kenya (LWK), individuals of Mexican 
ancestry in Los Angeles, California (MEX), Maasai in Kinyawa, Kenya (MKK), and 
Toscans in Italy (TSI).  One use of the HapMap data for researchers is to characterize 
haplotype patterns and allele frequencies of SNPs in the HapMap populations and 
compare such patterns to those observed in other populations.  This exercise offers an 
assessment of genetic variation across groups and helps researchers to more adequately 
understand global genetic diversity that can apply to our understanding of disease.   
A number of studies have described transferability or “portability” of tagSNPs in 
the HapMap populations to tagSNPs in other populations.  Most of these studies have 
focused on specific ENCODE regions 196-198, candidate genes 199; 200, or collections of 
SNPs genotyped across one to three chromosomes 201-204.  Few studies have incorporated 
populations of African ancestry, and no studies have included Malawian individuals. The 
goal of this work was to compare genetic variation among HapMap populations of 
African ancestry (AFA) to a population from Blantyre, Malawi.  Information on 617,715 
SNPs across 22 autosomal chromosomes of the human genome is described.  To our 
knowledge, this study is foremost in incorporating Malawians into the population 
genetics forum, and adds an additional assessment of genetic variability within Malawi in 
relation to self-reported ethnicity.  The findings from this study add to our understanding 
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of genomic variation across the African continent as well as within one urban area of 
Malawi. 
4.4 Methods 
4.4.1 Malawi Study Population 
The participants involved in this work are a subset of a larger previously conducted 
cohort study of malaria and HIV in pregnancy 25; 180.  The prospective cohort was 
conducted from 2000 to 2004 and included 3,825 consenting pregnant women admitted 
to Queen Elizabeth Central Hospital 180.  HIV testing was performed at delivery and 
patients were followed up at 6 and 12 weeks post delivery.  A total of 1,157 women 
tested positive for HIV, 884 of which delivered at Queen Elizabeth Central Hospital 
resulting in 807 singleton live births.  At delivery, 751 infants were tested for HIV, 
identifying 65 HIV positive infants at birth.  Of the 668 HIV negative infants, 179 were 
lost to follow-up.  A total of 507 infants were tested for HIV at 6 or 12 weeks, resulting 
in 89 additional HIV positive infants.  A subset of the cohort (N=246) consisting of all 
HIV positive (at birth, 6 weeks, or 12 weeks) infants and an equal proportion of HIV 
negative (at all visits) infants of HIV positive mothers.  The HIV negative infants were 
obtained from a random sample of the HIV-exposed negative infants and had a similar 
distribution across time of enrollment as the cases.  Both positive and negative infants 
were required to have quality DNA samples available.  This subset was originally used in 
a genome wide association study (GWAS) to assess the association between SNPs across 
infant genomes and susceptibility to maternal HIV infection (manuscript in preparation).  
The genome-wide SNP data was applied to this work in order to evaluate the external 
generalizability of our findings.   
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Self-reported ethnicity for our final dataset of 226 subjects after quality control (see 
below) was available for the Malawi dataset, which included the following groups:  
Ngoni (N=62), Lomwe (N=59), Yao (N=34), Chewa (N=18), Tumbuka (N=15), 
Mang’anja (N=13), Sena (N=13), Khokhola (N=4), Nyanja (N=2), Chipeta (N=1), 
Likoma (N=1), Nkhonde (N=1), Ntcheu (N=1), Portugues (N=1), and Tonga (N=1).  A 
categorical variable was created corresponding to the first six groups listed and the last 
seven groups were combined into one category (other), unless it was known that two 
groups could be combined.  For example, Nyanja and Mang’anja are considered to be 
very similar 193 and were included in the same category.  The study population included 
from our data collection will be referred to as individuals of various self-reported 
ethnicity in Blantyre, Malawi (BMW). 
4.4.2 Genotyping 
Genotyping was completed for 114 HIV-exposed, infected infants and 132 
exposed, uninfected infants.  Additional cases were not available because DNA samples 
were of poor quality or had a very low concentration of DNA.  The genotyping was 
performed at Duke University Genotyping Core Laboratories, using Illumina’s 
HumanHap650Y Genotyping BeadChip version 3 (Illumina, Inc., San Diego, CA).  This 
BeadChip enabled whole-genome genotyping of over 655,000 tagSNPs derived from the 
International HapMap Project 168 and over 100,000 tag SNPs selected based on the 
Yoruban Nigerian HapMap Population. The 650Y BeadChip v3 utilized information in 
dbSNP up to version 126.
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4.4.3 Quality Control 
For the Malawi study population, quality control for genotyping error was 
performed at Duke University Genomic Laboratories and as previously described 92.  
Briefly, all samples were brought into a BeadStudio data file using an Illuminum cluster 
file and clustering of samples was evaluated in order to determine random clustering of 
SNPs.  Samples with very low call rates (<95%) were excluded.  Subsequent reclustering 
of undeleted SNPs and additional exclusion by call rate was performed 92.  SNPs with 
heterozygosity value between -1.0 to -0.1 and 0.1 to 1.0 were evaluated to determine if 
raw and normalized data indicated clean calls for the genotypes 92. 
Statistical quality control measures were performed at UNC Chapel Hill.  
Individuals missing more than 10% of marker data and SNPs with a genotyping rate less 
than or equal to 10% were excluded from analyses. Gender verification was completed 
for all subjects to ensure that gender recorded in the covariate dataset matched with 
gender based on genetic data.  For mismatches, gender was imputed based on the X 
chromosome (N=9).  Related individuals were identified by first estimating identity by 
descent (IBD).  A small number of individuals with pair-wise IBD estimated values > 
0.05 were removed (N=5).  All statistical quality control measures were performed in 
PLINK version 1.05 182.   After completing quality control, a total sample size of N=226 
BMW subjects were included in subsequent data analyses. 
4.4.4 Data Management and Integration of HapMap Populations 
All HapMap populations from Phase 3 were included in this study.  HapMap data 
was downloaded in PLINK format from the International HapMap Project website 189.  
The samples from the 11 HapMap populations were genotyped on approximately 1.5 
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million SNPs using the Illumina Human1M and Affymetrix Genome-Wide Human SNP 
Array 6.0 platforms.  For this study, populations were processed through identical 
statistical quality control as completed for the Malawi population with the exception of 
gender verification and IBD estimates.  In order to ensure the populations included only 
unrelated individuals, offspring of populations with duos or trios (ASW, CEU, MEX, 
MKK, YRI) were removed.  HapMap populations were then merged, either individually 
or jointly, with the Malawi population.  Due to strand differences between the Malawi 
population and the HapMap populations, some Malawi strands were flipped and the files 
were remerged. The genotype data from HapMap and our sample was based on the same 
dbSNP build 126 189. 
4.4.5 Statistical Analysis  
Four analytic methods were conducted in order to compare genetic variation 
between populations: 1) the correlation of allele frequencies across the genome, 2) the 
correlation of adjacent SNP-SNP linkage disequilibrium (LD) across the genome, 3) 
allelic-based chi-square tests to evaluate the association between population and SNPs, 
and 4) principal component analysis to evaluate population substructure.  Each HapMap 
population was individually compared to the Malawi population and within Malawi; the 
self-reported ethnic groups were compared.  In all analyses, comparisons were only made 
between SNPs with minor allele frequency (MAF) > 0.05 in each included population 
sample. 
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4.4.5.1 Comparison of Allele Frequencies and Adjacent SNP-SNP Linkage 
Disequilibrium 
Allele frequencies were computed for each population using PLINK version 1.05 
182
.  Each allele frequency file was formatted and imported into STATA version 10 188.  In 
order to compare allele frequencies across populations, a generic coded allele was set for 
each SNP, using alphabetical hierarchy (A<C<T<G).  For example, if the alleles were A 
and G for a particular SNP, the coded allele would be designated as A and the non-coded 
allele as G, regardless of the observed allele frequency in a population. Spearman’s 
correlation coefficient was computed for each pair of populations (i.e. BMW vs. ASW, 
BMW vs. YRI, etc.) using all SNPs with MAF > 0.05 in both populations.  Adjacent 
linkage disequilibrium (LD) was estimated by calculating the standard r2 value for all 
pairs of adjacent SNPs using PLINK version 1.05 182.  For each pair of populations, 
Spearman’s correlation coefficient was calculated using all adjacent SNP pair r2 
estimates.  
Allelic-based (1 df) chi-square tests were systematically computed to identify SNPs 
with significantly different allele frequencies between the Malawi population and each 
HapMap population containing subjects of African ancestry. Specifically, we defined a 
dichotomous outcome variable, with value of ‘1’ assigned to the BMW population and 
value of ‘2’ assigned to the comparison population (ASW, LWK, MKK, or YRI).  Two 
measures of the genomic inflation factor, based on the median and mean chi-square 
statistic over all SNP comparisons, were computed for each genome-wide association 
analysis using PLINK version 1.05 182. Because chi-square statistics are affected by 
sample size under the alternative hypothesis, analyses were also performed using a 
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random selection of 42 individuals from each HapMap comparison group to facilitate 
more direct comparison of the results across the HapMap populations.  The value of 42 
was used as it represented the smallest group (ASW, N=42).  
4.4.5.2 Population Substructure 
Population substructure was evaluated with principal components (PC) analysis 
separately in the Malawi population and then in the combined subset of the HapMap 
populations of African ancestry (ASW, LWK, MKK, YRI) plus the Malawi population. 
The PC analyses were conducted using EIGENSOFT version 2.0 191. SNP inclusion in the 
PC analysis was restricted to autosomal SNPs that had MAF > 0.05 and observed 
genotype frequencies consistent with Hardy-Weinberg equilibrium expected proportions 
(p > 0.001) in each participating individual population.  Strict SNP pruning based on 
pair-wise SNP-SNP LD was conducted to identify a subset of independent SNPs for 
inclusion in PC analysis.  Specifically, we calculated pair-wise SNP-SNP LD, measured 
by r2, between all SNP pairs within 500 kb in the BMW sample using PLINK.  A custom 
computer program was used to select the largest number of SNPs from each chromosome 
such that each selected SNPs had no other selected SNPs within 500 kb that were in LD 
with it (defined by r2 > 0.01).  Based on these selection rules, we identified 23,612 and 
18,481 SNPs for use in the PC analyses of the Malawi and combined African HapMap 
and Malawi samples, respectively. 
4.5 Results 
4.5.1 Quality Control 
The HapMap data available at the time of this study contained approximately 1.5 
million SNPs for 1,115 individuals of 11 unique ethnic groups.  The Malawi data 
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included 112 males and 114 females, with a genotyping call rate of 99.975%.  Following 
quality control, the combined HapMap and Malawi dataset included 1,150 individuals, 
602 of which were of African ancestry, and 633,763 SNPs, 617,715 of which were on 
autosomal chromosomes and incorporated in the analyses. 
4.5.2 Comparison of Allele Frequencies across Populations 
The allele frequencies of the Malawi population were highly correlated with the 
allele frequencies of the HapMap AFA populations.  Among the AFA subgroups, the 
allele frequencies of the Yoruban of Ibadan, Nigeria and the Luhya in Webuye, Kenya 
were most strongly correlated to those of the Malawians (Table 4.1).  Interestingly, allele 
frequencies of the Malawi population were more closely correlated with allele 
frequencies of individuals of African ancestry in the Southwest USA than they were with 
that of the Maasai in Kinyawa, Kenya (Table 4.1).  Much lower correlations in allele 
frequencies were observed between the Malawi population and HapMap populations of 
other ancestry (r2<0.54).  
A total of 15 self-reported ethnic groups comprised the BMW group.  The 
genotyping was completed for infants of the mother-infant pairs, so the ethnic groups 
reflect self-reported maternal ethnicity.  Data on paternal ethnic group was not available.  
Allele frequencies were highly correlated across all ethnic groups in the Malawian study 
population (Table 4.2).  The greatest correlation in allele frequency was observed for 
Ngoni and Lomwe, which represented the majority of infants in the dataset (27.9% and 
26.1%, respectively).  The smallest correlation was observed between the Lomwe and 
Nyanja/Mang’anja ethnic groups (Table 4.2).  All SNPs summarized were restricted to 
having a MAF > 0.05.  This resulted in approximately 569,373 SNPs compared by 
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population.  This number was slightly different for each comparison, as the number of 
SNPs with a MAF > 0.05 varied by population. 
Similar to allele frequencies, adjacent LD was highly correlated across populations 
of African ancestry (Table 4.3).  A lower correlation in adjacent LD was observed 
between the Malawi population and other ancestry HapMap populations (r2<0.55, Table 
4.3). For each pair of populations compared, the allele frequency correlation was higher 
than the correlation of adjacent SNP-SNP LD (Table 4.2, 4.3).  The average LD between 
pairs of adjacent SNPs in the Malawi population was similar to that observed in the other 
African ancestry HapMap populations and substantially lower than the average LD 
observed between adjacent SNPs in the other ancestry HapMap populations (Table 4.S1). 
4.5.3 SNPs Associated with Population Membership 
Allelic-based (1-df) chi-square tests revealed that allele frequencies significantly 
differed between Malawi and all four HapMap populations comprised of individuals of 
African ancestry for many SNPs. The greatest differences in observed allele frequencies 
existed between Malawi and the Maasai in Kinyawa, Kenya (BMW vs. MKK genomic 
inflation factor (GIF) or median χ2 =9.21, mean χ2=9.16; random sample of 42 GIF=4.31, 
mean χ2=4.49).  The Malawians and the individuals of African ancestry in the Southwest 
United States (BMW vs. ASW) also demonstrated strong differences in allele frequencies 
(GIF=2.54, mean χ2=2.72, for 42 total individuals in the ASW group). Smaller, though 
still highly significant, differences in allele frequencies were observed between the 
Malawi population and the Luhya in Webuye, Kenya (BMW vs. LWK) (GIF=2.22, mean 
χ
2
= 2.25; sample of 42 GIF=1.77, mean χ2=1.78) and between the Malawi population and 
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the Yorubans in Ibadan, Nigeria (BMW vs. YRI) (GIF=2.59, mean χ2= 2.62; sample of 
42 GIF=1.78, mean χ2=1.81). 
The top SNPs associated with population membership were investigated for 
functional significance, for each BMW vs. population comparison.  Depending on the 
comparison of interest, many SNPs reached genome-wide statistical significance, having 
Bonferroni corrected p values < 0.05 (Figure 4.1, Table 4.4).  For the comparison of 
allele frequencies between BMW and MKK, over 100 SNPs had a Bonferroni corrected p 
value <1x10-23. The most significant SNPs (the top 16) were all found on chromosome 2.  
Of the 30 most significant SNPs within genes, 4 were located within the Lactase gene 
(LCT) (frequencies of 3 SNPs displayed in Figure 4.2).  This gene is involved in 
production of the lactase enzyme, essential for the digestion of lactose 138, and has 
clinical implications for lactose intolerance.  
Fewer SNPs were statistically significantly different between BMW and LWK.  
Nine SNPs had a Bonferroni corrected p≤1x10-7, 5 of which were located within genes 
(Table 4.4).  For BMW vs. YRI, 15 SNPs had a Bonferroni corrected p≤1x10-7, 3 of 
which were within the gene major histocompatibility complex, class II, DP alpha 1 (HLA-
DPA1), which is involved in many immunological functions, including interaction with 
HIV-1 138.  The comparison between BMW and ASW resulted in 69 SNPs with a 
Bonferroni corrected p≤1x10-7, most of which were not located within genes (66.7%).   
4.5.4 Population Substructure 
Two separate analyses were performed to evaluate population substructure: for the 
Malawi population by itself, and for the HapMap populations of African ancestry (ASW, 
LWK, MKK, YRI) combined with the Malawi population.  The eigenvalues (EVs) for the 
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first 10 PCs for each analysis is reported in the supplementary material (Table 4.S2).  
Principal components analysis for the Malawi population revealed little evidence for 
population substructure (Figure 4.3) and we were unable to detect any genetic variation 
across self-reported ethnicity.  The largest EV, corresponding to PC1, was only 1.21 and 
nine next largest EVs decreased very slowly (Table 4.S2). 
Principal component analyses using the HapMap African ancestry populations and 
the Malawi population revealed clear distinction among the different populations of 
African ancestry (Figures 4.4 and 4.5).  Overall, the BMW, LWK and YRI samples 
showed tight within population clustering of PC values while the ASW and MKK 
populations showed relatively strong dispersion.  PC1 (corresponding EV = 7.63) values 
were generally ordered MKK < ASW < LWK < YRI < BMW, with considerable overlap 
between ASW and both MKK and LWK (Figure 4.4). PC1 provided clear distinction 
between BMW and all HapMap populations of African ancestry with the exception of 
YRI.  PC2 (corresponding EV = 2.77) provided two very distinct clusters, YRI and ASW 
in one cluster and BMW, LWK and MKK in the other cluster (Figure 4.4, Figure 4.5).  
PC3 (corresponding EV = 1.80) provided an additional independent axis of separation 
between BMW and LWK and clearly separated LWK from ASW (Figure 4.5). 
4.6 Discussion 
The aim of this work was to compare genetic variation of HapMap populations of 
African ancestry (AFA) to a population of HIV-exposed infants from Blantyre, Malawi.  
We also present some results contrasting Malawians and HapMap populations of other 
ancestry.  HapMap populations were first compared to Malawians based on observed 
allele frequencies and adjacent SNP-SNP linkage disequilibrium (LD) r2 values across 
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the autosomal genome.  Allele frequency correlations were strong between the Malawi 
population (BMW) and the HapMap populations of African ancestry, with Spearman’s 
r2> 90%.  However, it was observed that the Malawi population appeared to be more 
closely related to the individuals of African ancestry in the Southwest United States 
(ASW) than they were with the Maasai in Kinyawa, Kenya (MKK).  This was interesting, 
as we expected the Caucasian ancestry in ASW subjects would dilute the correlation of 
allele frequencies between the Malawi and ASW samples. The stronger contrast in allele 
frequencies between BMW and MKK compared to BMW and other AFA populations is 
likely a reflection of the variable regional ancestry within the African continent.  The 
Maasai are classified as a Nilotic population and speak Maa, a Nilo-Saharan language 205.  
Thus, they may have stronger ancestral roots from North-Eastern Africa whereas the 
BMW, YRI, and LWK claim origins closer to West, Central Africa.  The ASW group 
appears to be more closely related to the BMW, YRI, and LWK, resulting in the MKK as 
a relative outlier in the African ancestry populations studied here. Results from the 
association analyses were consistent with the findings of the allele frequency 
comparisons by population, showing that the Malawi population is most similar to the 
YRI and LWK populations, less similar to the ASW, and least similar to the MKK.  
Local LD patterns, as measured by r2 for all adjacent SNP pairs, showed a similar pattern 
as observed when evaluating allele frequencies, with BMW having the most similar SNP-
SNP LD values to YRI and LWK, and less similar LD values to ASW and MKK.  Still, it 
is noted that the differences in the correlation of allele frequencies and pair-wise SNP-
SNP LD between BMI and MKK or ASW are considerably smaller than the differences 
between any sample of African ancestry and any HapMap sample of non-African 
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ancestry. The differences in allele frequencies and SNP-SNP LD values between the 
Malawi population and the HapMap populations of other ancestry (i.e. CEU, TSI, JPT, 
etc.) were striking.  These findings illustrate inter-continental and cross-continental 
genetic diversity and suggest that care must be taken when assessing generalization of a 
genetic study, e.g. the results of a drug clinical trial.  
A number of relative outlier SNPs identified by the comparison of allele 
frequencies across African ancestry populations were of interest with regards to function.  
This included four SNPs in the comparison of BMW to MKK located in the Lactase 
(LCT) gene.  This gene encodes a protein that is integral to plasma membrane and has 
both phlorizin hydrolase activity and lactase activity and has clinical relevance to lactose 
intolerance138.  We speculate that the differences between BMW and MKK for the LCT 
gene may be evidence of recent selective pressure.  The Maasai are a pastoralist 
community, relying heavily on the consumption of milk as part of a daily diet.  The SNPs 
discussed here were located within an intron of LCT, and functional value was 
undetermined. 
Our final analyses assessed population substructure by using principal components 
analysis.  The Malawi sample itself was found to be reasonably homogenous, exemplified 
by the high correlation in allele frequencies by self-reported ethnicity and by the lack of 
apparent population substructure.  The generalizability of these findings to the rest of 
Malawi is unclear, as this population was ascertained in Blantyre, the second largest city.  
Intermarriage or multiple ethnicities per household may be more common in urban areas 
compared to rural areas of Malawi.  It is also important to note that ethnicity was reported 
by mothers in the study, and genotyping was conducted in the infants.  Thus, the ethnicity 
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was known to be a surrogate for infant ethnicity in this study.  Because no separation was 
observed, we would not expect information on ethnicity from the father or any other 
family members to alter the findings that this group was very genetically homogenous. 
The principal components analyses showed that the Malawi population was 
genetically distinct from the other African ancestry populations.  In fact, all 5 African 
ancestry populations (BMW, ASW, LWK, MKK and YRI) could be distinguished by 
three PCs.  We speculate that the spread across PC2 in Figure 4.5 may reflect a north-
south gradient on the African continent, depending on what we assume about the 
geographic ancestry of individuals of African ancestry living in the south west United 
States.  The east-southern African populations were farther from the north-western 
African populations along PC2.  It is possible that this is a reflection of Malicot’s 
Isolation-by-Distance model, which predicts genetic similarity between populations will 
decrease exponentially as the geographic distance between them increases 206.  
While considerable efforts were made to include stringent quality control, there was 
a potential for batch effects in genotype calling between the Malawi and HapMap 
samples. It is conceivable that such batch effects contributed to the differences in allele 
frequencies observed between the populations. In order to determine whether or not this 
was the case, additional genotyping of the Malawi population simultaneously with 
HapMap samples and/or replication of these findings in other Malawi populations are 
necessary. 
4.7 Conclusions 
This study showed that the Malawi population in Blantyre does not exhibit strong 
genetic variability by self-reported ethnicity.  We also showed that although highly 
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correlated with regards to allele frequencies and adjacent SNP-SNP LD, the Malawi 
population and populations of African ancestry in the International HapMap Project are 
genetically distinct.  Furthermore, we determined that the allele frequencies and LD are 
not strongly correlated between Malawi and the HapMap populations of non-African 
ancestry.  The discordance in genetic variation observed both within and across 
continental lines highlights the necessity for researchers to consider ancestry and always 
account for population stratification.  It also suggests that such differences should be 
taken into account when predicting drug and vaccine efficacy. Future work may involve 
more fine-tuning of these results, including projects to sequence specific regions of 
interest in BMW subjects followed by a comparison of sequence variation by population. 
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4.9 Tables and Figures 
Table 4.1 Correlation of allele frequency across populations† 
Ancestry‡ Population BMW YRI LWK MKK ASW CEU CHB CHD GIH JPT TSI MEX 
AFA BMW 1                       
AFA YRI 0.972 1                     
AFA LWK 0.971 0.960 1                   
AFA MKK 0.913 0.906 0.932 1                 
AFA ASW 0.942 0.947 0.937 0.917 1               
EUA CEU 0.475 0.474 0.498 0.618 0.622 1             
ASA CHB 0.418 0.417 0.433 0.500 0.498 0.607 1           
ASA CHD 0.415 0.415 0.430 0.496 0.495 0.602 0.976 1         
ASA GIH 0.511 0.510 0.532 0.632 0.628 0.850 0.712 0.709 1       
ASA JPT 0.415 0.415 0.430 0.497 0.495 0.603 0.959 0.952 0.709 1     
EUA TSI 0.486 0.485 0.510 0.634 0.628 0.967 0.602 0.597 0.848 0.598 1   
MXA MEX 0.490 0.490 0.508 0.603 0.609 0.834 0.735 0.727 0.811 0.733 0.826 1 
† Spearman’s correlation coefficients for allele frequencies, MAF>0.05 
‡ Ancestry abbreviations recommended by HapMap: AFA: African ancestry, EUA: European ancestry, ASA: Asian ancestry,  
MXA: Mexican ancestry.  
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Table 4.2 Correlation of allele frequency across Malawi ethnic groups† 
Population Ngoni Lomwe Yao Chewa Tumbuka Mang'anja Sena Other 
Ngoni 1               
Lomwe 0.969 1             
Yao 0.958 0.956 1           
Chewa 0.937 0.935 0.925 1         
Tumbuka 0.928 0.927 0.916 0.897 1       
Nyanja/Mang'anja 0.919 0.918 0.907 0.888 0.880 1     
Sena 0.914 0.913 0.903 0.883 0.875 0.867 1   
Other 0.928 0.927 0.916 0.897 0.889 0.879 0.876 1 
† Spearman’s correlation coefficients for allele frequencies, MAF>0.05 
Table 4.3 Correlation of adjacent linkage disequilibrium across populations† 
Ancestry Population BMW YRI LWK MKK ASW CEU CHB CHD GIH JPT TSI MEX 
AFA BMW 1                       
AFA YRI 0.885 1                     
AFA LWK 0.873 0.842 1                   
AFA MKK 0.812 0.788 0.817 1                 
AFA ASW 0.797 0.791 0.775 0.783 1               
EUA CEU 0.518 0.509 0.530 0.646 0.616 1             
ASA CHB 0.498 0.489 0.504 0.582 0.551 0.684 1           
ASA CHD 0.495 0.486 0.501 0.577 0.545 0.678 0.929 1         
ASA GIH 0.538 0.527 0.547 0.651 0.614 0.838 0.750 0.744 1       
ASA JPT 0.494 0.485 0.501 0.576 0.545 0.676 0.918 0.910 0.743 1     
EUA TSI 0.525 0.515 0.537 0.655 0.617 0.925 0.678 0.672 0.833 0.670 1   
MXA MEX 0.527 0.518 0.535 0.630 0.604 0.813 0.745 0.738 0.794 0.739 0.802 1 
† Spearman’s correlation coefficients, MAF>0.05 Linkage disequilibrium measured in each population using adjacent marker r2. ‡ Ancestry 
abbreviations recommended by HapMap: AFA: African ancestry, EUA: European ancestry, ASA: Asian ancestry, MXA: Mexican ancestry. 
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Table 4.4 Top 10 Outlier SNPs for each comparison of BMW vs. HapMap populations of African ancestry† 
Comparison CHR SNP POS MAF1 MAF2 UNADJ BONF Gene 
BMW  
vs.  
MKK 
2 rs6430594 136435643 0.69 0.08 5.31E-68 2.64E-62 Aspartyl-tRNA synthetase (DARS) 
2 rs12472293 136364547 0.11 0.70 7.30E-61 3.63E-55 NA 
2 rs309143 136430648 0.78 0.18 4.70E-58 2.34E-52 Aspartyl-tRNA synthetase (DARS) 
2 rs3769013 136272652 0.81 0.23 8.33E-54 4.14E-48 Lactase (LCT) 
2 rs730005 136299164 0.71 0.16 2.13E-51 1.06E-45 Lactase (LCT) 
2 rs3769012 136272950 0.71 0.16 2.73E-50 1.36E-44 Lactase (LCT) 
2 rs961360 136110128 0.70 0.17 2.81E-48 1.40E-42 R3H domain containing 1 (R3HDM1) 
2 rs6430585 136223397 0.15 0.70 1.35E-47 6.72E-42 UBX domain protein 4 (UBXN4) 
2 rs3806502 136004743 0.73 0.21 6.98E-46 3.47E-40 R3H domain containing 1 (R3HDM1) 
2 rs2305248 135644782 0.72 0.21 9.44E-44 4.69E-38 RAB3 GTPase activating protein 
subunit 1 (catalytic) 
(RAB3GAP1) 
BMW  
vs.  
YRI 
19 rs2190687 14765415 0.50 0.06 9.26E-28 4.68E-22 NA 
2 rs6733349 231976556 0.44 0.06 2.48E-22 1.25E-16 NA 
7 rs1717725 38071558 0.05 0.30 1.50E-18 7.59E-13 NA 
7 rs6944302 79942827 0.49 0.17 5.20E-18 2.62E-12 Guanine nucleotide binding protein, 
alpha transducing 3 (GNAT3) 
7 rs12700014 18930601 0.54 0.23 1.19E-15 6.00E-10 Histone deacetylase 9 (HDAC9) 
9 rs3739821 129742298 0.32 0.08 8.61E-15 4.35E-09 Family with sequence similarity 102, 
member A (FAM102A) 
21 rs494619 18347077 0.35 0.07 1.84E-14 9.27E-09 NA 
6 rs2301220 33146744 0.26 0.57 6.68E-14 3.38E-08 Major histocompatibility complex, 
class II, DP alpha 1 (HLA-
DPA1) 
7 rs10216027 79968467 0.30 0.08 2.12E-13 1.07E-07 Guanine nucleotide binding protein, 
alpha transducing 3 (GNAT3) 
6 rs6457713 33185754 0.33 0.63 3.33E-13 1.68E-07 NA 
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Table 4.4, continued 
Comparison CHR SNP POS MAF1 MAF2 UNADJ BONF Gene 
BMW  
vs.  
LWK 
2 rs6733349 231976556 0.44 0.05 3.22E-19 1.62E-13 NA 
16 rs1017228 21971218 0.31 0.06 2.16E-17 1.08E-11 Chromosome 16 open reading frame 
52 (C16orf52) 
7 rs11772387 48019075 0.29 0.06 9.83E-15 4.95E-09 Sad1 and UNC84 domain containing 
1 (SUNC1) 
1 rs2236906 208038108 0.58 0.27 7.48E-13 3.77E-07 Interferon regulatory factor 6 (IRF6) 
1 rs4304614 107256813 0.25 0.55 1.08E-12 5.45E-07 NA 
2 rs3789106 111437355 0.28 0.07 1.54E-12 7.77E-07 Acyl-Coenzyme A oxidase-like 
(ACOXL) 
6 rs1572438 803970 0.16 0.42 3.71E-12 1.87E-06 NA 
7 rs1915960 48011003 0.07 0.27 9.55E-12 4.80E-06 Sad1 and UNC84 domain containing 
1 (SUNC1) 
7 rs10248243 47478639 0.05 0.24 1.09E-11 5.49E-06 Tensin 3 (TNS3) 
7 rs983186 27155184 0.06 0.25 1.36E-11 6.84E-06 Similar to hCG1644697 
BMW  
vs.  
ASW 
1 rs12030126 234879762 0.05 0.39 4.84E-20 2.43E-14 NA 
9 rs7020021 132242790 0.48 0.10 7.63E-19 3.83E-13 Hemicentin 2 (HMCN2) 
23 rs226711 98339530 0.08 0.49 9.45E-19 4.74E-13 NA 
2 rs282268 224628420 0.06 0.39 5.16E-18 2.59E-12 NA 
9 rs7045276 191644 0.07 0.39 3.87E-17 1.94E-11 NA 
2 rs282273 224631266 0.05 0.35 5.75E-17 2.89E-11 NA 
2 rs2577284 224637656 0.07 0.39 2.56E-16 1.28E-10 NA 
9 rs3739821 129742298 0.42 0.08 3.32E-16 1.66E-10 Family with sequence similarity 102, 
member A (FAM102A) 
1 rs6586395 232715442 0.10 0.45 4.77E-16 2.39E-10 NA 
8 rs7003117 115759827 0.08 0.39 6.30E-16 3.16E-10 NA 
† CHR: Chromosome, POS: base pair position, MAF1: Minor Allele Frequency in the Malawi Population, MAF2: Minor Allele Frequency in the 
Comparison Population, UNADJ: Unadjusted p-value, BONF: Bonferroni adjusted p-value, Gene: Official Gene Name (Symbol); NA if SNP not located 
within a gene. 
  
 
122 
Figure 4.1 SNP Associations with population membership.  Individuals in Blantyre, Malawi 
(BMW) were compared to each African ancestry HapMap population: Individuals of African 
ancestry in the Southwest USA (ASW), Luhya in Webuye, Kenya (LWK), Maasai in 
Kinyawa, Kenya (MKK), and Yoruban of Ibadan, Nigeria (YRI). 
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Figure 4.2 Lactase gene SNP frequencies by African ancestry population 
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Figure 4.3 No evidence of population substructure in Malawi population: Component 1 vs. 2.† 
 
† Analyses performed in EIGENSOFT version 2.0 175; 191 using 23,612 SNPs. 
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Figure 4.4 Separation of BMW and African ancestry HapMap populations: Component 1 vs. 2. 
 
† Analyses performed in EIGENSOFT version 2.0 175; 191 using 18,481 SNPs. 
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Figure 4.5 Separation of BMW and African ancestry HapMap populations: Component 2 vs 3. 
 
† Analyses performed in EIGENSOFT version 2.0 175; 191 using 18,481 SNPs 
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4.10 Supplementary Material 
Table 4.S1 Summary of adjacent linkage disequilibrium (r2) by population † 
 MAF>0 MAF>0.05 
Population N Mean SD N Mean SD 
BMW 570,561 0.17 0.23 484,054 0.17 0.24 
YRI 525,466 0.18 0.24 440,158 0.18 0.24 
LWK 546,763 0.18 0.24 455,593 0.18 0.24 
MKK 568,596 0.18 0.24 489,444 0.18 0.24 
ASW 574,549 0.19 0.24 499,283 0.19 0.24 
CEU 512,484 0.28 0.31 431,945 0.28 0.31 
CHB 445,490 0.32 0.34 328,135 0.32 0.34 
CHD 432,231 0.33 0.35 321,236 0.33 0.35 
GIH 513,496 0.28 0.31 422,745 0.28 0.31 
JPT 424,977 0.33 0.35 312,016 0.33 0.35 
TSI 515,987 0.28 0.32 431,967 0.28 0.32 
MEX 531,413 0.27 0.31 433,023 0.27 0.31 
† MAF: Minor allele frequency, SD: Standard Deviation 
 
 
 
Table 4.S2 First 10 eigenvalues corresponding to the 10 most significant principal 
components when analyzing only BMW subjects or when combining BMW, ASW, 
LWK, MKK, and YRI subjects. 
Principal Component (PC) BMW Only BMW, ASW, LWK, MKK, YRI 
PC1 1.21 7.63 
PC2 1.20 2.77 
PC3 1.20 1.80 
PC4 1.19 1.63 
PC5 1.19 1.54 
PC6 1.18 1.52 
PC7 1.18 1.52 
PC8 1.18 1.49 
PC9 1.18 1.49 
PC10 1.17 1.46 
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Figure 4.S1 Distribution of allele frequency by population.  Individuals in Blantyre, Malawi (BMW) were compared to 
each HapMap population. 
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Figure 4.S2 Distribution of adjacent linkage disequilibrium by population.  Individuals in Blantyre, Malawi (BMW) were 
compared to each HapMap population. 
 
  
 
CHAPTER 5 RESULTS MANUSCRIPT 2: A Whole Genome Association Study of 
Mother-to-Child Transmission of HIV in Malawi 
5.1 Summary 
This chapter describes the analysis of the genome wide association dataset, in order 
to assess infant genomic susceptibility to maternal HIV infection.   A key limitation of 
this work was inadequate power to establish genome wide statistical significance as the 
sample size was less than 250 individuals.  Although caution is warranted when 
interpreting the results of this chapter, it is important to include this information as it 
addresses the key goal of aim 1 and contributes novel information to our understanding of 
genetics and HIV MTCT.   
5.2 Abstract 
More than 500,000 children were newly infected with HIV in 2006, predominantly 
through mother-to-child transmission (HIV MTCT).  While antiretrovirals can 
substantially reduce transmission rates, only a small percentage of eligible mothers 
receive even the simplest single-dose nevirapine regimen.  Identification of host genetic 
traits associated with transmission may aid in the development of a vaccine to protect 
infants from infection.   Many studies have evaluated candidate genes for a role in fetal 
susceptibility to maternal virus, which may not entirely capture the role of human 
genetics in fetal susceptibility to maternal infection.   This study served as a hypothesis-
generating effort to identify novel single nucleotide variants which may be associated 
with HIV MTCT.  Mothers (N=3,821) in latent stages of labor were enrolled between 
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2000 and 2004 at the Queen Elizabeth Central Hospital, Blantyre Malawi, of whom 30% 
were HIV-positive.  HIV(+) mothers and their babies were treated with single-dose 
nevirapine.  Of 751 infants delivered to HIV (+) women, 65 (8.7%) were HIV(+) when 
tested within 48 hours.  Of the 507 HIV(-) infants followed for 6-12 weeks, 89 (17.5%) 
became HIV(+).  Whole genome scans (650,000 SNPs genotyped using Illumina 
genotyping assays) were obtained for 114 HIV(+) infants (at birth, 6, or 12 weeks) and 
132 HIV(-) infants (at birth, 6, and 12 weeks).  SNPs with minor allele frequency < 1%, 
missing more than 10% of genotype data, or with significant deviation from Hardy-
Weinberg equilibrium (P< 0.001) in the controls were removed.  Individuals missing 
more than 10% of genotype data or related individuals were also excluded.  We applied 
additive genetic models to 587,055 SNPs and no genome-wide significant evidence for 
association with HIV MTCT was obtained. Nineteen SNPs with p-values <5x10-5 were 
found within genes involved in several intracellular functions including transcription 
factor activities and signal transduction. Replication of these findings using a larger 
sample size may help us to differentiate true positive association findings. 
5.3 Introduction 
In sub-Saharan Africa, over 1,300,000 pregnant women were living with HIV in 
2007, 73,000 of which were in the small southern country, Malawi, landlocked between 
Tanzania, Zambia, and Mozambique, just North of Zimbabwe 207.  More than 500,000 
children were newly infected with HIV in 2006, predominantly through mother-to-child 
transmission (HIV MTCT) 1.  Much of the risk of HIV MTCT can be reduced by 
treatment with single dose nevirapine.  However, in many areas, mothers and their infants 
do not receive such regimens, and even in the context of prophylactic treatment, some 
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infants become infected whereas others remain free of infection.  Furthermore, HIV 
transmission can occur during pregnancy, labor and delivery, or through breastfeeding, 
by mechanisms which remain to be elucidated. 
There is growing evidence for genetic variants in the infant to be associated with 
the risk of HIV MTCT.  This includes variations in the genes, chemokine (CC motif) 
receptor 5 (CCR5), which encodes the (CC motif) receptor 5 co-receptor of CD4, two 
Human Leukocyte Antigen (HLA) genes (HLA-B and HLA-G), which encode cell-surface 
antigen-presenting proteins, and a gene encoding the mannose-binding lectin (MBL) 
protein (MBL2), which plays a role in innate immune responses to infection  111-114.  
Specifically, the CCR5 promoter polymorphisms -2459G and -2135T have been 
associated with HIV MTCT, at low levels of maternal HIV viral load 38; 39.  Mothers with 
HLA-B variants (*1302, *3501, *3503, *4402, *5001) were found to transmit HIV to 
their infant, even in the context of low viral loads, whereas mothers with other variants 
(*4901, *5301) did not transmit the virus despite high viral loads 94.  Maternal-fetal 
mismatches in the HLA-G variants C3743T, C634G, and 714insG/G have also been 
implicated with a variable risk of HIV MTCT, irrespective to maternal HIV viral load 
levels 96.  And several MBL2 polymorphisms can result in MBL deficiency, which has 
been associated with increased risk of HIV MTCT 118. 
Other genes have also been noted for association with adult disease progression or 
susceptibility to sexual transmission of HIV, but many of these effects are not replicated 
for association with HIV MTCT.  It is possible that the genetic risk factors involved in 
HIV infection and disease progression in adults do not directly overlap with the HIV 
MTCT phenotype and that the mechanisms with genetic underpinnings for HIV MTCT 
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await discovery.   To uncover new genes associated to HIV MTCT, we conducted a 
whole genome scan for fetal susceptibility to maternal HIV infection using information 
from consenting mother-infant pairs receiving antenatal care in Blantyre, Malawi.  We 
describe genetic risk factors in an understudied population with a high burden of HIV.   
Because HIV MTCT is a rare phenotype, it is difficult to ascertain thousands of 
cases in order to obtain adequate power for a typical genome wide association study.   
However, genome wide approaches to identify novel variants associated with such a 
phenotype are still important to assess and to apply towards future investigations.  
5.4 Methods 
5.4.1 Study Design and Population 
The study participants were a subset of a larger previously conducted cohort study 
of malaria and HIV in pregnancy 25; 180.  The prospective cohort was conducted from 
2000 to 2004 and included 3,825 consenting pregnant women admitted to Queen 
Elizabeth Central Hospital in Blantyre, Malawi 180.  Maternal HIV status was measured 
with the Determine HIV-1/2 Rapid Test (Abbott Laboratories, Illinois, USA) and the 
SeroCard HIV-1/2 Rapid Test (Trinity Biotech, Co Wicklow, Eire), as previously 
described 180.  Infant HIV status was determined at birth, 6, and 12 weeks using real time 
PCR 180.  HIV-infected women and their infants received a single dose (200 mg) of 
nevirapine at the onset of labor or at the time of delivery, respectively.  A total of 1157 
women tested positive for HIV, 884 of which delivered at Queen Elizabeth Central 
Hospital resulting in 807 singleton live births.  At delivery, 751 infants were tested for 
HIV, identifying 65 HIV positive infants at birth.  Of the 668 HIV negative infants, 179 
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were lost to follow-up.  A total of 507 infants were tested for HIV at 6 or 12 weeks, 
resulting in 89 additional HIV positive infants.   
A nested case control was conducted by selecting a subset of the cohort (N=246) 
consisting of all HIV positive (at birth, 6 weeks, or 12 weeks) infants and an equal 
proportion of HIV negative (at all visits) infants of HIV positive mothers.  The HIV 
negative infants were obtained from a random sample of the HIV-exposed negative 
infants and had a similar distribution across time of enrollment as the cases.  Both 
positive and negative infants were required to have quality DNA samples available.  
Because the control status of subjects were designated at the beginning of sample 
selection for the nested case control, this study was analyzed as a case-cohort study181.  
Mothers of infants could not be genotyped as the original IRB approval did not include 
this.  It was not possible to return to study participants in order to obtain informed 
consent for maternal genotyping.  Thus, no test of transmission disequilibrium or 
analyses involving mother-infant pairs could be conducted.  The focus was infant 
genomic susceptibility to HIV infection, given an HIV positive mother. 
5.4.2 Genotyping 
 Infant genotyping was performed at Duke University Genotyping Core 
Laboratories, by using Illumina’s HumanHap650Y Genotyping BeadChip.  This 
BeadChip enables whole-genome genotyping of over 655,000 tagSNPs derived from the 
International HapMap Project 168 and over 100,000 tag SNPs selected based on the 
Yoruban Nigerian HapMap Population.  The BeadChip contains over 4,300 SNPs with 
copy number polymorphism regions of the genome, 8,000 non-synonymous SNPs 
(nsSNPs), 1,800 tag SNPs in the Major Histocompatibility Complex (MHC) important 
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for immunological significance, 177 mitochondrial SNPs, and 11 Y-chromosome SNPs.  
The genotyping was completed for 114 HIV-exposed, infected infants and 132 exposed, 
uninfected infants.  Additional cases were not available because DNA samples were not 
available. 
5.4.3 Quality Control 
The quality control for genotyping error was performed at Duke University 
Genomic Laboratories as previously described 92.  Briefly, all samples were brought into 
a BeadStudio data file and clustering of samples was evaluated in order to determine 
random clustering of SNPs.  Samples with very low call rates (<95%) were excluded.  
Subsequent reclustering of undeleted SNPs and additional exclusion by call rate was 
performed 92.  SNPs with a heterozygosity value between -1.0 to -0.1 and 0.1 to 1.0 were 
evaluated to determine if raw and normalized data indicated clean calls for the genotypes 
92
.   
Statistical quality control was performed at the University of North Carolina at 
UNC Chapel Hill.  Individuals missing more than 10% of marker data, SNPs missing 
more than 10% of genotypes, SNPs with a minor allele frequency (MAF) ≤0.01, and 
SNPs out of Hardy-Weinberg Equilibrium (HWE) (p<0.001) in the control group were 
excluded.  Gender verification was completed for all subjects to ensure that gender 
recorded in the covariate dataset matched with gender based on genetic data.  For 
mismatched or missing gender, gender was imputed based on the X chromosome (N=9).  
Related individuals were identified by first estimating identity by descent (IBD).  A 
minimal list of individuals with IBD estimates <0.05 were removed (N=5).  Statistical 
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quality control was performed in PLINK version 1.05182.  Analyses were run without 
exclusions due to HWE in order to assess the difference in results. 
5.4.4 Statistical Analysis 
 Assuming an additive genetic model, logistic regression was performed where the 
outcome of interest was HIV status of the infant [(+)/(-)].  The null hypothesis was that 
the SNP of interest was not associated with HIV MTCT: Ho: β1=0, compared to the 
alterative hypothesis, that the SNP was associated with HIV MTCT: Ha: β1 ≠ 0.  All 
SNPs were assumed to be independent, and Bonferroni correction was used to adjust for 
multiple testing.  The Bonferroni adjusted p value corresponding to genome-wide 
statistical significance in this dataset was 0.05/587,055 SNPs=8.5x10-8.  These statistical 
analyses were conducted in PLINK version 1.05 182 and the results were visualized in 
WGAViewer 184.   
 Logistic regression was adjusted for maternal viral load (MVL), as it is a key risk 
factor for HIV MTCT.  MVL could not be evaluated for effect measure modification 
because of the small sample size.  Logistic regression results were presented for both 
unadjusted and MVL adjusted analyses. In order to evaluate population stratification, 
principal components analysis was performed by using EIGENSOFT version 2.0 175; 191. 
5.5 Power Analysis 
Power was calculated based on a Genome Wide scan of 587,055 SNPs, needing a p 
value of 1x10-8 in order to meet statistical significance after Bonferroni correction for 
multiple comparisons.  The Software Quanto 183 was used.  Per specifications of this 
software, power was computed using a log-additive model, allele frequency of 10%, a 
baseline risk of 25% (to approximate the proportion of infants that became infected with 
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HIV from HIV positive mothers in the GWAS study population), a case to control ratio 
of 1:1, and an alpha of 1x10-8 to account for multiple testing of over 587,055 SNPs.  Plots 
were created for varying relative risks (1.25 to 3.25). 
5.6 Results 
5.7 Quality Control and Power Analysis 
Data was available for 655,352 SNPs for 246 individuals (114 cases, 132 controls; 
116 males, 121 females).  Fifteen individuals were removed for low genotyping an 
additional 5 individuals were removed for having identity by descent (IBD) estimate p 
values≤0.05.  75,497 SNPs were removed due to HWE p<0.001 in the controls (n=431), 
low genotyping rate (n=21,589), and MAF<0.01 (n=53,477).  Following quality control, 
data was available for 231 individuals (103 cases, 128 controls, 114 males, 117 females) 
and 587,055 SNPs.  No evidence of population stratification was present (Eigen value 
range: 0.817 to 1.20, mean=0.995, Genomic Inflation Factor (GIF) based on median 
χ
2
=1.023, Mean χ2=1.013). 
The power analyses estimated that, depending on the effect estimate, at least 1000 
cases are needed in order to have 80% power to detect a p value of 1x10-8 and a baseline 
risk of 25%.  This implies that our current GWA dataset with a sample size of 231 for the 
MHP population is underpowered.  However, because additional cases could not be 
obtained, we were unable to increase sample size in order to boost power. 
5.8 Association Results 
No genome-wide significant SNPs were detected.  We identified 20 SNPs within 
12 genes with a p value<1x10-5 in either unadjusted analyses and/or analyses adjusted by 
maternal viral load (Table 5.1).   Although not statistically significant, several of the top 
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hits were localized in interesting genes.  This included 7 SNPs near or within genes 
involved in pregnancy and development (Table 5.2).  An additional 7 SNPs were located 
near or within genes with immunological function and/or HIV-1 protein interactions 
(Table 5.3).  One of the top SNPs corresponding to functional interest was rs8069770, 
located within the gene, HS3ST3A1 (Figure 5.1).  Analyses run including SNPs out of 
HWE in the control group show similar results (data not shown).   
5.9 Discussion 
We conducted a genome wide association study to detect genetic variants that 
influence HIV MTCT.  Although limited by sample size and the power to detect genome-
wide statistical significance, we were powered to detect large genetic effects for common 
variants.  No such genome wide statistically significant genetic effects were detected.  
Nonetheless, several findings were notable and may offer supportive data for other 
studies of the genetics of HIV MTCT. 
Several SNPs with p values <1x10-5 with biological significance were noted.  One 
of these is the SNP, rs8069770, located within the gene, HS3ST3A1.  This gene encodes 
the enzyme 3-O-sulfotransferase, which catalyzes the biosynthesis of a specific subtype 
of heparan sulfate (HS), 3-O-sulated heparan sulfate.  This HS subtype has specific 
functional significance for herpes simplex virus-1 152; 156 and heparan sulfate in general 
has been shown to be involved in HIV infection in some studies 22; 158; 208; 209.  However, 
to our knowledge, no sub-type specific investigations of heparan sulfate have been 
conducted for association with HIV MTCT.  Two SNPs were located within genes 
involved in embryonic development in animal models 138:  rs12306 (p=3.29x10-5) within 
the WD repeats and SOCS box-containing 1 (WSB1) gene, and rs1433666 (p=0.0001) 
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within the Glutamate receptor, ionotropic, delta 2 (GRID2) gene.  The role of these genes 
in human embryonic or the risk of HIV MTCT is uncertain.   
There were two SNPs (rs216743 and rs216744) with p values <1x10-5 identified in 
the cAMP responsive element binding protein 5 (CREB5).  The CREB5 product is part of 
the CRE (cAMP response element)-binding protein family.  One member of this family, 
CRE-BP1, is involved in mediating the adenovirus E1A-induced trans-activation 210.  
CREB5 has also been noted to serve as an integration site for xenotropic murine leukemia 
virus-related virus (XMRV) in prostate cancer tissue from patients homozygous for a 
reduced activity variant of the antiviral enzyme RNase L 211.  Another SNP, rs1358594 
(p=0.0003),  was of interest as it is within IL8, which mediates inflammatory response to 
HIV-1 infection 138.  Six other SNPs were found within genes that play a role in HIV 
infection.  We feel that this provides evidence for a similar role for such genes in HIV 
MTCT. 
Due to the nature and frequency of this rare HIV MTCT phenotype, we were 
unable to ascertain a sufficient number of cases to be powered for this genome wide 
association study.  However, this study did provide some new insights into the genetics of 
HIV MTCT and aims to facilitate replication studies for this phenotype.  
5.10 Conclusions 
This study evaluated over 587,000 SNPs for association with HIV MTCT in a 
collection of mother-infant pairs from Blantyre, Malawi.  Although we were unable to 
detect genome wide statistically significant effects, several SNPs with p values <1x10-5 
with biological significance were noted.   Replication of this work using a larger sample 
size will help us to differentiate true positive findings.
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5.11 Tables and Figures 
Table 5.1 Top SNPs selected by P value † 
CHR SNP BP A1 A2 MAF 
Unadjusted 
OR  
(95%CI) P 
Adjusted  
OR  
(95% CI) P Type Nearest Gene 
            
1 rs3861824 58519238 A G 0.11 0.23 
(0.11, 0.50) 
0.0001982 0.20 
(0.09, 0.44) 
6.29E-05 Intergenic Disabled homolog 
1 (Drosophila) 
 ( DAB1) 
3 rs4234621 192690338 C T 0.28 0.39 
(0.25, 0.61) 
5.03E-05 0.38 
(0.24, 0.60) 
4.58E-05 Intergenic Pyrin domain 
containing 2 
(PYDC2) 
5 rs6884962 172614988 G A 0.49 2.18 
(1.48, 3.21) 
7.31E-05 2.15 
(1.46, 3.17) 
0.0001068 Upstream AC008412.8 
6 rs2268993 88240830 C G 0.27 2.71 
(1.71, 4.28) 
2.20E-05 2.70 
(1.70, 4.28) 
2.65E-05 Intronic Solute carrier 
family 35 (CMP-
sialic acid 
transporter), 
member A1 
(SLC35A1) 
7 rs216743 28374947 A G 0.10 4.22 
(2.09, 8.53) 
6.16E-05 4.23 
(2.08, 8.61) 
6.89E-05 Intronic cAMP responsive 
element binding 
protein 5 ( CREB5) 
7 rs216744 28375004 G G 0.10 4.22 
(2.09, 8.53) 
6.16E-05 4.23 
(2.08, 8.61) 
6.89E-05 Intronic cAMP responsive 
element binding 
protein 5 ( CREB5) 
7 rs4722999 30467015 C C 0.32 2.46 
(1.58, 3.84) 
7.07E-05 2.38 
(1.52, 3.72) 
0.0001493 Intronic Corticotropin 
releasing hormone 
receptor 2 
(CRHR2) 
8 rs9314565 5217548 G C 0.47 0.42 
(0.27, 0.63) 
4.13E-05 0.41 
(0.27, 0.63) 
3.64E-05 Intergenic AC019176.4 
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Table 5.1, continued 
CHR SNP BP A1 A2 MAF 
Unadjusted 
OR  
(95%CI) P 
Adjusted  
OR  
(95% CI) P Type Nearest Gene 
            
8 rs476321 102578975 T C 0.27 2.55 
(1.65, 3.92) 
2.15E-05 2.50 
(1.62, 3.87) 
3.42E-05 Intronic Protein coding, 
protein info: 
transcription factor 
CP2-like 3, 
deafness, 
autosomal 
dominant 28, 
grainyhead-like 2 
(Drosophila)  
( GRHL2) 
9 rs12376718 29521579 T A 0.15 3.07 
(1.75, 5.39) 
9.79E-05 2.97 
(1.69, 5.20) 
0.000147 Intergenic RP11-48L13.1 
9 rs1889055 29529919 C N/A 0.24 2.52 
(1.61, 3.93) 
5.21E-05 2.48 
(1.59, 3.87) 
6.32E-05 Intergenic RP11-48L13.1 
12 rs12579934 24955685 T A 0.46 2.24 
(1.49, 3.36) 
9.59E-05 2.48 
(1.63, 3.78) 
2.45E-05 Intronic Branched chain 
aminotransferase 1, 
cytosolic ( BCAT1) 
14 rs2287652 77467201 C A 0.20 0.32 
(0.19, 0.56) 
5.15E-05 0.33 
(0.19, 0.57) 
7.12E-05 Intronic aarF domain 
containing kinase 1 
( ADCK1) 
16 rs12598821 12802357 T T 0.48 0.45 
(0.30, 0.68) 
0.0001199 0.43 
(0.28, 0.65) 
6.65E-05 Intronic AC010333.7 
16 rs6540013 85739442 G C 0.39 0.45 
(0.30, 0.68) 
0.0001158 0.44 
(0.29, 0.66) 
8.99E-05 Intergenic AC010531.8 
17 rs8069770 13417891 T G 0.14 0.27 
(0.14, 0.51) 
7.17E-05 0.25 
(0.13, 0.49) 
3.79E-05 Intronic Heparan sulfate 
(glucosamine) 3-O-
sulfotransferase 
3A1 (HS3ST3A1) 
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Table 5.1, continued 
CHR SNP BP A1 A2 MAF 
Unadjusted 
OR  
(95%CI) P 
Adjusted  
OR  
(95% CI) P Type Nearest Gene 
            
17 rs12306 22646238 A G 0.23 0.33 
(0.20, 0.55) 
2.02E-05 0.34 
(0.20, 0.57) 
3.92E-05 Intronic WD repeat and 
SOCS box-
containing 1 
(WSB1) 
18 rs8084223 20605148 T C 0.15 0.26 
(0.14, 0.49) 
3.41E-05 0.26 
(0.14, 0.50) 
4.21E-05 Intergenic AC104961.7 
22 rs131817 49245682 T G 0.23 0.37 
(0.22, 0.60) 
6.68E-05 0.36 
(0.22, 0.59) 
6.62E-05 Intronic Non-SMC 
condensin II 
complex, subunit 
H2 (NCAPH2) 
23 rs5934013 12307147 G A 0.15 4.18 
(2.12, 8.24) 
3.61E-05 4.09 
(2.08, 8.06) 
4.68E-05 Intronic FERM and PDZ 
domain containing 
4 ( FRMPD4) 
† SNPs with a P value < 5x10-5 in crude and/or adjusted by maternal HIV viral load analyses.  CHR: Chromosome, BP: Base pair location, A1: risk allele, A2: 
ancestral allele, MAF: Minor Allele Frequency, OR: Odds Ratio, 95% CI: 95% Confidence Interval of the OR, Adjusted OR: OR from analyses adjusted by 
maternal HIV viral load, Type: Location of the SNP with respect to the gene. 
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Table 5.2 Top SNPs in or near genes with roles in pregnancy and development† 
CHR SNP P Nearest Gene Presume Gene Function‡ 
17 rs8069770a 3.79E-05 Heparan sulfate (glucosamine) 3-
O-sulfotransferase 3A1 
(HS3ST3A1) 
Abundant expression in placenta; HIV-1 requires the gene product 
heparin sulfate proteoglycans for uptake in trophoblasts (cells 
forming the placental barrier). biosynthesis of an entry receptor for 
herpes simplex virus 1. 
17 rs12306a 3.92E-05 WD repeat and SOCS box-
containing 1 (WSB1) 
Unknown protein function induced by Hedgehog signaling in 
embryonic structures during chicken development. 
4 rs1433666a 0.0001 Glutamate receptor, ionotropic, 
delta 2 (GRID2) 
Mice homozygous for this mutation die shortly after birth from 
massive loss of mid- and hindbrain neurons during late 
embryogenesis. 
5 rs6884962b 0.0001 NK2 transcription factor related, 
locus 5 (Drosophila) 
(NKX2-5) 
Regulates tissue-specific gene expression essential for tissue 
differentiation; regulates temporal and spatial patterns of 
development (Shiojima et al., 1995) 
7 rs4722999a 0.0001 Corticotropin releasing hormone 
receptor 2 (CRHR2) 
Detected in placenta, myometrium, decidua, and fetal membranes; 
down-regulated expression in uterine tissues during pregnancy, 
most pronounced in laboring cervix; suggested paracrine role in 
birth process (e.g. effects on macrophages and endothelial cells). 
2 rs2677510b 0.0003 GLI-Kruppel family member GLI2 
(GLI2) 
Role during embryogenesis, DNA binding, Sonic hedgehog (Shh) 
signaling to potent oncogenes in the embryonal carcinoma cell. 
6 rs2268447a 0.0004 Pleiomorphic adenoma gene-like 1 
(PLAGL1) 
Mutations associated with congenital abnormalities, potential role 
in ovarian and other types of cancer; genetically imprinted in 
neonatal diabetes. 
† CHR: Chromosome, P: adjusted by Maternal Viral Load P value, a Intronic, b Intergenic SNP relative to the closest gene 
‡ Source: NCBI Entrez Gene and OMIM 
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Table 5.3 Top SNPs in or near genes with immunological function and HIV-1 protein interactions 
CHR SNP P Nearest Gene Presume Gene Function‡ 
6 rs3131036a 0.0002 Discoidin domain receptor family, 
member 1 (DDR1) 
Proximal to HLA genes; interacts w/collagen to up-
regulate IL-8 and inflammatory macrophages. 
10 rs3124199b 0.0002 Mitogen-activated protein kinase 
kinase kinase 8 (MAP3K8) 
Promotes production of TNF-alpha and IL-2 during T 
lymphocyte activation; promotes proteolysis of 
cytokine activator NFKB1 in rats. 
4 rs1358594b 0.0003 Interleukin 8 (IL8) HIV-1 Nef, Tat, and Vpr regulate IL-8 expression.  IL-
8 protein mediates inflammatory response including 
CD4+ response to HIV-1 infection. 
7 rs10254544d 0.0003 Nucleoporin like 2 (NUPL2) Interacts with HIV-1 Rev to mediates nuclear import 
of viral DNA and inhibit nuclear export of HIV-1 
mRNA. 
9 rs302923c 0.0003 General transcription factor IIIC, 
polypeptide 4, 90kDa 
(GTF3C4) 
HIV-1 Tat upregulates RNA polymerase III 
transcription by activating this gene. 
20 rs6037908b 0.0003 Prion protein (p27-30) 
(Creutzfeldt-Jakob disease, 
Gerstmann-Strausler-
Scheinker syndrome, fatal 
familial insomnia) (PRNP) 
HIV-1 Tat binds to a stem-loop structure in the mRNA 
of PrP, upregulating expression. 
7 rs6951646b 0.0004 Sp4 transcription factor (SP4) Activates the HIV-1 LTR promoter, possibly 
enhancing HIV-1 Tat-mediated transactivation of the 
viral promoter. 
a Intronic, b Intergenic, c Downstream, d Upstream SNP relative to the closest gene. 
‡ Source: NCBI Entrez Gene and OMIM 
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Figure 5.1 SNP rs8069770 within HS3ST3A1† 
 
† Gene context view of rs8069770 within HS3ST3A1.  The linkage disequilibrium 
(LD) is indicated where higher values of r2 correspond to higher LD between SNPs. 
  
 
CHAPTER 6 RESULTS MANUSCRIPT 3: Regulation of CCR5 expression in 
human placenta 
6.1 Summary 
This chapter represents the second manuscript that will be submitted for peer 
review, which will focus on the gene expression results from aims 2 and 3.  The results 
for CCR5, HS3ST3A1, and HS3ST3B1 are combined into one piece of work as genetic 
interactions and interplay within the placenta are important to note and because 
laboratory and statistical methods were similar. 
6.2 Abstract 
The chemokine co-receptor 5 gene (CCR5) plays a notable role in the risk of 
HIV/AIDS, where gene polymorphisms can lead to inhibited expression of the coreceptor 
for CD4, protecting the human host from infection and disease progression.  However, 
the association between host CCR5 polymorphisms and adult transmission of HIV does 
not directly replicate for the risk of mother-to-child transmission of HIV (HIV MTCT), 
and the mechanisms of HIV MTCT remain to be elucidated.  We have previously shown 
that the CCR5 promoter polymorphism, -2459G is protective among infants of mothers 
with low viral loads but not high viral loads 38. This polymorphism is associated with 
reduced receptor expression in vitro but has not been demonstrated in vivo.  To address 
this issue, we investigated the association between CCR5 expression in placental tissue 
and infant CCR5 polymorphisms in a population of mother-infant pairs receiving 
antenatal care in Blantyre, Malawi.  Placental gene expression was also described in 
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relation to maternal HIV infection, maternal malaria infection, maternal HIV viral load, 
and the expression of two genes involved in the biosynthesis of 3-O-sulfated heparan 
sulfate, HS3ST3A1 and HS3ST3B1, which play a role in herpes simplex virus 1 infection. 
Placental tissue samples were collected and immediately frozen at the time of delivery. 
RNA was extracted from placental tissue and used in multiplex real-time PCR run on 96-
well plates.  The percent change in target gene expression compared to the housekeeping 
gene was calculated and log-transformed. Linear regression was employed to evaluate the 
association between each predictor and CCR5 expression and logistic regression was 
used to evaluate associations with high vs. low expression of CCR5.  The CCR5 promoter 
polymorphisms CCR5-2554T (rs2734648, β= -0.67, 95% CI= -1.23, -0.11) and -2132T 
(β=-0.75, 95% CI=-0.131, -0.18) were significantly associated with reduced placental 
expression of CCR5.  An incremental increase in CCR5 expression was observed for 
increased expression of HS3ST3A1 (β=0.27, 95% CI=0.18, 0.35) and HS3ST3B1 (β=0.11, 
95% CI=0.06, 0.18).  Maternal HIV infection was not associated with CCR5 expression 
in the placenta (β=0.072, 95% CI=-0.57, -.72, p=0.826, N=194) although an incremental 
increase in maternal HIV viral load was statistically significantly associated with CCR5 
expression (β=0.76, 95% CI=0.12, 1.39; p=0.020, N=92).  Higher CCR5 expression was 
observed for mothers with malaria but this finding was not statistically significant 
(β=0.37, 95% CI=-0.43, 1.18, p=0.362, N=170). These results provide in vivo evidence 
for genetic factors and measures of infection involved in the regulation of CCR5 
expression in the placenta. 
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6.3 Introduction 
 In sub-Saharan Africa, over 1,300,000 pregnant women were living with HIV in 
2007, and more than 300,000 children were newly infected with HIV each year, primarily 
through mother-to-child transmission (HIV MTCT) 1. HIV MTCT can occur during 
pregnancy (intrauterine transmission), during labor and delivery (intrapartum 
transmission), or through breastfeeding (postpartum transmission).   
The chemokine (CC motif) receptor 5 (CCR5), a co-receptor of the CD4 receptor, 
is used by macrophage-tropic (R5) HIV-1 for cell entry 49 and is genetically regulated by 
the CCR5 gene 50.  It has been shown that HIV infection and progression is inhibited by 
competitive ligand binding with the CCR5 receptor 212; 213.  Furthermore, genetic variants 
of the CCR5 gene such as the 32-basepair deletion in the open reading frame the CCR5 
gene (CCR5 ∆32) or promoter polymorphisms are associated with variable human 
susceptibility to infection or progression of HIV-1 disease 47-49; 51; 52; 54-57,  likely 
explained by the loss of receptor expression resulting from mutation 53; 58; 59.   
The association between CCR5 variants in adult transmission may not directly 
apply to mother-to-child transmission of HIV (HIV MTCT).  A recent meta-analysis 
indicated that the CCR5∆32 mutation did not significantly alter the susceptibility to 
maternal infection among infants 60.  However, one study described modification of the 
effect of the ∆32 mutation by maternal HIV viral load 39.  Similar findings were observed 
for other CCR5 variants, and a promoter polymorphism, CCR5-2459G, was associated 
with a reduced risk of HIV MTCT but only in the context of low maternal viral load 38.  
CCR5 is expressed in the placenta 214 and its up-regulation has been associated with an 
increased risk of HIV MTCT 179.  To our knowledge, in vivo evidence of an association 
 149 
 
between infant CCR5 polymorphisms and CCR5 expression in the placenta has not been 
previously described.   
Heparan sulfate (HS), a highly sulfated polysaccharide in the form of a 
proteoglycan, made up of glucosamine and glucuronic/iduronic acid repeating 
disaccharide units, has also been noted to play a role in HIV infection.  HS can facilitate 
internalization of HIV-1 transactivator protein, Tat 215, which induces cytokine activity 
216
.  HIV-1 Tat is also known to bind to heparin 216.  This work is relevant to our study of 
CCR5 expression in the placenta and HIV MTCT as the attachment of HIV virus utilizing 
CCR5 as a coreceptor was shown to be less sensitive to treatment with heparinase 
compared to HIV virus utilizing the CXCR4 coreceptor 217.  HS and CCR5 are also 
known to interact, independent of HIV, and both bind to the chemokine RANTES218; 219.  
Furthermore, a gene (HS3ST3A1) that regulates the biosynthesis of a specific subtype of 
HS (3-O-sulfated HS) is highly expressed in the placenta.  The 3-O-sulfated HS subtype 
is of interest because it has been shown to play a role in HSV-1 infection in vitro 152; 153; 
155
. 
To our knowledge, the relationship between CCR5 and HS3ST3A1 expression in 
the placenta have not been described, in general, nor in the context of the risk of HIV 
MTCT. It is plausible that this relationship is important for understanding of the 
regulation of CCR5 expression in the placenta as well as the risk factors of HIV MTCT. 
The purpose of this study was to describe CCR5 regulation in the placenta from a 
cohort of consenting mother-infant pairs receiving antenatal care in Blantyre, Malawi.  
We investigated maternal measures of infection (maternal HIV infection, maternal HIV 
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viral load, and maternal malaria), CCR5 promoter polymorphisms, and heparan sulfate 
gene expression in relation to placental expression of CCR5.    
6.4 Methods 
6.4.1 Study Population 
The participants were a subset of a larger previously conducted cohort study of 
malaria and HIV in pregnancy 25; 180.  This study was conducted from 2000 to 2004 and 
included 3,825 consenting pregnant women admitted to Queen Elizabeth Central Hospital 
180
.  HIV testing was performed at delivery and patients were followed up at 6 and 12 
weeks post delivery.  A total of 1,157 women tested positive for HIV, 884 of which 
delivered at Queen Elizabeth Central Hospital resulting in 807 singleton live births.  At 
delivery, 751 infants were tested for HIV, identifying 65 HIV positive infants at birth.  Of 
the 668 HIV negative infants, 179 were lost to follow-up.  A total of 507 infants were 
tested for HIV at 6 or 12 weeks, resulting in 89 additional HIV positive infants. 
Information on maternal characteristics and viral load were available.  
 Fresh placental tissue samples from the MHP cohort were obtained from 
consenting study participants at delivery and immediately frozen at –4 degrees Celsius 
(0C).  Placental tissue samples from 723 HIV positive mothers and 419 HIV negative 
mothers were transported to the University of North Carolina at Chapel Hill.  Of the HIV 
positive mothers, a total of 411 samples had data on transmission status of the infant. 
 Power analyses showed that sample sizes of 157, 70, and 26 with 80% power was 
needed in order to detect a difference in mean gene expression of 25%, 15%, or 10% 
between two groups, respectively.  If multiple linear regression analysis was used, a total 
 151 
 
sample size of 200 was needed in order to obtain 80% power and a difference in r2 of 
0.03 between groups. 
 Based on this information and budget demands, a sample of 50 individuals were 
randomly selected from five transmission categories:  HIV negative mother/negative 
infant, HIV positive mother/negative infant at all visits, HIV positive mother/intrauterine 
transmission to the infant, HIV positive mother/intrapartum transmission to the infant, 
and HIV positive mother/postpartum transmission to the infant.   Only 47, 49, and 17 
mother-infant pairs were available for intrauterine, intrapartum, or postpartum 
transmission events, respectively.  The total sample size selected for RNA extraction and 
real time PCR was N=213. 
6.4.2 Gene Expression and Genotyping 
RNA was extracted from frozen placental tissue of mother-infant pairs (N=213) 
using RNeasy mini kit (Qiagen, Valencia, CA).  In order to quantify gene expression for 
each RNA sample, multiplex real-time PCR was run on 96-well plates using ABI 7700 
Sequence Detector according to methods previously described 194.  Each plate was 
normalized to an external placental RNA positive control sample.  The percent change in 
CCR5 expression and HS3ST3A1 expression for each sample compared to the positive 
control was calculated, log-transformed, and used as the primary outcome of interest in 
statistical analyses.  The gene HS3ST3B1 was also quantified as it is identical in function 
to HS3ST3A1.  Infant genotyping of CCR2-64I and CCR5 promoter polymorphsims were 
determined using multiplex ligase detection reaction (LDR) based method with flow 
cytometric technology as previously described 195. 
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6.4.3 Statistical Analysis 
The percent change in CCR5 expression was log-transformed in order to 
approximate a normal distribution.   CCR2/CCR5 SNPs were categorized into haplotypes, 
based on phylogeny and as previously described 220 (Supplementary Table 6.S1).  In 
order to evaluate the association between SNP/haplotype and CCR5 expression in the 
placenta, linear regression was performed using the continuous log-transformed CCR5 
expression as the outcome.   Logistic regression was also employed to evaluate the 
association between SNP/haplotype and high vs. low CCR5 expression, dichotomized at 
the median value.  Due to small cell sizes for some polymorphisms, SNPs and haplotypes 
were categorized as carriers of the variant/haplotype compared to non-carriers and 
analyzed according to a dominant model.  Because the SNPs were not completely 
independent, exhibiting variable pair-wise linkage disequilibrium (Supplementary Table 
6.S2), Bonferroni correction was not employed to adjust for multiple comparisons.    
The percent change in HS3ST3A1 expression and HS3ST3B1 expression were also 
log-transformed and individually evaluated for association with CCR5 expression 
through linear regression, using CCR5 expression as the continuous outcome.  Measures 
of maternal infection including maternal HIV, maternal HIV viral load (MVL), and 
maternal malaria were uniquely evaluated for association with continuous CCR5 
expression, also through linear regression.   
Finally, CCR5 expression was investigated for association with HIV MTCT.  
Logistic regression was used with HIV-1 HIV MTCT as the outcome, where transmission 
from mother to child was coded as 1 (transmission occurred) vs. 0 (no transmission).  
Different transmission time points (IU, IP, and PP) were also evaluated in independent 
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logistic regression models. Because CCR5 expression did not meet the assumption of 
linearity of the logit, it was categorized into tertiles for this model.  Because MVL is 
known to be a strong predictor of HIV MTCT, it was evaluated for effect measure 
modification of the association between CCR5 expression and HIV MTCT by calculating 
the Mantel-Haenszel Test of homogeneity of the odds ratios (OR) across strata.  It was 
also evaluated for confounding by using the percent change in estimate criterion: 
|ln(CoRR)|*100>10%, where |ln(CoRR)| = |ln(crude OR – adjusted OR)|*100 181.  
Because the data was analyzed as a case-cohort, the odds ratios from the logistic 
regression models estimated the risk ratios, regardless of the rarity of the outcome. 
6.5 Results 
6.5.1 Study Population 
A total of 212 mother-infant pairs evaluated for gene expression had previously 
been genotyped for CCR2/CCR5 polymorphisms 195.  This included 153 HIV positive 
mothers, 103 (67%) of which had infants who became HIV positive by 12 weeks post 
partum and 51 (33%) of which had HIV negative infants.  Following quality control, 
CCR5 SNP genotypes and placental expression was available for 198 mother-infant pairs.  
This included 44 (22.5%) HIV negative infants of HIV positive mothers, 98 (50.0%) HIV 
positive infants of HIV positive mothers, and 54 (27.6%) HIV negative infants of HIV 
negative mothers.  One hundred-sixty individuals also had data on HIV maternal viral 
load.   
6.5.2 CCR5 Gene Expression and CCR5 Variants 
The mean log %change in CCR5 expression for carriers was statistically 
significantly different between carriers of the CCR5-2132 T allele (mean log 
 154 
 
%change=5.53, range= -1.61, 9.40) compared to the wild type C allele (mean log 
%change=5.87, range=1.95, 14.55).  The CCR5-2132CT variant was statistically 
significantly associated with placental expression of CCR5, where carriers of the T 
variant displayed lower placental expression of CCR5 (Table 6.1).  The CCR5-2554 
GT variant was also statistically significantly associated with a lower expression of 
CCR5 (mean log %change for T allele=5.69, range=-1.61, 9.91; G allele mean log 
%change=5.77, range=1.95, 14.55), although this finding was not significant in the 
analysis of high vs. low expression (Table 6.1).   The minor allele frequency for CCR5-
2132T and -2554T was 0.23 and 0.29, respectively. CCR5 SNPs -2459G, -2135T, and -
1835T also corresponded to a lower risk of HIV MTCT, although these results were not 
statistically significant (Table 6.1). 
The A haplotype, which contains CCR5 -2132C and -2554G was associated with 
higher expression ofCCR5 in the placenta (Table 6.1).  A statistically significant 
association in the opposite direction (lower expression of CCR5) was observed for 
haplotype D, which contains CCR5 -2132T and -2554T (Table 6.1).  All other alleles 
were the same between haplotypes A and D.   Associations between CCR5 expression 
and other haplotypes were not statistically significant (Table 6.1). 
6.5.3 Gene Expression Interplay in the Placenta 
 An interesting interplay between placental expression of HS3ST3A1, HS3ST3B1, 
and CCR5 was observed in this study.  Higher expression of HS3ST3A1 or HS3ST3B1 
was associated with a higher expression of CCR5 (Figure 6.1).  Both gene expressions 
were highly associated with CCR5 expression in placenta (Table 6.2). 
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6.5.4 CCR5 Expression and Measures of Maternal Infection 
Maternal HIV infection was not associated with CCR5 expression in the placenta 
(β=0.072, 95% CI=-0.57, -.72, p=0.826, N=194).  Maternal HIV viral load, however, was 
associated with CCR5 expression, where an incremental increase in viral load 
corresponded to an incremental increase in CCR5 expression (β=0.76, 95% CI=0.12, 
1.39; p=0.020, N=92).  Maternal malaria infection was also associated with higher 
placental expression of CCR5, although not statistically significant (β=0.37, 95% CI=-
0.43, 1.18, p=0.362, N=170).  
6.5.5 CCR5 Expression and risk of HIV MTCT 
A general trend of increasing risk of HIV MTCT with increasing expression of 
CCR5 was observed but these findings were not statistically significant (Medium vs. low 
tertile: OR=1.16, 95% CI=0.49, 2.73; High vs. low tertile: OR=1.26, 95% CI=0.52, 3.03).  
Log maternal viral load did not modify the association between HIV MTCT and placental 
expression of CCR5 (ORMH=0.22, p=0.683).  In addition, MVL was not a confounder in 
the association based on a less than 10% change in the effect estimates after adjustment 
for MVL (%ln(CoRR)=6.7%) and because MVL was not associated with expression 
(β=0.02, 95% CI=-0.35, 0.39).  Although the estimates of the association between CCR5 
expression and each transmission time point were not very precise, a similar increased 
risk of transmission was observed for higher expression of CCR5 at all time points (Table 
6.3). 
6.6 Discussion 
This study evaluated the regulation of CCR5 expression in the placenta by known 
and unknown factors involved in the risk of HIV MTCT.  CCR5 promoter 
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polymorphisms -2132T and -2554T were associated with lower expression of CCR5 in 
the placenta, as illustrated by the associations of the haplotype D, which is tagged by 
these alleles.  Haplotype A was associated with significantly higher CCR5 expression in 
the placenta and differs from haplotype D in that it contains the wild type alleles, -2132C 
and -2554G (Supplementary Table 6.S2) 38.  These findings provide in vivo evidence for 
CCR5-2554 GT and CCR5 -2132CT down regulation of CCR5 expression in the 
placenta.   
We expected the SNPs associated with lower CCR5 expression to also be 
associated with a lower risk of HIV MTCT, and for SNPs associated with higher CCR5 
expression to be associated with a higher risk of HIV MTCT.  Referring to the 
association between CCR2/CCR5 SNPs and HIV MTCT previously described 38 and 
based on an replication analysis in this dataset, we found that this was not always the 
case.  Notably, CCR5 -2733G was associated with higher CCR5 expression compared to 
a lower risk of HIV MTCT, although the association with expression was not statistically 
significant (Supplementary Figure 6.S1).  CCR5 SNPs -2554T, -2132T, and 2086G also 
showed discrepant associations for CCR5 expression and HIV MTCT, with variable 
statistical significance. The only discrepant finding that was statistically significant for 
both associations was observed for the D haplotype, which was associated with lower 
CCR5 expression but a higher risk of HIV MTCT.  Haplotype D varies from all other 
haplotypes with regards to the -2132T allele, which displayed the same discrepant result 
(Figure 6.S1).  
We investigated the association between the expression of two genes involved in 
the biosynthesis of heparan sulfate and CCR5 expression in the placenta. Each gene was 
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independently evaluated for association with CCR5 expression.  Higher placental 
expression of HS3ST3A1 was significantly associated with higher expression of CCR5 in 
the placenta.  Similarly, higher expression of HS3ST3B1 was significantly associated 
with higher expression of CCR5 expression, although with a smaller effect size.  These 
findings suggest that each heparan sulfate gene may interact with CCR5 in the placenta, 
causing up-regulation, or that the genes may share a transcription regulatory region.   
We speculated whether this apparent co-expression was a reflection of maternal 
infection.  Thus, we investigated how maternal measures of infection are associated with 
CCR5 expression.  To our surprise, the HIV status of the mother was not a key predictor 
of CCR5 expression in the placenta.  Maternal malaria was also not a significant predictor 
of CCR5 expression.  However, higher maternal HIV viral load was significantly 
associated with higher CCR5 placental expression.  This suggests that CCR5 expression 
in the placenta among mothers with low viral load may not differ as greatly between HIV 
positive and negative mothers as it does between mothers with high MVL compared to 
mothers with low MVL. 
Because HIV viral load is associated with HIV MTCT, we expected CCR5 
expression to be associated with HIV MTCT.  However, we did not find support for this. 
Although higher levels of CCR5 expression corresponded to a higher risk of HIV MTCT, 
the findings were not statistically significant, suggesting a role of other factors in this 
association.  The confidence intervals were not remarkably wide, suggesting that 
precision and power were not a key issue for this analysis.  MVL was neither an effect 
measure modifier nor a confounder in this association.   
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To obtain the best power, the HIV MTCT outcome represented cumulative 
transmission status of the infant (occurring at birth, 6 weeks, or 12 weeks post partum).  
Thus, our measure of HIV MTCT may have combined variable mechanisms of HIV 
MTCT.  Because placenta samples were obtained at delivery, the placental expression of 
these genes is most representative of the expression occurring during labor and delivery.  
The association between gene expression and each transmission time point was evaluated 
and found to replicate our findings with the combined transmission variable with regards 
to the lack of statistical significance.  However, the IP transmission exhibited the greatest 
increase in risk for each incremental increase in CCR5 expression.  Although we 
evaluated the association between CCR5 expression and each time point of transmission, 
our estimates were not very precise, likely due to the small sample size per transmission 
time point.  Follow-up studies may need to address how these associations are replicated 
at different time points of transmission.  
6.7 Conclusions 
This study investigated the regulation of CCR5 in the placenta in a cohort of 
mother-infant pairs receiving antenatal care in Blantyre, Malawi.  We identified two key 
CCR5 polymorphisms associated with CCR5 expression and an association between the 
expression of two heparan sulfate genes and CCR5 expression in the placenta.  Although 
significantly variable by maternal HIV viral load, CCR5 expression was not significantly 
associated with maternal HIV infection or with HIV MTCT.  This information suggests 
that multiple factors may be involved in the regulation of CCR5 in the placenta and that 
such factors may not directly correlate to infection.  Additional work is needed in order to 
more clearly describe the mechanisms of HIV MTCT. 
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6.8 Tables and Figures 
Table 6.1 Frequencies and mean CCR5 expression by CCR5 SNP/haplotype category 
SNP/Haplotype 
Genotype 
/# Copies£ N 
Log % Change by Genotype 
N, Mean (Range) β (95% CI) † P OR (95% CI) ‡ P 
CCR2-64VI 
VV 
VI 
II 
142 
62 
10 
131, 5,82 (-1.61, 14.55) 
57, 5.59 (0.69, 12.33) 
10, 5.36 (2.30, 7.15) 
-0.27 (-0.87, 0.32) 0.374 0.69 (0.39, 1.24) 0.213 
CCR5-2733AG 
AA 
AG 
GG 
190 
21 
1 
177, 5.74 (-1.61, 14.55) 
19, 5.75 (2.56, 9.33) 
0, NA 
0.01 (-0.95, 0.97) 0.981 0.97 (0.38, 2.51) 0.957 
CCR5-2554GT 
GG 
GT 
TT 
102 
95 
15 
94, 6.09 (2.30, 14.55) 
89, 5.40 (-1.61, 9.91) 
13, 5.52 (2.77, 9.43) 
-0.67 (-1.23, -0.11) 0.019 0.61 (0.35, 1.08) 0.091 
CCR5-2459AG 
AA 
AG 
GG 
57 
113 
42 
53, 5.97 (-1.61, 14.55) 
105, 5.62 (0.69, 12.33) 
38, 5.76 (2.30, 9.25) 
-0.32 (-0.96, 0.32) 0.324 0.62 (0.33, 1.17) 0.142 
CCR5-2135CT 
CC 
CT 
TT 
58 
112 
42 
54, 6.00 (-1.61, 14.55) 
104, 5.62 (0.69, 12.33) 
38, 5.70 (2.30, 9.25) 
-0.36 (-0.99, 0.28) 0.269 0.59 (0.31, 1.11) 0.104 
CCR5-2132CT 
CC 
CT 
TT 
127 
71 
14 
114, 6.05 (2.30, 14.55) 
68, 5.09 (-1.61, 9.40) 
14, 6.33 (2.77, 9.43) 
-0.75 (-0.131, -0.18) 0.010 0.45 (0.25, 0.81) 0.007 
CCR5-2086AG 
AA 
AG 
GG 
182 
28 
3 
171, 5.70 (-1.61, 14.55) 
25, 6.15 (3.49, 9.91) 
1, 3.37 (3.37, 3.37) 
0.34 (-0.49, 1.18) 0.418 1.86 (0.80, 4.33) 0.149 
CCR5-1835CT 
CC 
CT 
TT 
130 
71 
12 
120, 5.93 (-1.61, 14.55) 
65, 5.41 (0.69, 12.32) 
12, 5.67 (2.30, 9.25) 
-0.48 (-1.05, 0.099) 0.104 0.59 (0.33, 1.05) 0.074 
  
 
160 
Table 6.1, continued 
SNP/Haplotype 
Genotype 
/# Copies£ N 
Log % Change by Genotype 
N, Mean (Range) β (95% CI) † P OR (95% CI) ‡ P 
Haplotype A  
(VAGGTCAC) 
0 
1 
2 
120 
81 
11 
110, 5.48 (0.69, 9.42) 
75, 5.82 (-1.60, 12.33) 
11, 7.80 (5.46, 14.55) 
0.59 (0.02, 1.16) 0.042 2.08 (1.17, 3.70) 0.012 
Haplotype B  
(VATGTCAC) 
0 
1 
2 
205 
7 
0 
189, 5.74 (-1.61, 14.55) 
7, 5.85 (3.14, 8.76) 
0, NA 
0.12 (-1.42, 1.65) 0.880 1.47 (0.32, 6.73) 0.622 
Haplotype C  
(VATGTCGC) 
0 
1 
2 
181 
28 
3 
170, 5.69 (-1.60, 14.55) 
25, 6.15 (3.50, 9.91) 
1, 3.37 (3.37, 3.37) 
0.35 (-0.49, 1.19) 0.411 1.89 (0.81, 4.40) 0.141 
Haplotype D  
(VATGTTAC) 
0 
1 
2 
138 
64 
10 
125, 6.09 (2.30, 14.55) 
61, 5.01 (-1.61, 9.40) 
10, 5.88 (2.77, 9.43) 
-0.96 (-1.54, -0.38) 0.001 0.36 (0.20, 0.67) 0.001 
Haplotype E  
(VAGACCAC) 
0 
1 
2 
141 
65 
6 
131, 5.66 (-1.61, 14.55) 
59, 5.97 (1.95, 9.76) 
6, 5.24 (4.38, 7.48) 
0.25 (-0.36, 0.85) 0.420 1.08 (0.60, 1.96) 0.802 
Haplotype F1  
(VAGACCAT) 
0 
1 
2 
200 
11 
1 
185, 5.77 (-1.61, 14.55) 
10, 5.17 (3.14, 9.25) 
1, 5.22 (5.22, 5.22) 
-0.60 (-1.83, 0.64) 0.342 0.60 (0.17, 2.13) 0.432 
Haplotype F2  
(IAGACCAT) 
0 
1 
2 
140 
62 
10 
129, 5.83 (-1.61, 14.55) 
57, 5.60 (0.69, 12.33) 
10, 5.36 (2.30, 7.15) 
-0.28 (-0.88, 0.32) 0.358 0.69 (0.38, 1.24) 0.214 
Haplotype G1  
(VGGACCAC) 
0 
1 
2 
190 
21 
1 
177, 5.74 (-1.61, 14.55) 
19, 5.75 (2.56, 9.33) 
0, NA 
0.01 (-0.95, 0.97) 0.981 0.97 (0.38 2.51) 0.957 
† Linear regression for the association between CCR5 expression and CCR5 variants: Continuous outcome of placental expression, SNPs and haplotypes 
grouped as carriers vs. non carriers using carriers of each SNP variant or Haplotype as the exposure of interest.‡  Logistic regression for association between 
CCR5 expression and CCR5 variants: Dichotomous outcome of high vs. low placental expression of CCR5; SNPs and haplotypes grouped as carriers vs. non 
carriers; β: Beta, OR: Odds ratio; 95% CI: 95% Confidence Interval for the Beta or Odds Ratio; P: P value; N=196 for all analyses in this table.£ # Copies: 
Number of copies of haplotype: 0, 1, or 2 copies possible per subject. 
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Table 6.2 Linear regression for the associations between expression variables 
Comparison† β (95% CI) P 
HS3ST3A1 vs. CCR5 expression (N=197) 0.27 (0.18, 0.35) <0.0001 
HS3ST3B1 vs. CCR5 expression (N=180) 0.11 (0.06, 0.18) <0.0001 
† Placental expression variables compared via linear regression; β: Beta coefficient; 
95% CI: 95% Confidence Interval; P: P value 
 
 
 
Table 6.3 Association between CCR5 placental expression and the risk of HIV MTCT at different time points 
Log %Change 
in Gene Expression 
Intrauterine Transmission Intrapartum Transmission Postpartum Transmission 
OR (95% CI)† P OR (95% CI) P OR (95% CI) P 
Medium low vs. Low 
Medium high vs. Low 
High vs. Low 
1.06 (0.37, 3.04) 
1.02 (0.34, 3.02) 
1.25 (0.42, 3.76) 
0.907 
0.974 
0.691 
1.11 (0.36, 3.42) 
1.88 (0.60, 5.96) 
1.21 (0.36, 4.08) 
0.862 
0.280 
0.757 
1.15 (0.25, 5.22 ) 
0.21 (0.02, 2.18) 
1.39 (0.28, 6.83) 
0.853 
0.190 
0.686 
†  Logistic regression for association between CCR5 expression and dichotomous outcome of yes/no HIV MTCT;  
OR: Odds ratio; 95% CI: 95% Confidence Interval for the Odds Ratio; P: P value. 
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Figure 6.1 Pattern of association between placental expression of heparan sulfate genes and CCR5† 
 
†Scatter Plots (left) and Predicted Linear Plots (right) 
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6.9 Supplementary Material 
Table 6.S1 CCR2/CCR5 haplotype identification and evolution 
Haplotype 
CCR2 
-64I 
CCR5 
-2733 
CCR5 
-2554 
CCR5 
-2459 
CCR5 
-2135 
CCR5 
-2132 
CCR5 
-2086 
CCR5 
-1835 
CCR5 
-ORF 
A V A G G T C A C WT 
B V A T G T C A C WT 
C V A T G T C G C WT 
D V A T G T T A C WT 
E V A G A C C A C WT 
F1 V A G A C C A T WT 
F2 I A G A C C A T WT 
G1 V G G A C C A C WT 
G2 V G G A C C A C ∆32 
 
Table 6.S2 Spearman’s correlation in CCR5 promoter polymorphisms 
SNP 
CCR5 
-2733 
CCR5 
-2554 
CCR5 
-2459 
CCR5 
-2135 
CCR5 
-2132 
CCR5 
-2086 
CCR5 
-1835 
CCR5-2733 1             
CCR5-2554 -0.09 1           
CCR5-2459 0.22 -0.58 1         
CCR5-2135 0.22 -0.57 0.98 1       
CCR5-2132 -0.13 0.70 -0.45 -0.44 1     
CCR5-2086 0.04 0.38 -0.19 -0.18 -0.30 1   
CCR5-1835 -0.12 -0.27 0.57 0.57 -0.21 -0.11 1 
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6.9.1 CCR5 Variants and HIV MTCT 
The findings of Pedersen et al. 38 were replicated in this subset of the original 
cohort from Malawi.  All findings were replicated with regards to the direction of 
association, with the exception of the association between CCR5-1835T and the risk of 
HIV MTCT, which varied slightly in direction was previous findings (OR=1.06 vs. 
RR=0.84).  Some findings also had variable statistical significance which may be a 
reflection of smaller sample size (Table 6.S3).  These discrepancies were not viewed to 
be problematic as the odds ratio typically overestimates the risk ratio in case control 
studies. 
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Table 6.S3 CCR5 SNP associations with CCR5 placental expression compared to CCR5 SNP associations with HIV MTCT 
SNP/Haplotype 
Genotype 
/#Copies£ 
Association with CCR5 expression Association with HIV MTCT Expression vs.  
HIV MTCT: 
Consistent  
Direction of  
Association? β (95% CI) † 
Direction of 
 association OR (95% CI) ‡ 
Direction of 
 association 
PlosONE RR 
(Consistent 
Direction of 
Association?)¥ 
CCR2-64VI 
VV 
VI 
II 
-0.27 (-0.87, 0.32) Lower  
expression 0.91 (0.45, 1.87) Near the null 1.00 (yes) No 
CCR5-2733AG 
AA 
AG 
GG 
0.01 (-0.95, 0.97) Near  the null 0.24 (0.086, 0.64) Lower risk 0.70 (yes) No 
CCR5-2554GT 
GG 
GT 
TT 
-0.67 (-1.23, -0.11) Lower  
expression* 1.59 (0.80, 3.14) Higher risk 1.18 (yes) No 
CCR5-2459AG 
AA 
AG 
GG 
-0.32 (-0.96, 0.32) Lower  
expression 0.50 (0.21, 1.14) Lower risk 0.78 (yes) Yes 
CCR5-2135CT 
CC 
CT 
TT 
-0.36 (-0.99, 0.28) Lower  
expression 0.56 (0.25, 1.27) Lower risk 0.78 (yes) Yes 
CCR5-2132CT 
CC 
CT 
TT 
-0.75 (-0.131, -0.18) Lower  
expression* 2.58 (1.23, 5.42) Higher risk 1.27 (yes) No 
CCR5-2086AG 
AA 
AG 
GG 
0.34 (-0.49, 1.18) Higher  
expression 0.34 (0.13, 0.93) Lower risk 0.73 (yes) Yes 
CCR5-1835CT 
CC 
CT 
TT 
-0.48 (-1.05, 0.099) Lower  
expression 1.06 (0.52, 2.16) Near the null 0.84 (no) No 
Haplotype A (VAGGTCAC) 
0 
1 
2 
0.59 (0.02, 1.16) Higher  
expression* 1.89 (0.94, 3.78) Higher risk 1.12 (yes) Yes 
Haplotype B (VATGTCAC) 
0 
1 
2 
0.12 (-1.42, 1.65) Higher  
expression 1.50 (0.15, 14.80) Higher risk 1.96 (yes) Yes 
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 Table 6.S3, continued 
SNP/Haplotype 
Genotype 
/# Copies£ 
Association with CCR5 expression Association with HIV MTCT Expression vs.  
HIV MTCT: 
Consistent  
Direction of  
Association? β (95% CI) † 
Direction of 
 association OR (95% CI) ‡ 
Direction of 
 association 
PlosONE RR 
(Consistent 
Direction of 
Association?)¥ 
Haplotype D (VATGTTAC) 
0 
1 
2 
-0.96 (-1.54, -0.38) Lower  
expression 2.63 (1.21, 5.72) Higher risk 1.24 (yes) No 
Haplotype E (VAGACCAC) 
0 
1 
2 
0.25 (-0.36, 0.85) Higher  
expression 0.79 (0.39, 1.60) Lower risk 0.97 (yes) No 
Haplotype F1 (VAGACCAT) 
0 
1 
2 
-0.60 (-1.83, 0.64) Lower  
expression NA NA 0.55 (NA) Yes 
Haplotype F2 (IAGACCAT) 
0 
1 
2 
-0.28 (-0.88, 0.32) Lower  
expression 0.90 (0.44, 1.85) Near the null 0.95 (yes) No 
Haplotype G1 (VGGACCAC) 
0 
1 
2 
0.01 (-0.95, 0.97) Near  the null 0.24 (0.09, 0.64) Lower risk 0.71 (yes) No 
† Linear regression for the association between CCR5 expression and CCR5 variants: Continuous outcome of placental expression, SNPs and haplotypes grouped 
as carriers vs. non carriers using carriers of each SNP variant or Haplotype as the exposure of interest. 
‡ Logistic regression for association between CCR5 variants and dichotomous outcome of yes/no HIV MTCT; OR: Odds ratio; 95% CI: 95% Confidence 
Interval for the Odds Ratio; P: P value.  
£ # Copies: Number of copies of haplotype: 0, 1, or 2 per subject. 
* Indicates statistically significant association (p<0.05). 
¥ Replication of findings from Pedersen et al. 38 with regards to the direction of association.  RR: Relative Risk. (N=151) 
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6.9.2 Gene Expression and Gene Variants: HS3ST3A1 & HS3ST3B1 
A total of 38 SNPs within 1kb of HS3ST3A1 were evaluated for association with 
placental expression of HS3ST3A1.  No SNPs were statistically significantly associated 
with HS3ST3A1 expression (Table 6.S4).  The association between HS3ST3B1 SNPs and 
HS3ST3B1 expression could not be determined as sample size and convergence issues 
occurred with the analyses. 
 
Table 6.S4 Crude associations for Model 8: Association of HS3ST3A1 SNPs with 
HS3ST3A1 expression 
SNP Sample Size Position β (95% CI)† P 
rs9896557 31 13376273 -0.04 (-1.24, 1.16) 0.944 
rs9916623 153 13384523 -0.26 (-0.99, 0.47) 0.481 
rs7224721 133 13385098 -0.46 (-1.10, 0.19) 0.167 
rs16948063 49 13385406 -0.06 (-1.08, 0.96) 0.906 
rs10521225 78 13392090 -0.08 (-2.30, 2.13) 0.941 
rs9941385 26 13392537 0.36 (-1.0, 1.73) 0.585 
rs10521226 121 13392554 -0.08 (-0.80, 0.65) 0.837 
rs1981629 152 13393581 -0.16 (-0.90, 0.58) 0.662 
rs10521227 43 13394685 0.14 (-0.79, 1.08) 0.758 
rs4399565 161 13407619 -0.14 (-0.92, 0.63) 0.713 
rs2098026 127 13411022 -0.67 (-3.48, 2.14) 0.639 
rs16948136 158 13417625 -0.17 (-0.97, 0.64) 0.684 
rs8069770 66 13417891 -0.18 (-1.10, 0.74) 0.696 
† Linear regression for the association between HS3ST3A1 SNPs and HS3ST3A1 
expression: continuous outcome of placental expression, SNPs grouped as carriers vs. 
non carriers.  β: Beta coefficient; 95% CI: 95% Confidence Interval for the Beta 
coefficient; P: P value. Effect estimates were undetermined for the following SNPs, due 
to small sample size: rs11078161, rs9909849, rs1029682, rs6502269, rs1860068, 
rs3785710, rs8073109, rs9897001, rs11651136, rs12941565, rs8082242, rs3785705, 
rs3785702, rs9303081, rs7212673, rs6502282, rs3785697, rs2098026, rs4588021, 
rs8082581, rs12952904, rs11078168, rs3785690, rs726799, rs8074072. 
  
 
CHAPTER 7 DISCUSSION 
7.1 Summary 
This chapter will summarize the key findings for each of the three aims.  It will also 
address strengths and weaknesses experienced throughout the body of work.  Finally I 
will address the public health significance of the findings from this work and its future 
applications. 
7.2 Summary of findings 
The first aim of this dissertation was to determine the association between infant 
polymorphisms and the risk of HIV MTCT in Malawi.  This was conducted through a 
genome wide association (GWA) study of over 650,000 single nucleotide polymorphisms 
(SNP) across infant genomes.  This study identified a variant, rs8069770, located within 
the gene, HS3ST3A1.  The gene produces the enzyme, 3-O-sulfotransferase, which 
catalyzes the reaction leading to the 3-O-sulfated subtype of heparan sulfate.  Although 
this finding did not reach genome wide statistical significance, the biological significance 
of HS3ST3A1 and the 3-O-sulfated subtype of heparan sulfate to MTCT are very 
interesting.   
In addition to the SNP discovery in the GWA study, we used the genome wide data 
to investigate how genetic variation in Malawi compares to populations from the 
International HapMap Project.  Allele frequencies and adjacent linkage disequilibrium 
(LD) across the genomes of Malawians were highly correlated to HapMap populations of 
African ancestry (r2>0.90), but not well correlated to other ancestry groups (r2<0.50).  
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However, the Malawi population was genetically distinct from other African ancestry 
populations.  The Malawi subpopulation was very homogenous showing no evidence of 
population stratification or genetic variation by self-reported ethnicity. 
The second and third aims of this proposal were to describe the expression of 
CCR5, HS3ST3A1, and HS3ST3B1 in the placenta.  HS3ST3A1 and HS3ST3B1 proteins 
have identical function and the genes are both located on chromosome 17.  The results of 
this work focused on the regulation of CCR5 in the placenta, as CCR5 plays a key role in 
the risk of HIV infection. Expression of CCR5 was highly correlated to the expression of 
the heparan sulfate genes, suggesting that regulation of expression or other environmental 
factors affecting expression in the placenta may be similar for these genes.  The 
regulation of CCR5 expression in the placenta was also found to be mediated by the 
infant CCR5 promoter polymorphisms CCR5-2132T and -2554T.  The SNP associations 
were also observed in the haplotype associations for haplotype A and D, which contain 
the wild type vs. variant alleles for -2554 and -2132, respectively.  Higher expression of 
CCR5 was not a direct result of maternal HIV infection, although higher expression was 
observed in mothers with higher levels of HIV viral load.  Overall, the work from aims 2 
and 3 provided in vivo evidence of regulatory factors of expression of two 
immunologically related genes in the placenta.   
7.3 Strengths 
One of the strengths of this work was the contribution of genetic information from 
an understudied population (with regards to genetics) of African individuals experiencing 
a high burden of HIV/AIDS.  Furthermore, there are few GWA studies of HIV MTCT 
published to date and this study provides new data regarding the genetic susceptibility to 
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HIV MTCT.  A better understanding of these mechanisms will have direct applications to 
both vaccine development and drug development including microbicides.  Microbicides 
are compounds that can be applied inside the vagina or rectum to protect against sexually 
transmitted infections including HIV 221.  Although viral genetics was not assessed, this 
information is relevant for populations afflicted by clade C of HIV, which is more 
common in populations living in Africa.  
The in vivo findings of gene expression of CCR5 in the placenta can be compared 
to what we know about in vitro regulation of CCR5.  We show some inconsistencies 
between SNP associations with HIV MTCT and SNP associations with CCR5 expression, 
suggesting that factors regulation this expression do not directly correlate to the risk of 
HIV MTCT..  It will be important to explore these discrepancies and more adequate 
capture the entire picture in future studies, building on the knowledge offered from this 
work. 
7.4 Limitations 
 The largest limitation in this work was the sample size for the GWA study.  Due 
to low power, we did not identify genome wide association SNPs. However, case 
availability was maximized and it was not possible to increase sample size.   
Mothers and their infants were ascertained at Queen Elizabeth Central Hospital 
(QECH), in Blantyre, Malawi.  One prerequisite for inclusion in this study was to obtain 
antenatal care at QECH.  If mothers who obtained antenatal care were different than 
mothers who were not able to or chose not to seek antenatal care at QECH, then the 
generalizability of the findings of this study may be limited.  Replication of this study 
may help to better assess this issue. 
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Many mother-infant pairs were lost to follow-up at clinic visits 6 and 12.  This 
was another reason for our limited sample size.  It is possible that this loss to follow-up 
resulted in missed identification of positive infants (cases).  This could have biased the 
association results towards the null, underestimating the true effects that could have been 
observed. 
7.5 Public health implications 
If the findings in the GWA work are replicated, there may be novel targets for drug 
and vaccine development aimed at prevention of HIV/AIDS in Africa.  We were 
specifically interested in obtaining novel information that may be applicable to the 
development of a vaccine to protect infants from infection or possibly for anti-viral 
medications used to prevent sexual transmission of HIV.  We were unable to show how 
heparan sulfate may interact with the HIV virus.  Follow-up studies are required to 
explore if heparan sulfate binds with HIV, and prevents HIV from crossing tissue barriers 
to cause infection  
For the work may include a more in-depth investigation of the genetic variation 
between Malawi and African ancestry populations from the HapMap Project.  The 
similarities and differences may be useful for future genetics research in Africa, including 
the ability to generalize the findings from Malawi to other populations.  Furthermore, 
variants in genes involved in drug metabolism may be necessary to compare across 
populations, as variable drug metabolism or tolerance is necessary to characterize.  
The collective power of this dissertation is to highlight the need to understand 
genetic influences of disease, including infectious disease such as HIV MTCT in Malawi, 
and to show how our understanding of genetics in one population corresponds to that in 
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other populations.  This work does not wish to undermine the valuable public health 
prevention efforts aimed at alleviating the burden of HIV/AIDS and other diseases in 
Malawi and throughout Africa.  Rather, it aims to facilitate new thoughts for 
pharmaceutical action or successive research with like ambitions. 
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